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ABSTRACT
Fanconi anaemia (FA) is a hereditary, heterogeneous disease that is characterized by 
chromosomal instability, hypersensitivity to DNA cross-linking agents and cancer. Fifteen FA 
genes are identified, mutations in any of which are known to cause FA: FANCA, B, C, Dl, D2, 
E, F, G, I, J, L, M, N, O, and P. Cell lines defective for any FA gene show cellular and 
cytogenetic hypersensitivity to DNA inter-strand cross-linking agents such as mitomycin C 
(MMC). The FA proteins function through several complexes in a poorly defined, intricate 
phosphorylation-ubiquitination DNA repair network (the FA-BRCA pathway) that mediates the 
removal of inter-strand cross-links (ICL). ICL removal requires the action several different repair 
activities including cross-link unhooking, translesion synthesis and subsequent repair of the 
double-strand break (DSB) formed by homologous recombination. Critical for ICL repair is the 
FA core complex (comprising A, B, C, E, F, G, L and M proteins) that is essential for the mono- 
ubiquitination of FANCD2 and FANCI and formation of the ID complex. FANCG, one 
component of the FA core complex, is involved in at least two further distinct protein complexes 
that likely have independent functional roles to the core complex. The G-ERCC-XPF complex 
(FANCG-XPF-ERCC1) is required for inter-strand cross link (ICL) unhooking. The G-BRCA2 
complex (FANCD 1 /BRCA2-FANCD2-FANCG-XRCC3) is hypothesised to be involved in 
modulating some aspect of homologous recombination repair (HRR). The aim of this study is to 
characterise the roles of FANCG and the G-BRCA2 complex in ICL and DSB repair. MMC and 
phleomycin, that induces DNA strand breaks, were utilized to evaluate the efficiency of the HRR 
pathway in Chinese hamster ovary FANCG mutant cells (NM3) and human FANCA (GM6914) 
and FANCD2 (PD20) fibroblasts. Drug hypersensitivity, chromosomal instability and HRR were 
evaluated using growth inhibition and clonal survival assays, metaphase analysis and a plasmid 
based HRR reporter assay respectively. Cell lines unable to form the G-BRCA2 complex are 
hypersensitive to phleomycin (in addition to MMC) and exhibit elevated chromosomal 
aberrations and reduced levels of HRR. This implicates the G-BRCA2 complex in the repair of 
both indirectly and directly induced DSB. Cell lines able to form the G-BRCA2 complex (such 
as FriiVCri-deficient cells) exhibit little or no hypersensitivity to phleomycin. The study also 
provides evidence that FANCD2 that is not mono-ubiquitinated has biological activity, 
specifically in the G-BRCA2 protein complex. The study provides important new insights into 
the molecular defects associated with FA and the role of the FA proteins in ICL and DSB repair.
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5-BU : 5-bromouracil
AA8 : Chinese hamster parental cell line (wild type)
AML : Acute myelogenous leukaemia 
APH : Aphidicolin (DNA synthesis inhibitor)
AT : Ataxia telangiectasia 
AT-LD: AT like disorder
ATM : Ataxia telangiectasia mutated
ATR: Ataxia telangiecasia and RADS related
ATRIP : ATR interacting protein (the binding partner of ATR)
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BACH1: BRCA1-associated C-terminal helicase 1
BER : Base excision repair
BFB : breakage-fusion-bridge
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BRCA1: Breast cancer susceptibility gene 1
BRCA2: Breast cancer susceptibility gene 2
BRIP1 : BRCA1-interacting protein 1
BS: Bloom syndrome
c DNA : Complementery DNA
C.G.H : Comparative genomic hybridization
CA: Chromosome aberration
CAs : chromosomal aberrations
Chkl : Checkpoint Kinase
CHK1 : S-phase checkpoint kinase (checkpoint kinase 1)
CHK1: Kinase checkpoint kinase 1 
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chro break : Chromosome break 
chro exch : Chromosome exchange 
CPDs : Cyclobutane pyrimidine dimers 
Cr: chromate
ctid break : Chromatid break 
ctid exch : Chromatid exchange 
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D37 value : The dose of agent that allows 37% of the cells to survive
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DMSO : Dimethylsulfoxide
DNA: Deoxyribonucleic acid
DNA-PKcs : DNA-dependent protein kinase
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dRP : deoxyribose-phosphate 
ds : Double strand
DSBs: Double strand breaks
dsDNA : Double strand DNA
EDTA: Ethylene di-amino-tetra-acetic-acid
EMS : Ethyle methane sulphonate
ERCC: Excision Repair Cross Complementing
ERCC1: Excision repair protein that in humans is encoded by the ERCC1 gene
ERCC4 : is a DNA repair endonuclease XPF enzyme that in humans is encoded by the ERCC4 gene
ESTs : Expressed Sequence Tags
F.I.S.H : Fluorescent in situ hybridization
FA: Fanconi anaemia
FAAP : FA-associated protein; or FANC associated polypeptides 
FA-ID : FANCI-FANCD2 complex
FANC J: Fanconi anaemia, complementation group J, (BRIP1) or (BACH1)
FANCA : Fanconi anaemia, complementation group A 
FANCB : Fanconi anaemia, complementation group B, FAAP95 
FANCC : Fanconi anaemia, complementation group C 
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FANCF : Fanconi anaemia, complementation group F
FANCG : Fanconi anaemia , complementation group G, XRCC9
FANCI: Fanconi anaemia , complementation group I
FANCL : Fanconi anaemia, complementation group L
FANCM : Fanconi anaemia, complementation group M, FAAP250
FANCN : Fanconi anaemia , complementation group N, PALB2
FANCO : Fanconi anaemia , complementation group O, RAD51C
FANCP : Fanconi anaemia , complementation group P,SLX4
G1 phase : Growth 1 phase, a period in the cell cycle during interphase, before the S phase
G2 phase: Growth 2 phase, is the final subphase of interphase in the cell cycle directly preceding mitosis
GI: Growth inhibition
GI-50 : The dose of agent that allows 50% of the cells to grow 
HCLK : a biological clock gene (clk-2)
HJs : Holliday junctions
HR: Homologous recombination 
HRR: Homologous recombination repair 
hygR : Hygromycin resistant gene
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ICL : Inter-strand cross-link 
ICLs : Interstrand cross-links
IKK2 : Inhibitor of nuclear factor kappa-B kinase subunit beta, (IKK-J3)
IR: Ionizing radiation
irslSF : Ionizing radiation sensitive cells 1 San Francisco 
KCL: Potassium chloride
KU70 : is a protein that, in humans, is encoded by the XRCC6 gene 
KU80 : Ku80 is a protein that, in humans, is encoded by the XRCC5 gene 
LOH : loss of heterozygosity
MHF : FANCM-associated histone-fold MHF heterodimer (MHF1-MHF2)
MI: Mitotic index
Mlhl : human gene on chromosome 3 commonly associated with hereditary nonpolyposis colorectal canc*
MMC: Mitomycin C
MMR: Mismatch repair
MN: Micronucleus
M-R-N complex: MreII-Rad50-NbsI
mRNA: Messenger RNA
NBS : Nijmegen breakage syndrome
neoR : G418 resistant gene
NER : Nucleotide excision repair
NHEJ: Non-homologous end joining
NiS04 : Nickel sulfate
NLS : nuclear localization signal
NM: Nitrogen mustard
NM3 : Chinese hamster cell line, a nitrogen mustered hypersensitive mutant to DNA damaging agents 
OH : Hydroxyl group 
P : Phosphorylation
PALB2: Partner and localizer of BRCA2 
PCR: Polymerase chain reaction 
PHF9 : PHD finger protein 9 
PolN : Human DNA polymerase N 
PTM: Post translational modifications 
RACE : Rapid Amplification of cDNA Ends
RAD51 : a member of the RAD51 protein family that assist in repair of DNA double strand breaks
RF : Recombination frequency
RIISp : Non-erythroid R spectrin (structural protein)
RNA: Ribonucleic acid 
RP A : Replication protein A 
SCEs : Sister chromatid exchanges 
SDS : Sodium dodecyl sulphate
siRNAs : Small interfering RNA, or short interfering RNA or silencing RNA
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SNX5 : Sorting nexin-5 is a protein that in humans is encoded by the SNX5 gene
S-phase : synthesis phase whhen DNA is replicated, occurring between G1 phase and G2 phase
SSA : Single strand annealing
ssDNA : Single strand DNA
STDEV: Standard deviation
SV40 : Human fibroblasts immortalized by Simian Virus 40
TAE: Tris-Acetic acid-EDTA
TBS : Tris buffer saline
TLS : Translesion DNA synthesis
TPR : Tetra-trico-peptide repeat motifs
Tris : tris (hydroxymethyl) methylamine
Ub : Ubiquitin
UBE2T : ubiquitin-conjugating enzyme E2T 
USP1 : Ubiquitin specific protease 1 
UV: Ultraviolet radiation
V(D) J : Variable, Diverse, and Joining 
VO : Vector only
WD40: Repeat motif found in b-transducin and other proteins.
WS: Werner's syndrome
WT : Wild type
XP : Xerodenna pigmentosum
XPA : is a protein that in humans is encoded by the XPA gene (Xeroderma pigmentosum-A)
XPF : xeroderma pigmentosum group F
XRCC: X-ray Repair Cross Complementing
XRCC3 : X-ray complementation FANC group, (RAD51 paralog)
XRCC9 : X-ray repair complementing defective repair 9
aSpIIE : The structural protein nonerythroid a spectrin (alphaSpIISigma)
VII
Abdulaziz Aladwani PhD
LIST OF CONTENTS
ABSTRACT.......................................................................................................................................II
ACKNOWLEDGEMENT........................................................................................................Ill
ABBREVIATIONS...................................................................................................................... IV
LIST OF CONTENTS.............................................................................................................VIII
LIST OF FIGURES...............................................................................................................XVIII
LIST OF TABLES.................................................................................................................... XXI
Chapter-1...............................................................................................................................................1
Introduction............................................................................................................................................1
1.1 DNA integrity and DNA damage.............................................................................................1
1.1.1 Spontaneous DNA damage........................................................................................... 2
1.1.2 DNA lesions......................................................................................................................2
1.1.3 Spontaneous Lesion Mechanisms............................................................................... 3
1.1.3.1 Deamination................................................................................................................ 3
1.1.3.2 Tautomeric shift.........................................................................................................4
1.1.3.3 Streisinger slipped mis-pairing............................................................................... 5
1.1.4 Induced Mutations.........................................................................................................5
1.1.4.1 Chemical mutagens.....................  5
1.1.4.1.1 Base analogs.......................................................................................................... 6
1.1.4.1.2 5-bromouracil (5-BU)..........................................................................................6
1.1.4.1.3 Ethylmethane Sulfonate (C3H803)................................................................. 7
1.1.4.1.4 Intercalating Agents........................  7
1.1.4.1.5 Radiomimetic agents..............................................................................  8
1.1.4.1.6 Cross-linking agents.......................................................................................... 10
1.1.4.1.6.1 Psoralens..........................    10
1.1.4.1.6.2 Platinum compounds..................................................................................10
1.1.4.1.6.3 Nitrogen mustards.......................................................................................10
VIII
Abdulaziz Aladwani PhD
1.1.4.1.6.4 Nitrosoureas...................................................................................
1.1.4.1.6.5 Diepoxybutane (DEB)..................................................................
1.1.4.1.6.6 Mitomycin C (MMC)...................................................................
1.1.4.2 Radiation Mutagens..................................................................................
1.1.4.2.1 Ultraviolet (UV) radiation..................................................................
1.1.4.2.2 Pyrimidine dimerization....................................................................
1.1.4.2.3 X-rays.....................................................................................................
1.2 DNA repair pathways...........................................................................................
\ 1.2.1 DNA repair mechanisms..............................................................................
1.2.2 Base excision repair (BER)..........................................................................
1.2.3 Nucleotide excision repair (NER).... ..........................................................
1.2.4 Mismatch repair (MMR)..............................................................................
1.2.5 Translesion synthesis (TLS)........................................................................
1.2.6 DNA DSBs Repair.........................................................................................
1.2.6.1 DNA repair through Homologous recombination repair (HRR)....
1.2.6.2 DNA repair through non-homologous end joining (NHEJ)............. .
1.2.7 Causes and repair of Inter-strand cross-links......................................... .
1.2.7.1 Causes of ICLs occurrence in prokaryotes and eukaryotes..............
1.2.7.2 ICL repair.................................................................................................. .
1.3 Instability Syndromes.......................................................................................
1.3.1 Instability syndromes and cancer..............................................................
1.3.2 Centrosome instability and telomere dysfunction.............................. ...
1.4 Fanconi anaemia...................................................................................................
1.4.1 Fanconi anaemia mode of Inheritance......................................................
1.4.2 Fanconi anaemia clinical manifestations.................................................
1.4.3 FA diagnosis and hypersensitivity to interstrand crosslinking agents
1.4.4 Fanconi anaemia pathway...........................................................................
1.4.5 The upstream FA pathway proteins..........................................................
1.4.5.1 Fanconi anaemia core complex..............................................................
.11
.12
.12
.16
.16
.16
.17
.18
.18
.18
.18
.19
. 19
.20
.21
. 24
.26
. 26
,. 27
.31
,31
,31
,34
, 34
,35
,37
,38
,41
,41
,41
,41
1.4.5.1.1 FANCA
1.4.5.1.2 FANCB
IX
Abdulaziz Aladwani PhD
1.4.5.1.3 FANCC................................................................................................................ 42
1.4.5.1.4 FANCE................................................................................................................ 42
1.4.5.1.5 FANCF................................................................................................................. 42
1.4.5.1.6 FANCG................................................................................................................ 43
1.4.5.1.7 FANCL................................................................................................................ 43
1.4.5.1.8 FANCM............................................................................................................... 44
1.4.6 The downstream FA pathway proteins.................................................................. 46
1.4.6.1 FANCD1.................................................................................................................. 46
1.4.6.2 FANCD2....................................................................................................................46
1.4.6.3 FANCI.......................................................................................................................47
1.4.6.4 FANCJ.......................................................................................................................48
1.4.6.5 FANCN......................................................................................................................48
1.4.6.6 FANCO..................................................................................................................... 48
1.4.6.7 FANCP..................................................................................................................... 49
1.4.7 Fanconi anaemia FANCG.................... .....................................................................49
1.4.7.1 FANCG and its role in the FA pathway............................................................. 49
1.4.7.2 FANCG- tetratricopeptide repeat motifs (TPRs).............................................53
1.4.7.3 FANCG protein is a phospho-protein phosphorylated at mitosis at two
amino acids; S383 and S387........................................................................... ......................56
1.4.7.4 FANCG is a phospho-protein phosphorylated at serine 7.............................57
1.4.8 Fanconi anaemia FANCA................................................................................. ........58
1.4.8.1 FANCA protein...................................................................................................... 58
1.4.8.2 FANCA is part of the multi-subunit nuclear complex (FA-core complex).. 60
1.4.8.3 FANCA protein interactions with a wide range of other proteins.............. 60
1.4.8.4 FANCA involvement in other complexes.......................................................... 61
1.4.8.5 FANCA protein is phospho-protein phosphorylated at serine-1449........... 62
1.4.9 Fanconi anaemia FANCD2.......................................................................................64
1.4.9.1 FANCD2 protein....................................................................................................64,
1.4.9.2 Functional and non functional FANCD2 isoforms.......................................... 65
1.4.9.3 The mono-ubiquitination of FANCD2 and the FA-core complex............... 65
X
Abdulaziz Aladwani PhD
1.4.9.4 FANCD2 mono-ubiquitination requirement for functional complementation
and foci formation.................................................................................................................. 66
1.4.9.5 FANCD2 phosphorylation by ATM and ATR and the role of CHK1 kinase.. 
.................................................................................................................................... 67
1.4.9.6 Hypersensitivity of FANCD2 mutant cells PD20, PD20-K561R and PD20-
S331A to cross linking agent MMC......................................................................................67
1.4.9.7 FANCD2 phosphorylation at S331 is critical for its in vivo interaction with
FANCD1/BRCA2.....................................................................................................................68
1.4.9.8 FANCD2 forms with FANCD1/BRCA2, FANCG and XRCC3 the G-BRCA2
complex...................................  70
1.4.9.9 FANCD2 and FANCI forms the FAN CD2-F AN Cl complex......................... 70
1.4.9.10 FANCD2 and its roles in sustaining chromosomal integrity..................... 71
1.5 Model systems to study Fanconi anaemia.......................................................................73
1.5.1 Model systems utilized in FA research.....................................................................73
1.5.2 Use of Chinese hamster cell mutants to study FA and FANCG......................... /73 1
1.5.2.1 The use of hamster model in cloning homologous recombination repair
genes ......................................................................................................................................73
1.5.2.2 Use of a hamster model to express FANCG mutations............................ .......74
1.5.3 Use of human FANCA fibroblasts (GM6914) in FA research.......................... 75
1.5.3.1 Isolation of GM6914 cells and assigning them to FA complementation group
A ......................................................................................................................................75
1.5.3.2 FANCA protein is found in both the cytoplasm and the nucleus................. 76
1.5.3.3 FANCA protein is a FA-core complex component............................................. 76
1.5.3.4 FANCA mutant cells exhibit cellular hypersensitivity to MMC.................... 77
1.5.3.5 Reported cytogenetic profile of GM6914 cell line.............    78 J
1.5.4 Use of human FANCD2 fibroblasts (PD20) in FA research.................................78
1.5.4.1 Pin pointing the FANCD2 gene using PD20 cells and mutation analysis .... 78
1.5.4.2 PD20 cells are FANCD2 deficient and FANCD2 cDNA complemented
functionally FANCD2 deficient cells................................................................................... 79
1.6 Aims........................................................................................................................................80
XI
Abdulaziz Aladwani PhD
Chapter-2........................................................................................................................................... 81
Material and methods....................................................................................................................... 81
2.1 Materials and methods................................................................................................................81
2.1.1 Material......................................................................................................................................81
2.1.1.1 Cell lines used.........................................................................................................81
2.1.1.1.1 Chinese hamster (CH) cell lines {FANCG lines).........................................81
2.1.1.1.2 Human fibroblast FA cell lines.................................................................. 82
2.1.1.1.2.1 FANCA cell lines........................................................................................82
2.1.1.1.2.2 FANCD2 cell lines......................................................................................83
2.1.1.2 Vectors for HRR assay...........................................................................................85
2.1.1.3 Antibodies for Western blotting...........................................................................85 \
2.1.1.3.1 Primary antibodies...........................................................................................85
2.1.1.3.2 Secondary antibodies........................................................................................85
2.1.1.4 Chemical agents used............................................................................................. 86
2.1.1.4.1 Mitomycin C (MMC)........................................................................................86
2.1.1.4.2 Phleomycin.........................................................................................................86
2.1.2 Methods.........................................................................................................................87
2.1.2.1 Cell culture and maintenance............................................................................... 87
2.1.2.2 Cell storage..............................................................................................................87
2.1.2.3 Growing cell lines from frozen stocks................................................................ 88
2.1.2.4 Cell passage.......................................................................................... ....................88
2.1.2.5 Fibroblast cell line growth inhibition assay...................................................... 8£/
2.1.2.6 Transfection.............................................................................................................89
2.1.2.7 Homologous recombination repair (HRR) assay.............................................90
2.1.2.7.1 Introduction......................................................................................... ............. 90
2.1.2.7.2 HRR Protocol.................................................................................................... 91
2.1.2.8 Survival assays........................................................................................................ (9J/
2.1.2.9 Immunoblotting (Western Blot)...........................................................................93
2.1.2.10 Cytogenetic methods................................. ........................... .......................... . 94
2.1.2.10.1 Cytogenetic methods introduction.............................................. ............... 94
XII
Abdulaziz Aladwani PhD
2.1.2.10.2 Cytogenetic protocols......................................................................................96
2.1.2.10.2.1 The Micronucleus Assay...........................    96
2.1.2.10.2.2 Metaphase spreads preparation for cytogenetic analysis................97
2.1.2.10.3 Chromosomal aberration scoring........................................  99
2.1.2.10.4 Converting exchanges to chromatid breaks............................................. 100
Chapter-3.......................................................................................................................................... 107
Investigating the role of FANCG protein in the repair of induced inter cross links.........107
3.1 Introduction........................................................................................................................107
3.1.1 FANCG and the repair of ICLs.................  107
3.1.2 FANCG is a scaffold phospho-protein central to many repair complexes.... 108
3.1.3 Cell lines used in this chapter...................................    109
3.1.4 Role of FANCG in HRR and ICL repair.............................................................. 110
3.2 Results......................................................................................................................  Ill
3.2.1 Validation and growth inhibition responses of cell lines used for metaphase
analysis........................................................................................................................................Ill
3.2.1.1 Immunoblotting.....................................................................................................Ill
3.2.1.2 Growth inhibition assays results.................................................................  114
3.2.2 Chromosomal aberration analysis results............................................................ 116
3.2.2.1 Chromosome and chromatid aberration rates in control cell cultures....... 117
3.2.2.2 Chromosome and chromatid aberration rates in treated cell cultures....... 117
3.2.2.3 Aberration types and predominance...................................  127
3.2.2.4 Classification of cytogenetic aberrations...........................................................128
3.2.3 Homologous recombination repair assay results.....................................................132 i
3.3 Discussion...............................................................  135 j
3.4 Summary of the chapter................................................................................................... 142 j
XII!
Abdulaziz Aladwani PhD
Chapter-4........................................................................................................................................ 145
Investigating the role of FANCG protein in the repair of induced DNA double strand 
breaks.................................................................................................................................................145
4.1 Introduction.......................................................................................................................145
4.1.1 DNA strand breaks.................................................................................................. 145
4.1.2 NM3 cells hypersensitivity to radiomimetic agents............................................ 145|
4.1.3 Cell lines used in this chapter..................................................................................146 j
4.2 Results............................ ................................................................................................... 147
4.2.1 Survival assays results.............................................................................................147
4.2.2 Growth inhibition assays results....................................................  147i
!
4.2.3 Chromosomal aberration analysis results............................................................ 151 i
4.2.3.1 Preliminary metaphase analysis in NM3 and NM3-gWT post exposure to
low doses of phleomycin..................................................................................................... 151
4.2.3.2 The introduction of NM3-S7A ceU line to phleomycin cytogenetic structural
aberration assays using selected doses..............................................................................156
4.2.3.3 The introduction of NM3-S387A cell line to phleomycin cytogenetic
structural aberration assays using selected doses..........................................................156
4.2.3.4 Chromosome and chromatid aberration rates in control cell cultures......157
4.2.3.5 Chromosome and chromatid aberration rates in treated cell cultures......157
4.2.3.6 Average aberrations per cell, percentage aberrant cells and number of total
chromatid breaks per cell................................................................................................... 158
4.2.3.7 Aberration type and predominance.................................. ...............................173
4.2.3.S Cytogenetic numerical aberration rates in control and treated cell cultures..
4.2.3.9 Chromatid Gaps in phleomycin-treated cell lines
4.2.4 Homologous recombination repair assay results.....
4.2.5 MN assay..........................................................................
4.2.5.1 Optimizing the MN assay procedure......................
4.2.5.2 Problems encountered in the MN procedure........
4.3 Discussion................................................................................
4.3.1 Discussion.........................................................................
4.3.2 Survival and growth inhibition data..........................
183 
192 
192 
196 
196 f 
198 
201 
201 
201
XIV
Abdulaziz Aladwani PhD
4.3.3 Cytogenetic data.........................    202
4.3.3.1 Chromosomal aberrations rate and type in FANCG cell lines................... 202
4.3.3.2 Chromatid lesions produced post treatment with DNA strand breakers.. 203
4.3.3.3 Cytogenetic data comparison to other repair deficient mutants................ 204
4.3.3.4 Numerical instability in response to phleomycin applied to FA cell lines.. 206
4.3.4 Homologous recombination repair assay data.....................................................207
4.4 Summary of the chapter....................................................................................................20$
Chapter-5..........................................................................................................................................210
Investigating the role of FANCA protein in the repair of induced DNA double strand 
breaks and (ICLs)............................................................................................................................. 210
5.1 Introduction........................................................................................................................210
5.1.1 Cell lines used in this chapter................................................................................. 210
5.1.2 Investigation of the induction of chromosome aberrations in GM6914
fibroblasts................................................................................................................................... 211
5.2 Results................................................................................................................................. 212
5.2.1 GM6914 fibroblasts exposed to phleomycin growth inhibition results...........212
5.2.2 GM6914 fibroblasts cytogenetic findings............................................................. 214
5.2.2.1 GM6914 fibroblasts cytogenetic analysis results after exposure to
phleomycin.............................................................................................................................. 214
5.2.2.1.1 GM6914 fibroblasts chromosome and chromatid aberration rates in
control cell cultures...........................................................................................................214
5.2.2.1.2 GM6914 fibroblasts chromosome and chromatid aberration rates in
treated cell cultures exposed to phleomycin................................................................ 215
5.2.2.1.3 The cytogenetic aberration types and predominance in GM6914
fibroblasts exposed to phleomycin................................................................................. 224
5.2.2.2 GM6914 fibroblasts chromosomal aberration analysis results to MMC... 228
5.2.2.2.1 GM6914 fibroblasts chromosome and chromatid aberration rates in
control cell cultures exposed to MMC...........................................................................228
5.2.2.2.2 GM6914 fibroblasts chromosome and chromatid aberration rates in
treated cell cultures to MMC..........................................................................................229
5.2.2.2.3 The cytogenetic aberration types and predominance in GM6914
fibroblasts to MMC...........................................................................................................241
XV
Abdulaziz Aladwani PhD
5.3 Discussion............................................................................................................................246
5.4 Summary of the chapter.................................................................................................. 250
Chapter-6.........................................................................................................................................252
Investigating the role of the FANCD2 protein in the repair of DNA double strand breaks 
and inter-strand cross-links...........................................................................................................252
6.1 Introduction........................................................................................................................252
6.1.1 Introduction................................................................................................................ 252
6.1.2 Cell lines utilized in this chapter............................................................................253
6.2 Results...............................................................................................................  253
6.2.1 Growth inhibition assays results of PD20 cells exposed to phleomycin........ 253
6.2.2 Metaphase analysis in PD20 cells...........................................................................256
6.2.2.1 Phleomycin-induced chromosomal aberration in PD20 cell lines..............256
6.2.2.1.1 Spontaneous chromosome and chromatid aberrations............................ 256
6.2.2.1.2 Phleomycin-induced chromosome and chromatid aberrations.............. 257
6.2.2.1.3 Aberrations per cell, percentage aberrant cells and total chromatid
breaks per cell.................................................................................................................... 264
6.2.2.1.4 Types of cytogenetic aberrations induced by phleomycin....................... 268
6.2.2.1.5 Phleomycin-PD20 cytogenetic experiments with high variability due to
an unidentified technical problem.......................................................  273
6.2.3 Growth inhibition assays results of PD20 cells exposed to MMC..................274
6.2.4 MMC- PD20 cytogenetic experiments that have suffered an unidentified
technical problem................................................. 274
6.3 Discussion.........................................................................................................    277
6.3.1 Requirement of post-translational modifications of FANCD2 for efficient DNA
repair ........................................................................................................................................277
6.3.2 Functions of S331-phosphorylated FANCD2 and non-ubiquitinated FANCD2. 
........................................................................................................................................278
6.3.3 Problems encountered with metaphase analysis of PD20 cell lines................. 280
6.4 Summary of the chapter.................................................................................................. 281
6.5 Appendix of Chapter-6.................................................................................................... 283
XVI
Abdulaziz Aladwani PhD
Chapter-7..........................................................................................................................................299
General discussion........................................................................................................................... 299
7.1 Discussion.................................................................................................................................299
7.1.1 Introduction................................................................................................................ 299
7.1.2 DNA inter-strand cross-link repair........................................................................300
7.1.2.1 Unhooking............................................................................................................... 300
7.1.2.2 Processing of Double Strand Breaks in ICL Repair...........................  304
7.1.2.3 Determining the role of the G-BRCA2 complex (comprising BRCA2-
FANCD2-FANCG-XRCC3) in ICL and DSB repair.....................................................306
7.1.3 Conclusions..................... 317
References........................................................................................................................................319
Appendix.......................................................................................................................................... 350
XVII
Abdulaziz Aladwani PhD
List of Figures 
Chapter-1
Figure (1.1): Phleomycin chemical structure.............................................................................. 9
Figure (1.2): Mitomycin C chemical structure....................................................................... 15
Figure (1.3): Model illustrating DSBs repair by error free homologous recombination . 23 
Figure (1.4): Schematic representation of DSB repair by error prone NHEJ pathway... 25
Figure (1.5): Model of FANCG role in ICL repair via the upstream FA pathway...........29
Figure (1.6): Model for Inter-strand cross-link repair.................................................... ......30
Figure (1.7): Telomeric dysfunction leading to structural and numerical chromosome 
instability................................................................................................................................  33
Figure (1.8): The FA pathway activation: Upstream FA-BRCA regulation......................39
Figure (1.9): The FA pathway activation: downstream FA-BRCA regulation model 40
Figure (1.10): FANCG complexes in inter-strand-cross link (ICL) repair.........................51
Figure (1.11): Model of alISp, FANCG, and ERCC1-XPF interactions in ICL repair... 52
Figure (1.12): FANCG tetratricopeptide repeat motifs and phosphorylation sites..........55
Chapter-2
Figure (2.1): Assay for homologous recombination repair (HRR) using an integrated 
vector with a neomycin reporter gene........................................................................................92
Figure (2.2): Formation of complex chromatid exchanges...................................................103
Figure (2.3): Chromosome aberrations formation..................................................................104
Figure (2.4): Triradial formation............................................................  105
Figure (2.5): Quadri-radial formation............................................................................  106
XVIII
Abdulaziz Aladwani PhD
Chapter-3
Figure (3.1): Western blot of FANCG protein in NM3 cell lines........................................112
Figure (3.2): Western blot of FANCG protein in NM3 cell lines........................................113
Figure (3.3): Growth Inhibition -NM3- MMC.......................................................................115
Figure (3.4): NM3- MMC Average Aberrations per cell......................................................124
Figure (3.5): NM3- MMC Average % Aberrant cells...........................................................125
Figure (3.6): NM3- MMC Average of Total Chromatid Breaks (after converting 
exchanges) per cell......................................................................................................................... 126
Figure (3.7): HRR-Non-induced Recombination Frequency - MMC...............................133
Figure (3.8): HRR-Induced Recombination Frequency - MMC........... ............................ 134
Chapter-4
Figure (4.1): NM3-Phleomycin survival.................................................................................. 149
Figure (4.2): NM3-Phleomycin- Growth Inhibition.............................................................. 150
Figure (4.3): NM3- phleomycin -Average Aberrations per cell..........................................169
Figure (4.4): NM3- phleomycin —Average % Aberrant cells.............................................. 170
Figure (4.5): NM3- phleomycin —Average of Total Chromatid Breaks (after converting 
exchanges) per cell...............................................................................................  171
Figure (4.6): NM3- Average Number of chromosomes post phleomycin treatment.......191
Figure (4.7): NM3-HRR-Non-induced Recombination Frequency -Phleomycin............. 194
Figure (4.8): NM3-HRR-Induced Recombination Frequency -Phleomycin.............. ......195
Figure (4.9): Micronucleus assay cells.......................................................................................200
XIX
Abdulaziz Aladwani PhD
Chapter-5
Figure (5.1): Growth Inhibition - 6914 A cells - Phleomycin............................................. 213
Figure (5.2): 6914 A cells - phleomycin —Average Aberrations Per cell..........................219
Figure (5.3): 6914 A cells - phleomycin —Average % Aberrant cells............................... 222
Figure (5.4): 6914 A cells - phleomycin —Average number of Chromatid Breaks (after
converting exchanges) per cell....................................................................................................223
Figure (5.5): 6914 A cells - MMC Average Aberrations Per cell.......................................238
Figure (5.6): 6914 A cells - MMC Average % Aberrant cells............................................ 239
Figure (5.7): 6914 A cells -MMC Average number of Chromatid Breaks (after 
converting exchanges) per cell....................................................................................................240
Chapter-6
Figure (6.1): Growth Inhibition - PD20 cells - Phleomycin............................................... 255
Figure (6.2): PD20 cells - phleomycin —Average Aberrations Per cell........................... 262
Figure (6.3): PD20 cells - phleomycin —Average % Aberrant cells..................................263
Figure (6.4): PD20 cells - phleomycin —Average number of Chromatid Breaks (after 
converting exchanges) per cell....................................................................................................267
Figure (6.5): PD20 cells -Growth Inhibition - MMC............................................................ 276
Chapter-7
Figure (7.1): The proposed model to repair ICLs and double strand DNA breaks via 
FANCG complexes........................................................................................................................303
XX
Abdulaziz Aladwani PhD
List of Tables 
Chapter-1
Table (1.1): Fanconi anaemia clinical manifestations.............................................................. 36
Table (1.2): Fanconi anaemia genes/proteins.....................................................................  45
Chapter-2
Table (2.1): Converting chromosome and chromatid exchanges into chromatid breaks 
..........................................................................................................................................................102
Chapter-3
Table 3.1.A: NM3- MMC treated cell lines and aberrations found in experiment.......... 119
Table 3.2.A: NM3- MMC treated cell lines and aberrations found in experiment.......... 120
Table 3.3.A: NM3- MMC treated cell lines and aberrations found in experiment..........121
Table 3.4: NM3- MMC - Average / Standard deviation - Table results for (Tables 3.1.A, 
3.2.A and 3.3.A)............................................................................................................................. 123
Table 3.1.B: NM3- MMC types of chromatid /chromosome exchanges...........................129
Table 3.2.B: NM3- MMC types of chromatid /chromosome exchanges............................ 130
Table 3.3.B: NM3- MMC types of chromatid / chromosome exchanges...................   131
XXI
Abdulaziz Aladwani PhD
Chapter-4
Table (4.1) NM3- phleomycin treated cell lines and structural aberrations......................153
Table (4.2) NM3- phleomycin treated cell lines and structural aberrations......................154
Table (4.3) NM3- phleomycin treated cell lines and structural aberrations......................155
Table (4.4.A): NM3- phleomycin treated cells and aberrations found in experiment.... 161
Table (4.5.A): NM3- phleomycin treated cells and aberrations found in experiment.... 162
Table (4.6.A): NM3- phleomycin treated cells and aberrations found in experiment.... 163
Table (4.7.A): NM3- phleomycin treated cells and aberrations found in experiment.... 164
Table (4.8.A): NM3- phleomycin treated cells and aberrations found in experiment.... 165
Table (4.9.A): NM3- phleomycin treated cells and aberrations found in experiment.... 166
Table (4.10.A): NM3- phleomycin treated cells and aberrations found in experiment.. 167
Table (4.11.A): NM3- phleomycin treated cells and aberrations found in experiment.. 168
Table (4.12): NM3-phleomycin - Average /Standard deviation (STDEV) - Tables- results 
for tables- (4.4.A, 4.5.A, 4.6.A, 4.7.A, 4.8.A, 4.9.A, 4.10.A & 4.11.A)................................ 172
Table (4.4.B):NM3-phleomycin types of chromatid and chromosome exchanges........... 175
Table (4.5.B):NM3-phleomycin types of chromatid and chromosome exchanges........... 176
Table (4.6.B):NM3-phleomycin types of chromatid and chromosome exchanges......... 177
Table (4.7.B):NM3-phleomycin types of chromatid and chromosome exchanges........... 178
Table (4.8.B):NM3-phleomycin types of chromatid and chromosome exchanges........... 179
Table (4.9.B):NM3-phleomycin types of chromatid and chromosome exchanges........... 180
Table (4.10.B):NM3-phleomycin types of chromatid / chromosome exchanges.............. 181
Table (4.11.B):NM3-phleomycin types of chromatid / chromosome exchanges.............. 182
Table (4.13): Phleomycin treated NM3 cells - Average chromosome numbers count.... 185
Table (4.14): Phleomycin treated NM3 cells- Average chromosome numbers count..... 186
Table (4.15): Phleomycin treated NM3 cells- Average chromosome numbers count.....187
Table (4.16): Phleomycin treated NM3 cells- Average chromosome numbers count.... 188
Table (4.17): Phleomycin treated NM3 cells- Average chromosome numbers count.... 189
Table (4.18): Phleomycin treated NM3 -Average Number of chromosome in five 
experiments as shown in tables (4.13, 4.14,4.15, 4.16, and 4.17)........................................190
XXII
Abdulaziz Aladwani PhD
Chapter-5
Table (5.1-A): 6914-phIeomycin treated cells and structural aberrations.........................216
Table (5.2-A): 6914-phleomycln treated cells and structural aberrations.........................217
Table (5.3-A): 6914-phieomycin treated cells and structural aberrations.........................218
Table (5.4): Average /Standard deviation (STDEV) - Tables-Results for Human cells 
6914 cells - phleomycin...............................................................................................................221
Table (5.1-B): 6914A-phleomycin types of chromatid and chromosome exchanges......225
Table (5.2-B): 6914A-phleomycin types of chromatid and chromosome exchanges.......226
Table (5.3-B): 6914A-phleomycin types of chromatid and chromosome exchanges.......227
Table (5.5-A): MMC treated 6914 cell lines and aberrations............................................ 232
Table (5.6-A): MMC treated 6914 cell lines and aberrations............................................ 233
Table (5.7-A): MMC treated 6914 cell lines and aberrations ..............................................234
Table (5.8-A): MMC treated 6914 cell lines and aberrations............................................ 235
Table (5.9): Average /Standard deviation -Table results for 6914 cells MMC................ 236
Table (5.5-B): 6914A- MMC - types of chromatid and chromosome exchanges........... 242
Table (5.6-B): 6914A- MMC - types of chromatid and chromosome exchanges........... 243
Table (5.7-B): 6914A- MMC - types of chromatid and chromosome exchanges........... 244
Table (5.8-B): 6914A- MMC - types of chromatid and chromosome exchanges........... 245
Chapter-6
Table (6.1-A): PD20- phleomycin treated cells and structural aberrations found.........259
Table (6.2-A): PD20- phleomycin treated cells and structural aberrations found.........260
Table (6.3-A): PD20- phleomycin treated cells and structural aberrations found.........261
Table (6.4): Average / Standard deviation- Table results for PD20 cells - phleomycin.. 266
Table (6.1-B): PD20- phleomycin types of chromatid and chromosome exchanges........270
Table (6.2-B): PD20- phleomycin types of chromatid and chromosome exchanges........271
Table (6.3-B): PD20- phleomycin types of chromatid and chromosome exchanges........272
XXIII
Abdulaziz Aladwani PhD
Appendix of chapter-6:
Table (6.5-A): PD20- phleomycin treated cells and structural aberrations....................283
Table (6.6-A): PD20- phleomycin treated cells and structural aberrations....................284
Table (6.7-A): PD20- phleomycin treated cells and structural aberrations....................285
Table (6.8-A): PD20- phleomycin treated cells and structural aberrations....................286
Table (6.9-A): PD20- phleomycin treated cells and structural aberrations.................... 287
Table (6.5-B): PD20- phleomycin types of chromatid and chromosome exchanges.......288
Table (6.6-B): PD20- phleomycin types of chromatid and chromosome exchanges.......289
Table (6.7-B): PD20- phleomycin types of chromatid and chromosome exchanges.... 290
Table (6.8-B): PD20- phleomycin types of chromatid and chromosome exchanges.... 291
Table (6.9-B): PD20- phleomycin types of chromatid and chromosome exchanges.... 292
Table (6.10-A): PD20- MMC treated cells and structural aberrations found.................. 293
Table (6.11-A): PD20- MMC treated cells and structural aberrations found.................. 294
Table (6.12-A): PD20- MMC treated cells and structural aberrations found.................. 295
Table (6.10-B): PD20- MMC types of chromatid and chromosome exchanges............... 296
Table (6.11-B): PD20- MMC types of chromatid and chromosome exchanges........... 297
Table (6.12-B): PD20- MMC types of chromatid and chromosome exchanges............... 298
Chapter-7
Table (7.1): FANCG cell lines findings to MMC and phleomycin......................................310
Table (7.2): FANCA cell lines findings to MMC and phleomycin.......................................311
Table (7.3): FANCD2 cell findings to MMC and phleomycin.................................. .........316
XXIV
Abdulaziz Aladwani PhD
Chapter-1
Introduction
1.1 DNA integrity and DNA damage
The integrity of the genetic material is essential for continuous stable cellular replication, which 
enables the transfer of deoxyribonucleic acid (DNA) to new daughter cells. An intricate network 
of systems such as cell cycle arrest, DNA damage recognition and repair collaborate to evade the 
transfer of damaged DNA during mitosis ensuring accurate functionality of the DNA (Futaki 
and Liu, 2001). However, DNA damage can be encountered spontaneously or it may be 
induced. Exogenous agents, such as ultraviolet radiation (UV), ionizing radiation (IR) or 
naturally occurring or manufactured chemicals may cause DNA damage. Chromosomal integrity 
is dependent upon the proficient repair of these DNA lesions. In the absence of comprehensive 
DNA repair and surveillance systems, chromosomal aberrations (CA) are allowed to accumulate 
in cells leading to genome instability which can have devastating consequences for growth and 
development. Ataxia telangiectasia (AT), Ataxia telangiectasia-like disorder, Bloom syndrome 
(BS), Fanconi anaemia (FA) and Nijmegen breakage syndrome (NBS) are examples of 
recessively inherited syndromes that are likely to develop chromosomal aberrations. They arise 
from specific defects in DNA damage response genes and are classified as chromosomal 
instability or breakage syndromes (Futaki and Liu, 2001). A simplistic ‘cytogeneticists’ 
definition of chromosomal instability would be the situation where cells have both numerical and 
structural chromosomal aberrations as a result of developing continually new chromosomal 
mutations, at an elevated rate compared to that of normal cells (Taylor, 2001; Talwar et ah, 
2004).
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1.1.1 Spontaneous DNA damage
DNA is subjected to damage from several sources. DNA damage is an expression encircling the 
several chemical alterations that may modify the DNA structure. Damage can occur through 
reactions disrupting the DNA phosphate groups, the deoxyribose sugar ring, or bonds in the 
nucleotide-bases or by the addition of chemical groups such as methyl groups, hydroxyl groups, 
or groups derived from polycyclic molecules. These additions are usually called DNA adducts 
(Lange et al9 2011). Spontaneous DNA lesions may occur due to errors in normal cellular 
processes such as DNA metabolism, replication and recombination (Marnett and Plastaras., 
2001). Inevitable reactions such as water-catalysed reactions and attack by reactive oxygen 
species (ROS) lead to recurrent damaging alterations in DNA (Lange et alt 2011). Normal 
cellular respiration produces highly-reactive oxygen radicals that can harm the DNA (Joenje 
and Oostra, 1983).
1.1.2 DNA lesions
Damaged to DNA is frequently due to denaturing in weak hydrogen bonds implicated in base 
pairing. DNA lesions include the presence of an irregular base in the DNA or injured sugar- 
phosphate backbone. DNA damage can arise in either: the template strand or in the new 
synthesized strand. A lesion is a physical change in DNA, unlike a mutation, which involves 
modification of the DNA sequence. DNA lesions can be repaired unlike several mutations 
(Pages and Fuchs, 2002).
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1.1.3 Spontaneous Lesion Mechanisms
Spontaneous mutations arise during cell processes. DNA lesions lead ultimately to mutations. 
DNA lesions are produced via two main ways; transversion or the more common transition. 
Ionizing radiation and alkylating agents may cause Transversions which are defined as the 
substitution of a purine for a pyrimidine or vice versa leading to dramatic change in the chemical 
structure. For instance, longer bonds result and a shift of the bases would occur enabling a (C) to 
pairs with a (T). Transitions are defined as the substitution of a pyrimidine for a pyrimidine or a 
purine for a purine (Golo and Volkov 2003).
1.1.3.1 Deamination
Deamination is defined as eliminating an amine group facilitated by deaminase. Oxidation, 
reduction, or hydrolysis causes amino acid deamination (Frankel et al, 1980). Turning cytosine 
into uracil via hydrolysis is an example of DNA deamination. A major source of spontaneous 
mutations is cytosine deamination (Duncan and Miller, 1980). When a cytosine in a normal GC 
pair converts to a uracil, then following replication, an adenine will bind to the uracil. As uracil 
causes the DNA to be chemically modified then this is termed a lesion. Nevertheless, following 
the next replication a transition mutation results as the adenine binds to a thymine which 
illustrates how DNA lesions lead to mutations. Deamination can also be caused via chemical 
mutagens such as Nitrous acid (HN02) deaminating cytosine to uracil or deaminating adenine to 
hypoxanthine (Frankel et al, 1980; Sidorkina et al, 1997).
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1.1.3.2 Tautomeric shift
Spontaneous DNA mutations result from tautomeric transitions (Golo and Volkov 2003). 
Normally, cytosine pairs with guanine forming (CG pair) and likewise adenine pairs with 
thymine forming (AT pair), Nevertheless, these bases occur rarely in tautomeric forms also 
(Tsolakidis and Kaxiras 2005). Guanine and thymine are usually found in their keto-tautomeric 
form, however, as hydrogen from their NH group reallocates to the double bonded oxygen to 
construct an OH group; the base is altered to its rare enol form (Tsolakidis and Kaxiras 2005). 
Likewise, cytosine and adenine are usually found in their amino structure, however as a 
hydrogen (H) from their NH2 group reallocates to the single nitrogen in the ring constructing an 
NH group, the base is altered to its rare imino structure (Tsolakidis and Kaxiras 2005).
Each tautomeric form (tautomer) pairs with the wrong, normal base of the correct (pyrimidine or 
purine) type. As a result of the hydrogen shifts, these tautomers result in incorrect base pairs, so 
the enol fonn of T pairs with the keto form of guanine, forming a TG pair and in the same way, 
enol guanine pairs with keto thymine , imino adenine with amino cytosine and imino cytosine 
with amino adenine (Tsolakidis and Kaxiras 2005). After the first round of DNA replication, 
these tautomeric fonns result in an irregular DNA sequence in the new synthesised strand. 
Following the next replication round, the transcription of this irregular DNA sequence leads to a 
mutation on the newly synthesized strand. This genetic modification is termed a transition 
mutation (Golo and Volkov 2003).
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1.1.3.3 Streisinger slipped mis-pairing
Many repetitive sequences in DNA are thought to be a result of a DNA lesion termed Streisinger 
slipped mis-pairing. This is supported by Streisinger and Owen, (1985) who proposed a model 
supporting the occurrence of high frequencies of frame shift mutations in DNA segments of 
repeated base sequences. Streisinger model shows frame shifts arising when loops in single- 
stranded segments are stabilized via the “slipped mis-pairing” of DNA repeated sequences 
(Thomas et al., 1998).
This strand slippage takes place mostly in repetitive non-coding DNA. Nucleotide bases may slip 
and pair with other bases leading to a bulge consisting of additional bases. This strand slippage is 
likely to happen in the presence of repetitive sequences (Levinson and Gutman, 1987) and 
probably do not occur in the absence of sequence repeat. Three repeated unpaired bases can 
generate a loop in the strand (Lovett, 2004). Due to the absence of complementary bases in the 
other strand, the additional nucleotide or nucleotides in either strand becomes conspicuous 
plugging and sticking out from the rest of the strand (Streisinger and Owen, 1985). Gain of 
additional nucleotides occurs if slippage arises in the newly produced DNA strand as a bulge is 
formed. Conversely, nucleotide bases are lost or deleted if slippage arises in the template DNA 
strand (Streisinger and Owen, 1985).
1.1.4 Induced Mutations 
1.1.4.1 Chemical mutagens
DNA is susceptible to induced chemical damage. Transitions or transversions (point mutations) 
are induced through the action of chemical mutagens. Chemical mutagens include base analogs,
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base modifiers, intercalating agents, intercalating agents, ionizing radiation such as; gamma rays, 
x-rays, and ultraviolet light. The exposure to enviromnental chemicals such as some 
hydrocarbons found in cigarette smoke (Talwar et al., 2004) or glycopeptide antibiotics such as 
DNA strand breaker phleomycin (Tevethia and Rapp, 1969) or the application of antitumour 
agents in chemotherapy such as DNA cross linker mitomycin C (MMC) (Tomasz, 1995) will 
induce DNA damage.
1.1.4.1.1 Base analogs
Base analogs are chemical mutagens that replace normal DNA bases as a result of similarity in 
their chemical structure. Base analogs are inconsistent in base pairing as they base pair with two 
different bases, therefore leading to mutations. The inability of DNA polymerase to differentiate 
between base analogs and normal DNA bases results in the incorporation of base analogs in 
DNA during DNA replication (Pierce, 2007). Examples of base analogs include; 5-bromouracil 
(5-BU) and azydothymidine (AZT).
1.1.4.1.2 5-bromouracil (5-BU)
Mutation inducer; 5-bromouracil is a base analogs that replaces thymine modifying the 
chromatin structure through altering DNA and the nuclear matrix interactions (Ogino 
et al, 2002). 5-bromouracil has two tautomeric forms: one as a keto form (imitating T) 
pairing with (A) and a second enol form (imitating C) pairing with (G), therefore base 
pairing of A: T shifts to G: C (Ronen et al.f 1976). DNA and proteins interaction is
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altered when 5-bromouracil becomes incorporated into the DNA (Ogino et al, 2002).
1.1.4.1.3 Ethylmethane Sulfonate (C3H803)
Mutation inducer; ethylmethane sulfonate is an agent that alkylates (Keightley et al, 2000) the 
keto groups at position number 6 of guanine and at position number 4 of thymine to form 0-6- 
ethylguanine and O-4-ethylthymine, respectively.
After the first round of DNA replication, DNA polymerase will pair thymine with 0-6- 
ethylguanine rather than pairing a cytosine with a normal guanine. Following the next replication 
round, the earlier pervious CG pair will be modified to an AT pair, therefore resulting a 
mutation. This genetic modification is termed a transition mutation (Golo and Volkov, 2003; 
Keightley et al., 2000). It has been found that ethylmethane sulfonate has mutagenic inclination 
favoring transitions of GC to AT (Vidal et al., 1995).
1.1.4.1.4 Intercalating Agents
Intercalating gents have the ability to insert themselves between successive DNA bases, resulting 
in DNA deformation preventing its proper functioning. The DNA double helix becomes so 
stressed that the backbones stretch distorting the helixes. Hydrodynamic DNA modifications 
also result via intercalation; these alterations are reversible as long as the intercalator elimination 
does not damage the DNA duplex structure (Richards and Rodger, 2007). Reagents ethidium 
bromide, acridine orange and proflavin are examples of intercalating agents. Consequent to 
DNA deformation DNA polymerase may insert an additional base opposite the intercalating
7
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agent, or it may also be incapable of inserting a complementary base, thus leading to a deletion. 
Therefore, an insertion or deletion mutation may result from, the DNA deformation.
Based on the intercalating agents’ shape and structure, each agent has a different unwinding and 
lengthening effect on DNA strands (Long and Barton, 1990) which usually prevents proper 
DNA replication and transcription.
1.1.4.1.5 Radiomimetic agents
Bleomycin and phleomycin are termed radiomimetic as they are DNA damaging agents that 
mimic functionally the effect of IR. Hydroxyl radicals; which are an example of reactive oxygen 
species (ROS) can be produced in the presence of metal ions such as Fe+2 and Cu+2 by 
radiomimetic agents (Sugiura, 1979). The action of the free radicals produced is parallel to the 
indirect effect of IR which involves the oxidation and breaking of the deoxyribose.
Phleomycin Fig.1.1; is a glycopeptide antibiotic related to the bleomycin family that displays 
similar specificity of DNA base release as bleomycin. Cu (II)-complexes which approximate 
DNA and induce oxidative DNA degradation are produced by both bleomycin and phleomycin 
(Povirk et at, 1981). Phleomycin which is produced by Streptomyces verticullus induces DNA 
strand breaks and is a strong inhibitor of DNA replication (Sleigh, 1976; Chen et at, 2008).
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1.1.4.1.6 Cross-linking agents
1.1.4.1.6.1 Psoralens
Psoralens belong to a family of natural products known as furocoumarins found in plants and 
cosmetics (Scott et ah, 1976) and is used therapeutically in several skin diseases. UVA light 
activates Psoralens to inducing thymine mono-adducts and ICLs between thymines. Both the 
wavelength and dose of UVA may influence the ratio of ICLs to mono-adducts Thus, up to 40% 
of adducts conversion to ICLs could take place via altering wavelength and dose of UVA 
(Brendel and Ruhland, 1984; Dronkert and Kanaar, 2001).
1.1.4.1.6.2 Platinum compounds
An example of platinum compounds is ds-Diamminedichloroplatinum (II) (cisplatin) which 
induces DNA damage mainly as intra-strand cross-links, mono-adducts and di-adducts, while 
ICLs between guanines are a minor product (Malinge et al, 1999). Carboplatin is another 
example of platinum compounds that induces mainly DNA damage as adducts similar to 
cisplatin adducts, with ICLs as a minor product (Blommaert et al, 1995). Another example; is 
transplatin also called trans-diamminedichloroplatinum (II) induces mainly both intra-strand 
cross-links and ICLs (Brabec and Leng, 1993).
1.1.4.1.6.3 Nitrogen mustards
Nitrogen mustards are bi-functional alkylating agents used widely in cancer chemotherapy. 
Nitrogen mustards induce inter-strand N7-N7 cross-links involving the two guanines also induce 
mono-functional guanine-N7 adducts (Povirk and Shuke, 1994). Intra-strand cross-links and
10
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DNA-protein cross-links are the major products of the DNA damage induced by nitrogen 
mustards and its derivatives while ICLs and mono-adducts are a minor product (Ewig and 
Kohn, 1977; Balcome et ah, 2004). Nitrogen mustards produce a number of lesions including; 
DNA-protein cross-links, N-7 guanine ICLs and guanine mono-adducts, (Dronkert and 
Kanaar, 2001). N-3 adenine adducts are also produced by the aromatic mustards Melphalan and 
chlorambucil (Povirk and Shuke, 1994).
1.1.4.1.6.4 Nitrosoureas
Nitrosourea compounds are DNA alkylating agents that act on several sites within DNA such as 
N3 of the cytosine and O6 and N7 of the guanine and N1 of the adenine (Goth and Rajewsky, 
1974; Kramer et ah, 1974; Tong and Ludlum, 1979; Bodell et ah, 1988). Bis-chloroethyl- 
nitrosourea (BCNU or carmustin) is an example of nitrosoureas which post metabolic activation 
forms guanine-cytosine ICLs, guanine intra-strand cross-links and guanine and cytosine mono­
adducts. In addition, BCNU produces DNA-protein cross-links and DNA strand breaks. The 
BCNU carbamoylating activity attacks proteins as well (Dronkert and Kanaar, 2001; Ewig 
and Kohn, 1977). Thus a range of DNA lesions is produced by nitrosourea compounds such as 
DNA-protein cross-links, guanine-cytosine ICLs, guanine intra-strand cross-links and guanine 
and cytosine mono-adducts (Kramer et ah, 1974; Ewig and Kohn, 1978; Bodell et at., 1985; 
Bodell et ah, 1990).
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1.1.4.1.6.5 Diepoxybutane (DEB)
Diepoxybutane (1, 2, 3, 4-diepoxybutane) (DEB) produces a range of DNA lesions, including 
guanine-guanine, guanine-adenine DNA cross-links and mono-adducts (Tretyakova et al., 
1997a; Tretyakova et al., 1997b; Park et al., 2004), leading to point mutations and 
chromosomal aberrations (Cochrane and Skopek, 1994; Recio et al, 2001). DEB alkylation 
activity targets adjacent bases (Lawley and Brookes, 1967) and acts on N3, N6, N7, N1 of the 
adenine and N7 of the guanine (Tretyakova et al, 1997a; Tretyakova et al, 1997b; Park et al, 
2004).
1.1.4.1.6.6 Mitomycin C (MMC)
In the 1950s in the fermentation cultures of Streptomyces caespitosus a group of natural product 
antibiotics were discovered in Japan and were given the family name ‘mitomycins’ (reviewed by 
Champeil et al, 2010). The significant antitumor properties of these mitomycins were 
recognized soon following their isolation.
One member of the family ‘mitomycins’ is Mitomycin C Fig.1.2; isolated as blue-violet crystals 
in 1958, which demonstrates both antibacterial and antineoplastic activity. Mitomycin C is more 
effective than the previously isolated fractions (mitomycin A and B) (reviewed by Crooke and 
Bradner et al, 1976). Mitomycin C is utilized in clinical cancer chemotherapy owing to its 
antitumor antibiotic properties (Champeil and Tomasz, 2006). It has been shown to cause the 
formation of covalent DNA mono-adducts, DNA inter-strand and intra-strand cross-links 
through the mono-functionally and bi-functionally DNA alkylation (Tomasz and Palom, 1997).
12
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This covalent linkage is generally irreversible. These DNA lesions, adducts (Bizanek et al, 
1993) and cross-links (Fracasso and Sartorelli, 1986; are assumed to be primarily responsible 
for MMC observed cytotoxcic biological effect to cancerous cells, especially when the formation 
rate of ICLs demonstrates correlation with MMC cytotoxicity and that inter-strand cross links 
(ICLs) are more accountable than mono-adducts (Palom et al, 2002) or intra-strand cross links 
for cellular death (reviewed by Deans and West, 2011). In 2011 Deans and West reviewed how 
ICLs may be repaired via complex networks of DNA repair processes.
In the 1960’s MMC Japanese clinical trials were reviewed and further experimentation to refine 
MMC dosage had been conducted until MMC became commercially available in 1974 in 
America (reviewed by Crooke and Bradner et al, 1976).
MMC becomes activated via chemical or enzymatic reduction (Tomasz and Lipman, 1981) 
generating an electrophilic center which interacts with DNA, triggering the formation of a 
second electrophilic center for a second interaction with DNA (Tomasz et al, 1987). The minor 
and major grooves of DNA at N and N positions of guanine respectively are the sites of MMC 
action (Tomasz et al, 1986; Prakash et al, 1993).
Reports by (Paz et al, 2008; Champeil and Tomasz, 2006) point out that despite current 
knowledge of the six main adducts produced by MMC in the process of alkylating and creating 
cross-links in DNA strands, further work is required to study these adducts. They propose 
alternative methods in this cause such as an altered organic synthetic assay (Champeil and 
Tomasz, 2006) or a mass spectrometry assay (Paz et al, 2008) in order to achieve better 
understanding of these adducts. When in aqueous solution mitomycin C becomes inactivated by
13
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direct light hence the precautions one must consider when using MMC solution in laboratory 
experiments (Yajima and Mizunoya, 1981).
Oxidative stress effect is more pronounced in producing chromosomal aberrations in MMC 
treated FA cells (Joenje and Oostra, 1983). If left unrepaired, DNA lesions such as DSBs can 
lead to cell cycle arrest, apoptosis, or cell death caused by loss of genomic integrity. If repaired 
incorrectly, they can lead to carcinogenesis through translocations, inversions, or deletions
(Rothkamm et aL, 2003).
14
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1.1.4.2 Radiation Mutagens
Ultraviolet, Gamma rays and X-ray are high energy radiation which results in a variety of DNA 
lesions.
1.1.4.2.1 Ultraviolet (UV) radiation
Bonds between adjacent pyrimidine bases on the same strand are found in most UV 
photoproducts. UVB rays directly damage DNA via pyrimidine dimers fonnation. DNA 
polymerase misinterprets these dimers as two adenine bases throughout replication, thus 
inserting two thymine bases in its place.
Squamous cell carcinoma of the skin has been linked to ultraviolet light excessive exposure. 
(Brash et ah, 1991). Mutation of tumor suppressor gene (the p53) has been attributed mostly to 
(UVB) and linked with 58% of squamous cell carcinomas of the skin (Brash et at, 1991).
1.1.4.2.2 Pyrimidine dimerization
Pyrimidine dimers are structurally altered DNA bases due to the fonnation a cyclobutane ring 
between two successive pyrimidines. These dimers inhibit the action of polymerase III and the 
replication fork movement. Cytosine or thymine bases in DNA can fonn pyrimidine dimers, 
which are molecular lesions formed through photochemical reactions (Goodsell, 2001). 
Ultraviolet light induces the formation of covalent bonds and induces the fonnation of 
pyrimidine dimers, (Goodsell, 2001). Cyclobutane pyrimidine dimers (CPDs, including thymine 
dimers) and 6, 4 photoproducts are two common UV products (Brash et ah, 1991). These 
premutagenic lesions alter the structure of DNA and consequently inhibit polymerases and arrest
16
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replication. Pyrimidine dimers may be repaired and neutralized by photo-reactivation or 
nucleotide excision repair (Whitmore et ah, 2001; Goodsell, 2001) and unrepaired dimers 
remain mutagenic.
1.1.4.2.3 X-rays
Genetic mutations may arise by direct or indirect exposure of low doses of X-ray radiation. After 
cellular exposure to radiation, genomic instability may be induced and transmitted to following 
generation of cells through cellular replication. (Giovanetti et aL, 2008). It has been reported 
that phosphorylation of a histone protein, H2AX, occurs in places of DNA double-strand breaks, 
post exposure to X-ray radiation (MacPhaii et al.> 2003). This phosphorylation event precedes 
the enzymatic repair action that takes place at these sites of DNA damage.
Free radicals produced by X-ray radiation modify the DNA in living cells (Ratnapalan et ah, 
2008). These extremely reactive free radicals are able to penetrate cells to react with other 
compounds producing other radicals leading to a chain reaction throughout the organism 
(Gordy, 1958). Lesions are formed when these radicals react with a base pair. As the gene with 
the lesion undergoes a number of replication cycles, a mutation results from that lesion. These 
mutations may be genn line or somatic mutations. Germ-line mutations are inherited, while 
somatic mutations are not, as somatic cells do not produce gametes.
17
Abdulaziz Aladwani PhD
1.2 DNA repair pathways 
1.2.1 DNA repair mechanisms
DNA repair involves both the removal of incorrect or damaged bases, and DNA re-synthesis by 
DNA polymerases utilizing as a template the undamaged strand.
1.2.2 Base excision repair (BER)
The removal and replacement of single base residues is established usually by base excision 
repair (BER). Substrates comprise damaged DNA bases and uracil residues resulting from 
methylation, reactive oxygen species and hydrolytic reactions. A particular DNA glycosylase 
eliminates single damaged bases. An endonuclease (APEX1) incises the resulting apurinic or 
apyrimidinic abasic site and a deoxyribose-phosphate (dRP) lyase removes the 5'- dRP residue 
producing a one nucleotide gap which is filled later via the action of DNA polymerase |3 (Pol (3) 
(Lange et al, 2011).
1.2.3 Nucleotide excision repair (NER)
Identification of bulky deformations in the DNA double helix is achieved by nucleotide excision 
repair enzymes which also remove the deformed short single-stranded DNA segment enclosing 
the lesion, leaving a single-strand gap in the DNA, which is filled later via the action of DNA 
polymerase using the undamaged strand as a template.
18
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Once the deformed DNA segment is identified, the damaged DNA adduct is excised via two 
incisions made on either side. Polymerases; Pol 8 or Pol £ and Pol k fill the resulting 27-29 
nucleotide gap. A range of helix-distorting adducts, such as those caused by polycyclic aromatic 
hydrocarbons, UV radiation and cisplatin and are removed by NER (Lange et al., 2011).
1.2.4 Mismatch repair (MMR)
Mismatched bases are repaired by an excision repair process termed Mismatch repair (MMR) 
which starts via mismatch identification proteins recognizing mismatches. Following DNA 
segment excision, Pol 5 fills the resulting DNA gap (Lange et ah, 2011).
1.2.5 Translesion synthesis (TLS)
TLS polymerases assist in tolerating DNA damage by bypass DNA lesions resisting the effects 
of DNA-damaging agents, enabling the reestablishment of stalled replication forks or filling in 
ssDNA gaps post DNA damage. Nevertheless, elevation in mutation frequency occurs in TLS 
(Waters et al, 2009). In translesion synthesis DNA lesions are bypassed via the incorporation of 
a nucleotide opposite to the lesion. Many specialized TLS polymerases that belong mostly to the 
Y family (Ohmori et aL, 2001) of DNA polymerases are utilized such as; Revl (Baynton et al, 
1999), Pol i (Zhang et al, 2000), Pol p (eta) (McDonald et al, 1999) and others. Also other 
polymerases from the B-family for example; Pol £ (zeta) (Nelson et al, 1996) and polymerase N 
also called Pol v from the A-family (Takata et al, 2006) and others.
19
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1.2.6 DNA DSBs Repair
Many external agents and spontaneous endogenous processes cause DNA damage continuously 
(Friedberg et al, 1995). An array of DNA lesions may be produced by an agent or a process; for 
instance, free radicals that induce numerous base alterations destroy deoxyribose residues and 
make single and double strand breaks, are generated by ionizing radiation (Frimmer et ah, 
1976), Ionizing radiation or enzymes that cleave DNA yield DNA ends that require processing or 
trimming and re-synthesis of bases in order to ligate these strand breaks. Many repair pathways 
operate to repair the dangerous DNA DSBs, mainly HRR and NHEJ (Lange et al, 2011; van 
Gent and van der Burg, 2007). An essential DNA DSBs repair process is the essentially error- 
free, precise mode of repair HRR which employs a homologous sequence at a comparable 
location on a sister chromatid as a template in repairing and restoration of the original sequence 
of the damaged chromosome (Jablonovich et ah, 1999). However, HRR may also employ allelic 
sequences at a comparable location on homologous chromosomes in resolving DSBs. This mode 
of allelic sequences employment in repair may be associated with loss of heterozygosity (LOH) 
thus the uncovering of recessive mutations (Lasko et al., 1991).
Genomic instability can arise through the accumulation of double stand breaks (Wyman et al, 
2008; O’Driscoll and Jeggo, 2006).The most severe form of DNA damage is perhaps DSBs due 
to the consequences that they have on the progress of transcription, replication, and chromosome 
segregation. Chromosomal instability leading to abnormal gene expression and carcinogenesis 
may result if DSBs fail to be repaired (Hoeijmakers, 2001). HRR and NHEJ are the DNA repair 
mechanisms standing out in the literature as possible repair pathways for DNA double strand 
damage (Rothkamm et al, 2003; van Gent and van der Burg, 2007; Wyman et al, 2008; 
Wyman and Kanaar, 2006).
20
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1.2.6.1 DNA repair through Homologous recombination repair (HRR)
It seems that to repair these DSBs, cells have evolved these two distinct pathways: homologous 
recombination (HR) Fig.1.3 and non-homologous end joining (NHEJ) (Jackson, 2002). Most 
HR-based repair occurs at late S- and G2-phases of the cell cycle when an undamaged sister 
chromatid is accessible and can be used as a repair template. The RAD52 epistasis group of 
proteins (RAD50, RAD51, RAD52, RAD54, and MRE11) is involved in mediating this process 
(Sonoda et al., 2001). RAD52 protein is probably, the initial sensor of the damaged DNA ends. 
Processing of the damaged ends produces of a new 3' single-stranded DNA (ssDNA) overhangs 
which bound by RAD51 to form a nucleoprotein filament. Accessory factors in filament 
assembly and subsequent RAD51 activities include: RPA, RAD52, RAD54, BRCA1, BRCA2, 
and several additional RAD51-related proteins (Jackson, 2002). BRCA2 loads RAD51 onto 
ssDNA then, RAD51 nucleoprotein filament identifies the undamaged DNA on the sister 
chromatid to use as a template for homologous repair. Following that DNA strand exchange 
occurs, where the damaged DNA strand invades the undamaged DNA duplex. A DNA 
polymerase then extends the 3' end of the invading strand and subsequent ligation by DNA 
Ligase I produces a heteroduplexed DNA structure. By resolving this recombination 
intermediate, the error-free correction of the DSB completes. Eukaryotic resolvases are still hard 
to define, despite the recognition of many resolvases with Holliday junctions processing activity 
in prokaryotes. For example, whether or not RAD51C and XRCC3 are involved in Holliday 
junction resolution in mammalian cells is controversial (Sharan and Kuznetsov, 2007).
The homologous recombination mechanisms and their exact role in rebuilding stalled or broken 
replication forks are still widely unknown (Barre et al, 2001). A study by Barlow et al, (2008)
21
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in budding yeast suggests that the DNA repair machinery is able to differentiate between 
different types of DNA damage in G1 and by doing so it specifies the most appropriate repair 
pathway. The path to repair is dependent on the circumstances under which the DSB is generated 
such as the chemical structure of the DNA ends. This specificity was also suggested earlier by 
Wyman and Kanaar, (2006).
22
A
 m
od
el
 ill
us
tr
at
in
g D
SB
s r
ep
ai
r b
y e
rr
or
 fre
e h
om
ol
og
ou
s r
ec
om
bi
na
tio
n
Abdulaziz Aladwani PhD
cocnQ
a.'*->u
CUDc
C15
ec a
i
<Occ
CD
CO
_i
£
<u
Cdco
TD
CTO
JCyTOOts>
QO
23
Abdulaziz Aladwani PhD
1.2.6.2 DNA repair through non-homologous end joining (NHEJ)
Non Homologous End Joining (NHEJ) is the primary DSB repair process in higher eukaryotes. 
NHEJ involves the ligation of two DNA ends regardless of their homology to one another 
(Lewis and Resnick, 2000, Karran, 2000) and most frequently associated with processing or 
remodeling of the DNA broken ends before rejoining them. The DSBs presence in the cell can 
lead to the joining of DNA ends that are located on two different chromosomes through NHEJ 
mechanism. Therefore, NHEJ is error-prone and is normally coupled with genomic 
rearrangements such as translocations and or deletions.
Error prone NHEJ Fig.1.4 requires no sequence homology to rejoin broken ends (O’Driscoll 
and Jeggo, 2006). Essential to the NHEJ pathway is the activity of the Ku70/Ku80 
heterodimeric protein (Featherstone et al, 1999). NHEJ is initiated through the Ku heterodimer 
by binding to the free ends of the DNA and recruiting DNA-dependent protein kinase (DNA- 
PK), XRCC4, and DNA Ligase IV and other NHEJ factors to the site of DNA damage (Jackson, 
2002). Upon binding to the DNA, DNA-PK is activated. It is thought that the activated DNA-PK 
then further facilitate the repair process by phosphorylating p53, Ku, and the DNA Ligase IV 
cofactor XRCC4. Limited processing of the damaged DNA strand ends are needed by nucleases 
and/or polymerases before NHEJ can proceed. The nucleases responsible for this step are 
unknown. Ligation is the final step in NHEJ repair involving joining the DNA ends by Ligase IV 
in a complex that includes XRCC4 and Ku as well.
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1.2.7 Causes and repair of Inter-strand cross-links
1.2.7.1 Causes of ICLs occurrence in prokaryotes and eukaryotes
Both genomic and cellular integrity are compromised by DNA ICLs as they block replication by 
forming covalent links between the two DNA strands that form the double helix, thus preventing 
essential genome maintenance and transcription proteins from translocating along the DNA 
strands. In bacteria or yeast, cellular death may result from a single, unrepaired ICL (Lawley 
and Brookes, 1968; Grossmann et aL, 2001). In mammalian cells which are unable to repair 
ICLs, 20 or more ICLs per genome are enough to bring about their death (Lawley and Phillips, 
1996). DNA ICLs may be produced due to exposure to endogenous, exogenous or naturally 
occurring compounds. One chief source of endogenous stresses that provoke endogenous DNA 
damage is sugar moieties and base oxidation (Barnes and Lindahl, 2004). The endogenous ICL 
formation is difficult to study due to its rarity, however evidence from in vitro studies support 
their occurrence (reviewed in Pang and Andreassen, 2009). Endogenous ICL may form due to 
malondialdehyde, which is an endogenous metabolic product that forms through lipid 
peroxidation, (Niedernhofer et aL, 2003). ICLs may be introduced through toxic, exogenous 
chemicals such as nitrogen mustard, cisplatin and mitomycin C compounds which are frequently 
used in certain cancers as chemotherapy (reviewed in Scharer, 2005). ICLs may also be 
produced by the action of psoralen- related furocoumarins or Photoactive furocoumarins which 
are naturally occurring compounds found in small quantities in numerous plants such as parsley 
leaves, a Nile Valley weed called Ammi majus (Umbelliferae), or Psoralea corylifolia 
(Manderfeld et at, 1997; Scott et aL, 1976). To survive this ICLs blockade and restore essential 
DNA maintenance processes, cells have to proficiently identify and eliminate this DNA lesion 
(ICLs).
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1.2.7.2 ICL repair
Replication forks are stalled by ICLs and the FA pathway is activated as shown in Fig.1.5. 
FANCG recruits endonucleases that are involved in the incision step of cross link repair. A 
double strand break is produced as an intermediate structure of this repair process and this 
eventually leads to the formation of ssDNA which activates the ATR complex and its binding
partners: a biological clock gene (elk-2) (HCLK) and ATRIP. FANCM helicase is recruited by
HCLK to the site of damage. FANCM helicase binds to and stabilises the replication fork then 
recruits and loads the FA core complex to chromatin at the lesion site (Deakyne and Mazin, 
2011; Kitao and Takata, 2011). The FA core complex then recruits the FANCI-FANCD2 (FA- 
ID) complex to the site of damage by FANCI and FANCD2 mono-ubiquitination permitting FA- 
ID complex phosphorylation and activation by ATR. The crosslink is then excised by the FA-ID 
complex and FAN1 (Liu et at, 2010) allowing lesion repair via translesion polymerases. 
FANCG interacts with other downstream proteins including FANCN, FANCD2, FANCJ, 
BRCA1, BRCA2, RAD51 to initiate DSB repair via HRR and restart the replication fork as 
shown in Fig.1.5 (Deakyne and Mazin, 2011).
The initial, two incision events occur in cross-links repair on the DNA strand flanking the ICL at 
stalled replication forks catalysed by XPF-ERCC1, MUS81-EME1 or FAN1 nuclease as shown 
in Fig.1.6 (Smogorzewska et aL, 2010; Kee and D’Andrea, 2010; Kitao and Takata, 2011). 
Then bypass synthesis follows the repair of the DNA lesion via the action of a translesion 
polymerase, probably Revl (Simpson and Sale, 2003; Niedzwiedz et alf 2004; Kitao and 
Takata, 2011) and possibly other translesion polymerases such as Rev3, Rev7 and PolN, 
(Lehmann et aL, 2007; Raschle et aL, 2008; Moldovan et aL, 2010; Zietlow et aL, 2009). 
Another two more incisions take place following bypass synthesis, permitting ICL lesion
27
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excision as shown in Fig.1.6. The ubiquitinated ID complex is critical for the occurrence of the 
incision and the bypass polymerase activity (Raschle et al, 2008; Knipscheer et al, 2009; 
Kltao and Takata, 2011). Homologous recombination machinery then repairs the initial cleaved 
strand (Section 1.4.7.1 for more details). Although the details of the nucleases implicated in ICL 
repair are still unclear, XPF-ERCC1 and Mus81 complexes have been pointed out as complexes 
connected to the nuclease activity accountable for the incision and excision action in ICL repair 
(Ciccia et al., 2008). Also recently, FANCP also known as SLX4 has been implicated in the 
nuclease action in ICL repair. SLX4 interacts with endonuclease complexes, such as MUS81- 
EME1 and XPF-ERCC1 and combines with SLX1 to form a Holliday junction resolvase (Kim et 
al, 2011, Stoepker et al, 2011). Whether conferring resistance to DNA cross-links is due to 
SLX4 activity or SLX4 activity is not clear yet (Fekairi et al, 2009; Munoz et al, 2009; Saito 
et al, 2009; Svendsen et al, 2009). Homologous recombination machinery then repairs the 
double strand breaks generated. Unresolved questions in the FA pathway include questions 
related to the nature of the role of ubiquitination and the mechanistic role the ID complex in 
regulating repair. Is it a structural role sustaining the complex at sites of DNA damage, or a role 
in repair factors recruitment? Also unknown are the enzymatic factors involved in lesion repair 
and if other ICL repair pathways exist in the absence of FA (Smogorzewska et al, 2010).
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1.3 Instability Syndromes
1.3.1 Instability syndromes and cancer
Defective genes responsible for chromosome breakage syndromes such as the FA-associated 
genes, NBS1, ATM and ATR (ataxia telangiecasia and RAD3 related) work through intricate 
networks in response to DNA damage sustaining chromosomal stability throughout the cell 
cycle (Eyfjord et aL, 2005). Elevated cancer susceptibility is evident in many instability 
syndromes which show sensitivity to a number of DNA damaging agents (Eyfjord et al., 2005, 
Lindh et al, 2006; Van der Heijden et al, 2004). Cell transformation which is a precursor of 
cancer may result if genome integrity is lost. The normal functionality of several tumor 
suppressor genes is connected to the regular DNA repair process (Eyfjord et al, 2005, 
Smogorzewska et al, 2007).
1.3.2 Centrosome instability and telomere dysfunction
It has been suggested that the origins of genetic instability may be related to telomeric 
dysfunction (Pathak et al, 2002). Throughout life, the normal cell-ageing process produces 
shorter telomeres as age progresses. As cellular DNA repair rate fails to compensate efficiently, 
the natural DNA damage occurring throughout the aging process, complex chromosomal 
aberrations, genome instability and cancer may result. Whether this is due to DNA damage 
accumulating or other molecular or physiological processes is controversial (DePinho et al., 
2000, Maser et al, 2003).
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Telomeric erosions were proposed to be the initial structural aberrations initiating genetic 
instability (Maser et ai, 2003, Feldser et al., 2003). As shown in Figure 1.7; a cascade of 
events follows telomeric DNA erosions: starting from secondary structural aberrations such as 
dicentric or ring chromosomes, followed by endomitosis and centrosomal amplification, 
chromosomal aneuploidy induction and finally cancerous tissue formation (Pathak et al., 2002, 
Lingle et al., 2002, Eyfjord et al, 2005).
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1.4 Fanconi anaemia
In 1927, a Swiss pediatrician noted the presence of “perniziosiforme anaemia” (macrocytic red 
cells and pancytopenia) along with several physical anomalies in 3 siblings and described the 
first cases of Fanconi anaemia (Shimamura and Alter, 2010). Fanconi anaemia diagnostic 
criteria today doesn't simply require the presence of aplastic anaemia and birth defects, but are 
much more extensive, and requires the illustration of chromosomal aberrations in cells cultured 
with mitomycin C induced chromosomal breakage test (Tonnies et at, 2003; Talwar et ah, 
2004; Ameziane et al, 2008).
1.4.1 Fanconi anaemia mode of Inheritance
Fanconi pancytopenia, or Fanconi anaemia, is mainly an autosomal recessive chromosomal 
instability syndrome with an incidence of approximately one to three per 105 live births 
(Schroeder et al., 1976) and a heterozygote frequency of about 1 in 300 in Europe and the 
United States (Swift, 1971). The Fanconi anaemia (FA) carrier frequency is remarkably high in 
the Ashkenazi Jewish population (Kutler and Auerbach, 2004). Fanconi anaemia is associated 
with progressive bone marrow failure and an elevated cancer risk, particularly solid tumors and 
acute myelogenous leukemia (AML) (Joenje and Patel, 2001; Tischkowitz and Hodgson, 
2003; Van der Heijden et al, 2004; Swift, 1971).The one exception to FA being autosomal 
recessive is FANCB, as this gene is found to be localized at Xp22.31 on the X chromosome 
(Meetei et al, 2004a). Mutations in FANCB are inherited in an X-linked manner making FA
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both an autosomal recessive and an X-lmked heritable disease. FA carriers are asymptomatic and 
are not identified by the either DEB or MMC test.
1.4.2 Fanconi anaemia clinical manifestations
FA clinical manifestations include pre- and postnatal developmental retardation, hearing loss, 
hypogonadism and reduced fertility, kidney, heart and skeleton malformations, absent or 
abnonnal thumbs, a typical 'elfin' facial appearance, caused by microcephaly, small eyes and 
mouth and cutaneous abnormalities such as hyper-pigmentation or hypo-pigmentation 
(reviewed by Joenje and Patel, 2001). Chromosomal instability and hypersensitivity to DNA 
cross-linking agents is characteristic of FA cell lines (Joenje and Patel, 2001). More FA clinical 
manifestations are illustrated in Table 1.1.
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1.4.3 Fanconi anaemia diagnosis and hypersensitivity to inter-strand 
cross-linking agents
Fanconi anaemia (FA) cells are characterized by their cellular hypersensitivity to DNA inter­
strand cross-linking (ICL) agents (Busch et aL, 1996; Wilson et al., 2001; reviewed by Joenje 
and Patel, 2001; Taniguchi and D’Andrea, 2006; Moldovan and D’Andrea, 2009). This 
hypersensitivity is reflected at the level of the chromosome allowing Fanconi Anaemia (FA) to 
be diagnosed by cytogenetic testing for increased chromosomal breakage or rearrangement in the 
presence of bi-functional alkylating (inter-strand cross-linking) agents such as mitomycin C 
(MMC) and diepoxybutane (DEB) (Sasaki and Tonomura , 1973; Cervenka et al, 1981, 
Auerbach and Wolman, 1976; Auerbach, 1993; Esmer et al, 2004).
Typically the induced cytogenetic aberrations are predominantly chromatid exchanges such as 
triradials and quadri-radials due to inability to repair cross-links produced by these agents (Kuhn 
and Therman, 1982; Busch et al, 1996; Joenje and Patel, 2001; Moldovan and D’Andrea, 
2009).
The clinically diverse disorder FA should be confirmed at the cellular level by means of a 
mitomycin C induced chromosomal breakage test (Tonnies et al, 2003; Talwar et al, 2004; 
Ameziane et al, 2008) which is a cytogenetic test facilitating the diagnostic differentiation 
between FA and similar disorders such as "idiopathic" Aplastic anaemia. This method is based 
on the effect of the alkylating agent mitomycin C (MMC) on chromosomes of peripheral 
lymphocytes in culture. At higher concentrations of MMC, elevated rates of CA are observed 
along with reduced mitotic activity in FA lymphocytes compared to average values of either 
healthy control or aplastic anaemia cells (Cervenka J, et al; 1981). FA clinical and cellular 
features can result from any disorder within the FA pathway (Kennedy and D'Andrea, 2005).
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1.4.4 Fanconi anaemia pathway
The FA pathway promotes the repair of crosslink damage and other types of DNA damage. So 
far, fifteen FA genes have been reported; [A, B, C, D1 (BRCA2), D2, E, F, G, I, J 
(BMP 1/BACH 1), L, M, N (PALB2), O (RAD51C), and P (SLX4) (reviewed by Thompson and 
Hinz, 2009). however the range of many of their protein functions or the intricacy of their 
interactions remains to be determined (Levitus et al, 2006). Despite FANCD2 lacking any 
recognizable domains that are found in DNA-repair molecules, its mono-ubiquitination is crucial 
in the FA-BRCA network. The concentration of mono-ubiquitinated FANCD2 increases when 
cells are either engaged in DNA replication or exposed to DNA-damaging reagents (Garcia- 
Higuera et al, 2001; Taniguchi et al, 2002b). Various elements in the FA pathway are still 
unknown (Kennedy and D’Andrea, 2005). Schematic illustrations of the FA proteins involved 
in upstream and downstream interactions are shown in Fig. 1.8 and Fig 1.9.
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1.4.5 The upstream FA pathway proteins
1.4.5.1 Fanconi anaemia core complex
The FA nuclear core complex is composed of eight FANG proteins (FANCA/B/C/E/F/G/L/M 
proteins) accompanied by FANG associated polypeptides FAAP24 and FAAP100 (Ciccia et aL, 
2007). This core complex and the presence of FANCI are required for the mono-ubiquitination 
of FANCD2 through the activity of the E3 ubiquitinase ligase (FANCL) (Meetei et aL, 2004b; 
Levitus et aL, 2006, Sims et aL, 2007, Smogorzewska et aL, 2007). The upstream FA proteins 
are the FA core complex proteins and these are presented below.
1.4.5.1.1 FANCA
FANCA is located at chromosome number 16 on locus 16q24.3 encoding for FANCA protein as 
shown in Table 1.2. FANCA is a phospho-protein and a component of the FA core complex. 
FANCA is phosphorylated following DNA damage (Wang, 2007a). Collins et aL, (2009) 
suggested that ATR kinase may phosphorylate FANCA at serine 1449. FANCA pathologic 
mutations are various and highly variable among different populations (Levran et aL, 1997, 
Morgan et aL, 1999, Wijker et aL, 1999) (Section 1.4.8 for more details about FANCA).
1.4.5.1.2 FANCB
FANCB also known as FAAP95 encodes for FANCB protein. FANCB is located at the X 
chromosome on locus Xp22.31 as shown in Table 1.2. Mutations in FANCB are inherited in an 
X-linked manner (Meetei et aL, 2004a). FANCB is a component of the FA core complex and 
contains a putative bipartite nuclear localization sequence (NLS) (Meetei et aL, 2004a; Wang, 
2007a).
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1.4.5.1.3 FANCC
FANCC is located at chromosome number 9 on locus 9q22.3 encoding for FANCC protein as 
shown in Table 1.2. FANCC is a component of the FA nuclear core complex, nevertheless it can 
also be found in the cytoplasm and may have cytoplasmic functions (Yamashita et al.f 1994; 
Wang, 2007a).
1.4.5.1.4 FANCE
FANCE is located at chromosome number 6 on locus 6p22-p21 encoding for FANCE protein 
which is a component of the FA core complex as shown in Table 1.2. FANCE directly binds to 
FANCD2 and is phosphorylated by CHK1 post DNA damage (Wang, 2007a). Theoretically, 
FANCE has a phospho-dependent role as a shuttle protein between FANCD2 and the nuclear FA 
core complex (Wang, 2007a).
1.4.5.1.5 FANCF
FANCF is located at chromosome number 11 on locus lip 15 encoding for FANCF protein 
which is a component of the FA core complex (de Winter et ah, 2000a; de Winter et al, 
2000b; Garcia-Higuera et al., 2001) as shown in Table 1.2. FANCF is regarded as an agile 
adaptor protein for the FA core complex assembly (Leveille et al., 2004). The N-terminus of 
FANCF has been found to be important for FANCC/FANCE binding also stabilizes 
FANCA/FANCG interaction. Through its C-terminus, FANCF is able to directly interact with 
FANCG (Leveille etal, 2004).
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1.4.5.1.6 FANCG
FANCG is located at chromosome number 9 on locus 9pl3 encoding for FANCG protein which 
is a component of the FA core complex as shown in Table 1.2. FANCG mutations are various 
and highly variable among different populations. Some populations may hold specific mutations 
(Demuth et ah, 2000, Nakanishi et al, 2002). FANCG consists of seven tetratricopeptide repeat 
motifs (TPRs) (Blom et al, 2004). FANCG is a phospho-protein with phospho-sites at serines 7, 
383 and 387. FANCG serines 383 and 387 are essential for FANCG exclusion from chromatin 
in mitosis and are phosphorylated most likely by cdc2 in the M phase of the cell cycle (Mi et al, 
2004). FANCG phospho-site (serine 7) is phosphorylated post DNA damage (Qiao et al, 2004). 
FANCG complexes with FANCD1, FANCD2, and XRCC3 forming the G-BRCA2 complex 
implying that FANCG plays several roles in DNA repair processes as it is found to be part of 
several complexes such as the FA core complex, the G-BRCA2 complex (Wang et al, 2007b) 
and the G-XPF complex (Wang and Lambert, 2010) (Section 1.4.7 for more details about 
FANCG).
1.4.5.1.7 FANCL
FANCL is located at chromosome number 2 on locus 2pl6.1 encoding for FANCL protein which 
is an E3 ubiquitin-protein ligase. This E3 ubiquitin ligase activity is vital for mono-ubiquitination 
of the FA-ID complex (Wang, 2007a). FANCL is a component of the FA core complex as 
shown in Table 1.2 (Meetei et al, 2003) and is assumed to be the FA core complex catalytic 
subunit for FANCI and FANCD2, UBE2T (E2 ubiquitin conjugating enzyme) directly interacts 
with FANCL (Machida et al, 2006).
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1.4.5.1.8 FANCM
FANCM is located at chromosome number 14 on locus 14q21.3 encoding for FANCM protein 
which is a component of the FA core complex as shown in Table 1.2. FANCM is a phospho- 
protein that is phosphorylated post DNA damage and participates with, a FANCM binding 
protein (FAAP24) in a checkpoint regulation in response to DNA damage (Huang et al, 2010).
It is arguable whether people with FANCM mutations should be assigned in to a formal 
complementation group as only one reference cell line (family) has been recognized and that cell 
line had shown biallelic mutations in both FANCM and FANCA. Nevertheless, FA phenotype is 
obtained via knocking down FANCM in laboratory conditions (Singh et al, 2009).
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1.4.6 The downstream FA pathway proteins
1.4.6.1 FANCD1
FANCDl, also known as BRCA2 is located at chromosome number 13 on locus 13ql2.3 
encoding for FANCD1 protein as shown in Table 1.2 Breast cancer type two susceptibility 
protein (BRCA2) modulates homologous recombination repair (HRR) via RAD51 recombinase 
activity regulation (Davies et at, 2001; Moynahan et ah, 2001a; Moynahan et aL, 2001b; 
Wang, 2007a). FANCD1 plays other roles in cytokinesis regulation and stalled replication forks 
stabilization (Daniels et aL, 2004). FANCD1 works with RAD51 in processing DNA double 
strand break ends, where FANCD1 loads RAD51 onto ssDNA to repair these lesions. FANCD1 
is involved in other various sub-complexes with other FA proteins, such as FANCN, FANCG, 
and FANCD2 (Wilson et at, 2010; Xia et at., 2007). FANCD1 complexes with FANCG, 
FANCD2, and XRCC3 formulating the G-BRCA2 complex (Wilson et at., 2010).
1.4.6.2 FANCD2
FANCD2 is located at chromosome number 3 on locus 3p25.3 encoding for FANCD2 protein as 
shown in Table 1.2. FANCD2 has two isoforms; isoform (a) and isofonn (b) which give rise to 
functional and non-functional FANCD2 protein variants (Montes de Oca et at., 2005). FANCD2 
has shown to have a role in resection of ends surrounding cross-links in DNA lesion repair 
(Knipscheer et aL, 2009). Huang and D’Andrea (2010) illustrated that FANCD2 binds to 
FAN1 nuclease.
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FANCD2 is mono-ubiquitinated on lysine 561 via the FA core complex and is transported to 
chromatin fraction after ubiquitination, to form nuclear foci with RAD51, BRCA1, BRCA2 
(Taniguchi et ah, 2002b) and FANCI where the repair of DNA lesions is thought to takes place.
FANCD2 is a phospho-protein that is phosphorylated and mono-ubiquitinated post DNA 
damage. FANCD2 interacts with FANCI forming the FA-ID complex which seems to be the 
heart of the FA pathway. FANCD2 phosphorylation may be performed via ATM (Ho et al, 
2006) and possibly by ATR (Andreassen et aL, 2004) post DNA damage. CHK1 phosphorylates 
FANCD2 at serine 331 to bind BRCA2 (Zhi et al., 2009) (See Section 1.4.9 for more details 
about FANCD2).
1.4.6.3 FANCI
FANCI is located at chromosome number 15 on locus 15q25-q26 encoding for FANCI protein 
which is a component of the FANCI-FANCD2 (FA-ID) complex as shown in Table 1.2. FANCI 
is a phospho-protein that is phosphorylated and mono-ubiquitinated post DNA damage and is a 
partner for FANCD2 in the (FA-ID) complex. FANCI is mono-ubiquitinated on lysine 523 prior 
translocation to nuclear foci to co-localize with other proteins such as FANCD2, RAD51, 
BRCA1, and FANCD1. FANCI and FANCD2 function in a similar manner thus can be analyzed 
in the same way by assays involving cellular survival, mono-ubiquitination or DNA nuclear 
repair foci (Ishiai et al., 2008).
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1.4.6.4 FANCJ
FANCJ also known as BR1P1 (BRCA1 interacting protein C-terminal helicase 1) and has also 
been called BACH1 (BRCA1-associated C-terminal helicase 1). FANCJ is located at 
chromosome number 17 on locus 17q22 encoding for FANCJ protein as shown in Table 1.2. 
FANCJ is a phospho-protein that is phosphorylated post DNA damage. FANCJ is a S'-to-S1 DNA 
helicase (DEAH helicase) and a DNA-dependent ATPase which binds directly to BRCA1 
(Cantor et aL, 2001).
1.4.6.5 FANCN
FANCN is also known as the partner and localizer of BRCA2 protein (PALB2). PALB2 or 
FANCN is located at chromosome number 16 on locus 16pl2 encoding for FANCN protein as 
shown in Table 1.2. BRCA2 stability and nuclear localization requires FANCN as a central 
regulating partner (Wang, 2007a). As FANCN regulates FANCD1/BRCA2 stability and nuclear 
localization, then it plays a role in the HRR pathway (Xia et aL, 2007).
1.4.6.6 FANCO
FANCO also known as RADS 1C is located at chromosome number 17 on locus 17q22 encoding 
for RAD51C protein as shown in Table 1.2. RAD51C is a component of several distinct protein 
complexes involved in HRR. RAD51 C and RAD51 variants work with FANCD1 and bind to 
single strand overhangs arising post DNA lesion processing (Somyajit et aL, 2010). It is 
arguable whether people with FANCO mutations should be assigned to a formal
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complementation group since only one reference consanguineous cell line (family) has been 
recognized (Vaz et al., 2010).
1.4.6.7 FANCP
FANCP also known as SLX4 is located at chromosome number 16 on locus 16pl3.3 encoding for 
SLX4 protein as shown in Table 1.2. SLX4 is a scaffold for various DNA repair nucleases and 
seems to interact with endonuclease complexes, such as MUS81-EME1 and XPF-ERCC1 and 
appear to be connected to the resolution of homologous recombination intermediates, for 
example; Holliday junctions (Kim et al, 2011, Stoepker et at, 2011). It is arguable whether 
people with FANCP mutations should be assigned to a formal complementation group since only 
few reference families have been recognized (Kim et aL, 2011, Stoepker et al., 2011).
1.4.7 Fanconi anaemia FANCG
1.4.7.1 FANCG and its role in the FA pathway
Fanconi anaemia, complementation group G (FANCG) is located on the short arm of 
chromosome 9 coding for a 68 kDa protein (Wang, 2007a). FANCG represents one of fifteen 
complementation FA groups that have been confirmed to date [A, B, C, Dl, D2, E, F, G, I, J, L, 
M, N, O, and P] (reviewed by Thompson and Hinz, 2009). These complementation groups can 
be recognized through the identification of the cDNA of the FA-related genes (Pulsipher et al, 
1998; Chandra et al, 2005).
The FA nuclear core complex is composed of eight FANG proteins (FANCA/B/C/E/F/G/L/M 
proteins) accompanied by FANG associated polypeptides FAAP24 and FAAP100 (Ciccia et al,
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2007). As shown in Fig.1.10; this entire core complex including FANCG and the presence of 
FANCI are required for the mono-ubiquitination of FANCD2 through the activity of the E3 
ubiquitinase ligase (FANCL) (Levitus et ah, 2006, Sims et al.9 2007, Smogorzewska et al., 
2007).
In addition to its function as part of the FA core complex, FANCG is thought to be involved in 
another independent protein complex. Thus it is likely to have functional roles in addition to that 
associated with the core complex. The G-BRCA2 complex as shown in Fig.1.10 which 
encompasses: FAN CD 1 /BRC A2-F AN CD2-F AN CG-XRCC3 (Wilson et al, 2008). It has been 
suggested that the homologous recombination repair (HRR) stage of the ICL repair process is 
modulated through a distinct complex G-BRCA2, which if any of its components is defective the 
promotion of HRR process will be compromised (Wilson et al, 2008). In addition FANCG may 
be present as a third complex Fig.1.10. Findings of Kumaresan et al, in 2007 supporting the 
failure of FA cells to proficiently produce incisions at the site of a cross-link combined with 
findings of Wang and Lambert in 2010 which demonstrated that FANCG binds directly to 
ERCC1-XPF endonuclease establishes the importance of FANCG protein in the unhooking step 
of the ICL repair pathway Fig.1.11. At the site of the ICL a structural protein termed non- 
erythroid R spectrin (RIISp) binds to the DNA, then FANCG binds to the SH3 domain of RIISp. 
Following FANCG-RIISp binding, ERCC1-XPF is recruited to the ICL by FANCG. Then the 
DNA on the 5' side of the ICL is incised by ERCC1-XPF unhooking the cross-link as shown in 
Fig.1.11 (Wang and Lambert, 2010).
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1.4.7.2 FANCG- tetratricopeptide repeat motifs (TPRs)
FANCG protein is thought to play a central role of complex assembly and/or stabilization (Blom 
et al, 2004) through the identification of seven tetratricopeptide repeat motifs (TPRs) Fig. 1,12. 
TPRs are degenerate 34-amino acid repeat motifs which function as scaffolds mediating protein- 
protein interactions, often found in multi-protein complexes. Studies showed that most FANCG 
TPRs are required for the interaction between FANCG and FANCA, confirming the structural 
importance of these TPR motifs (Blom et al, 2004). Further studies showed the requirement of 
these TPRs in the interaction of FANCG protein with other proteins that are involved in DNA 
damage repair (Hussain et at, 2006). Hussain et al (2006) illustrated by yeast-two-hybrid that 
the interaction of FANCG-FANCA, FANCG-XRCC3, BRCA2 N-terminal-FANCG and 
FANCG-FANCF required both TPRS and TPR6. TPR1 and TPR2 were required also for 
FANCG-FANCF interaction. Hussain et al, (2006) suggested that TPR1 and TPR2 most likely 
bind to BRCA2 C-terminus, thus recruiting XRCC3 and BRCA2 together in a protein complex. 
Co-immunoprecipitation experiments carried out later by Wilson et al, (2010) demonstrated 
using Chinese hamster FANCG mutant NM3 cell lines, that mutating TPR motifs TPR1, TPR2, 
TPRS and TPR6 at a conserved consensus residue compromised the FANCG in vivo binding 
activity leading to the inability to bring together the components or formulate either the FA core 
complex or the G- BRCA2 protein complex. These TPR FANCG mutants fail to interact with 
BRCA2, XRCC3, FANCA or FANCF proteins. Wilson et al, (2010) also demonstrated that 
despite the fact that TPR7 (R563E)-mutated FANCG protein co-precipitating with FANCA, 
BRCA2 and XRCC3, a mutation at TPR7 (R563E) is associated with reduced FANCG -FANCF 
interaction and leads to sub-optimal interactions of FANCG in the core complex and the G- 
BRCA2 complex explaining the encountered MMC and phleomycin hypersensitivity in NM3
53
Abdulaziz Aladwani PhD
cells. Wilson et al, (2010) data suggests the importance of FANCG role in mediating 
interactions linking proteins and hence the formulations of multi-protein complexes such as the 
FA core complex and the G- BRCA2 protein complex.
Wang and Lambert in 2010 showed by yeast two-hybrid experiments that FANCG had 
moderate affinity for XPF but great affinity for ERCC1. Wang and Lambert, (2010) 
determined using site-directed mutagenesis the requirement of TPRs 1, 3, 5, and 6 for binding of 
FANCG directly to ERCC1 which in turn binds to XPF via a different binding region from that 
of FANCG.
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1.4.7.3 FANCG protein is a phospho-protein, phosphorylated at mitosis 
at two amino acids, S383 and S387
FANCG is phosphorylated at mitosis (Qiao et at, 2001). In 2004, through the use of mass 
spectrometry analysis, kinase motif analysis and PCR-directed in vitro mutagenesis, Mi et aL, 
(2004) mapped the phosphorylation sites of FANCG at mitosis at two amino acids; S383 and 
S387 and confirmed their findings through utilizing phospho-specific antibodies Fig.1.12. Mi et 
alf (2004) evaluated the functional value of these phosphorylation sites and concluded that the 
phosphorylation of FANCG at mitosis is compromised in S383 and S387 mutant cells. Both 
mutants; S387A and S383A did not affect the binding ability of FANCG to FANCA (Mi et alt 
2004), suggesting the FA core complex presence, despite the notion that, in the case of 
FANCG(S387A) diminished stability of or reduced affinity for FANCA may have occurred 
(Garcia-Higuera et al, 2000). Mi et al, (2004) demonstrated that S387A mutant stopped 
FANCG phosphorylation by cdc2 and showed how the phosphorylation of FANCG participates 
in regulating the FA pathway which is tightly controlled through a chain of phosphorylation 
steps that are essential to its function generally. These FANCG mitosis phospho-mutants caused 
the inability of FANCG to correct FANCG mutant cells in either hamster or human cells (Mi et 
alt 2004). FANCG S383 and S387 amino acids are found in human, mouse and hamster. 
FANCG was first cloned from a CHO line hypersensitive to ionizing radiation and MMC (de 
Winter et alf 1998; Liu et al, 1997) therefore; the hamster would be an encouraging model to 
use in transgenic experiments for the expression of these FANCG mutants.
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1.4.7.4 FANCG is a phospho-protein phosphorylated at serine 7
FANCG protein is phosphorylated (Qiao et al, 2004; Qiao et al., 2001; Futaki et al, 2001). 
Using mass spectrometry analysis, Qiao et al., in 2004 identified a phosphopeptide at FANCG 
amino acid serine 7 determining that FANCG phosphorylation occurs at phosphoamino acid 
serine 7 Fig.1.12. Via PCR-mediated site-directed in vitro mutagenesis, Qiao et al., (2004) 
mutated serine 7 to alanine and employed CHO cells to observe that FANCG (S7A) partially 
correct FANCG mutant cells post MMC treatment and only wild-type FANCG cDNA fully 
corrected FANG mutant cells. Qiao et al, (2004) concluded that FANCG phosphorylation at 
serine 7 is functionally essential in the FA pathway. Notably, the FANCG (S7A) mutant is itself 
stable, binds to and stabilizes both FANCA and FANCC proteins via their interaction. As 
FANCG (S7A) was shown to localize to chromatin at damaged DNA sites (Qiao et al, 2004), 
the observed partial function in FANCG (S7A) could be explained by the stability in FANCG 
(S7A) interactions despite the fact that FANCG (S7A) like other FANCG mutant cells expresses 
increased nuclear bridges, especially post MMC treatment (Qiao et al, 2004). Inter-nuclear 
bridging is an event observed in cells exhibiting genomic instability.
Accumulating evidence indicate the involvement of FANCD2, FANCC (Niedzwiedz et al, 
2004), FANCA (Yang et al, 2005), FANCG and other FANC proteins in HRR (Taniguchi and 
D’Andrea, 2006). In 2003, 2004 and 2006, Hussain et al. demonstrated the occurrence of a 
direct interaction between the following pairs of proteins: FANCG-BRCA2; FANCD2-BRCA2; 
FANCG-XRCC3. XRCC3 gene encodes a member of the RecA/Rad51-related protein family, 
which is involved in HRR (Thacker, 2005). In 2008, Wilson et al. illustrated using human and 
hamster cells that for BRCA2-FANCD2 co-precipitation, FANCG protein is required unlike the 
other core complex protein. Wilson et al, (2008) also illustrated the requirement of FANCG
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serine 7 for the direct interaction of BRCA2-FANCD2 and for FANCG co-precipitation with 
BRCA2, XRCC3 and FANCD2. These findings in 2008 suggest an independent role of FANCG 
other than its role in the nuclear FA-core complex. It has been suggested that FANCG-(serine 7) 
phosphorylation is the signaling event required prior the formation of the G-BRCA2 complex 
which is suggested to be liable for promoting proficient HRR in DNA crosslink repair (Wilson et 
al, 2008). A role for G-BRCA2 complex in (HRR) is suggested by the Wilson et aL, finding, 
using DT40 chicken cells, in 2008 that FANCG and XRCC3 are epistatic for sensitivity to DNA 
cross-linking agents.
1.4.8 Fanconi anaemia FANCA 
1.4.8.1 FANCA protein
The FANCA gene has been mapped through linkage analysis to chromosome 16q24.3 (Pronk et 
al, 1995; Levran et al, 1997). About 60-66% of FA cases are caused by FANCA mutations 
(Buchwald, 1995; Gschwend et al, 1996; Faivre et al, 2000). Employing linkage and allelic 
association analysis, Apostolou et al, (1996) have isolated FANCA gene which encodes a 
protein that has no striking homology to any other known proteins, and was classified as a new 
class of genes connected to DNA damage prevention and repair. Through mutation analysis, 
Castella et al, (2011) revealed a wide FANCA mutational spectrum and argued that the lack of 
negative selection for biallelic FANCA mutations did not hinder human embryonic development 
which may partially explain the observed FANCA complementation group predominance among 
FA patients. The presence of high mutability or hyper-mutable region in FANCA may also 
explain FANCA mutations predominance (Wijker et al, 1999). Mutations in some FA genes
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have been associated with embryonic lethality, such as with FANCD2 as illustrated by van de 
Vrugt et al., (2009) using mouse model to study the effects of combined mutations in FANCD2 
and mismatch repair (Mlhl).
Magdalena et al, (2005), Callen et al, in 2005 and others (Savino et al, 2003; Tipping et al, 
2001; Tamary et al, 2000; Tachibana et al, 1999) demonstrated that specific FANCA 
mutations may be more predominant in different populations, however FANCA gene is highly 
polymorphic (Levran et al, 2005a), with over a hundred mutations reported, without a specific 
allele in other populations being outstandingly high, ruling out mutation screening as a 
conclusive diagnostic method (Savino et al, 1997; Levran et al, 1997). Nevertheless, the 
majority of, FA patients may be diagnosed employing mutation screening for FANCD2 protein 
mono-ubiquitination as the absence of the mono-ubiquitinated FANCD2 isoform in immunoblots 
correlates with a positive diagnosis of FA (Magdalena et al, 2005; Ameziane et al, 2008).
In order to farther characterize the role of FANCA in the repair process of both radiomimetic 
agent (phleomycin) induced damage (DNA strand breaks) and cross-linking agent (MMC) 
induced damage (DNA ICLs), the role of FANCA in maintaining chromosome stability in 
response to ICL was investigated using FANCA deficient cells. In doing so, the types of 
aberrations induced may give an insight into the role of the FANCA containing complex (FA- 
core complex) in these repair processes and the types of chromosome aberrations that may arise.
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1.4.8.2 FANCA is part of the multi-subunit nuclear complex (FA-core 
complex)
FANCA and FANCC proteins interact forming a cytoplasmic and nuclear complex in normal 
cells. FANCA and FANCC cooperate in perfonning a nuclear function through multi-subunit 
nuclear complex formation that has been illustrated by (Kupfer et al, 1997; Naf et ah, 1998) 
who suggested a function for this nuclear complex in chromosomal stability preservation. For 
binding between FANCA and FANCC to occur FANCG is required (Garcia-Higuera et al, 
1999) and FANCA, FANCC and FANCG are elements in this nuclear protein complex which is 
essential in preventing cellular and clinical phenotype seen in most FA complementation groups. 
The FANCA N-terminal nuclear localization signal is necessary for FANCC binding, FANCG 
binding, and for complementation of MMC sensitivity in FANCA lymphocytes, as well as for 
nuclear localization. Garcia-Higuera et al, (1999) findings suggested that the binding of 
FANCC needed both FANCA/FANCG binding and the products of other FA genes, while 
FANCA/FANCG interaction was constitutive and probably direct without the need to FANCC or 
any FA genes products for regulation.
1.4.8.3 FANCA protein interactions with a wide range of other proteins
A wide range of proteins interact with FANCA protein such as those mentioned earlier to form 
the FA core complex FANCG (Garcia-Higuera et al, 1999; Otsuki, et al, 2002; Taniguchi 
and D'Andrea, 2002), FANCC (Garcia-Higuera et al, 1999; de Winter et al, 2000a; Otsuki, 
et al, 2002; Taniguchi and D’Andrea, 2002; Meetei et al, 2003) , FANCF (de Winter et al, 
2000a; Meetei et al, 2003), FANCE (Taniguchi and D’Andrea, 2002; Meetei et al, 2003), 
BRCA1 (Folias, et al, 2002), or other proteins such as; SNX5 (Otsuki, et al, 1999),
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nonerythroid a spectrin(a SpIIZ) (McMahon, et al, 2001; Sridharan, et at, 2003), IKK2 
(Otsuki, et al, 2002) and DNA repair endonuclease XPF encoded by (ERCC4) (Sridharan, et 
al., 2003).
1.4.8.4 FANCA involvement in other complexes
Despite evidence implicating the involvement of FA proteins in DNA interstrand cross-links 
(ICLs) repair, the exact mechanism through which they act is still undetennined (Niedernhofer 
et al., 2005; Thompson and Hinz, 2009). Nevertheless, evidence suggests the interplay of a 
number of repair pathways such as; NER, HR, and translesion synthesis (TLS) in this repair 
process (Dronkert and Kanaar, 2001; Zheng et al., 2003; Thompson et al., 2005; Hanada et 
al, 2006). Studying inter-strand cross-links repair employing immunoprecipitation in 2003, 
Sridharan, et al, (2003) indicated that XPF and FANCA co-immunoprecipitated with aSpIIS. 
Using anti-FANCA and anti-XPF immunoprecipitation confirmed that aSpIIS, XPF and FANCA 
bind to one another which led Sridharan, et al, (2003) to propose a model for the involvement 
of FANCA with the structural protein nonerythroid a spectrin (aSpIII) and XPF in the nucleus 
suggesting a common nuclear functional relationship between these proteins where aSpIIE 
(alpha SpII Sigma), acts as a scaffold recruiting and organizing repair proteins at sites of DNA 
damage. Sridharan, et al, (2003) suggested that FANCA-XPF- aSpIIE complex has an 
important role in DNA inter-strand cross-links repair. The involvement of FANCG had also been 
suggested in this complex, repairing ICLs as early as 2001 as reported by McMahon, et al 
(2001) in human cells post MMC exposure. In 2010, Wang and Lambert (2010) 
demonstrated that FANCG binds directly to ERCC1-XPF endonuclease which is involved in
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ICLs unhooking as shown in Fig. 1.11 and argued that their findings did not support direct 
binding of FANCA to XPF.
1.4.8.5 FANCA protein is a phospho-protein phosphorylated at serine- 
1449
ATM (ataxia telangectasia mutated) and ATR (ATM and Rad3-related) regulate through 
phosphorylation the DNA damage response including the FA pathway which is controlled by 
ATR. Responding to exposed or naked ssDNA during replication stress, ATR is activated. 
However, it is not yet determined how ATR manages cell-cycle repair or cell-cycle arrest 
(McGowan and Russell, 2004). The mono-ubiquitination of FANCD2 post DNA damage is 
dependent on ATR (Andreassen et aLy 2004) and the phosphorylation FANCD2 is managed by 
both ATM (Taniguchi et al., 2002a) and ATR (Ho et ah, 2006).
The FA pathway is a heavily phospho-regulated pathway that requires phosphorylation to a 
number of components of the FA pathway such as phospho-proteins; FANCG (Qiao et aLy 2004; 
Mi et aly 2004), FANCM (Meetei et al, 2005), FANCE (Wang et al, 2007b), FANCD2 
(Taniguchi et aly 2002a), and FANCI (Smogorzewska et al, 2007), FANCA (Yamashita et 
aly 1998; Kupfer et at, 1999; Thomashevski et at, 2004). It was in 2009, when Collins et al, 
identified the amino acid position where phospho-protein FANCA is phosphorylated by possibly, 
ATR which may act as a FANCA kinase phosphorylating its binding partner, ATR interacting 
protein (ATRIP) so as to relocate ATR-ATRIP complex (Itakura et al, 2004) along with 
phosphorylated FANCA to chromatin (Thomashevski et aly 2004; Qiao et aly 2001). Unlike 
ATR, neither checkpoint kinase (CHK1) (Jackson et al, 2000), nor ATM activation is required 
for FANCA phosphorylation post DNA damage.
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Collins et al, (2009) illustrated the functional significance of FANCA phosphorylation in 
connection to normal FANCD2 mono-ubiquitination as part of a functional FA pathway. Normal 
levels of mono-ubiquitinated FANCD2 were diminished when FANCA phosphorylation was 
defective (Collins et al, 2009). Mass spectrometry was used to show that FANCA undergoes 
phosphorylation at serine amino acid in position 1449 and is localized to chromatin following 
induction of DNA damage, but not during S phase (Qiao et al, 2001). This is unlike other post- 
translational modifications of FA proteins which take place usually during the S phase (Collins 
et al, 2009).
Collins et al, (2009) findings pointed out that mutating FANCA at serine 1449 to alanine 
(SI449A) did not compromise FANCG-FANCA association indicating the presence of at least 
partially intact FA core complex in the phospho-defective cell line FANC-S1449A and FANCA 
(S1449A) exhibited MMC hypersensitivity. Using a mono-ubiquitinated FANCD2 assay Collins 
et al, (2009) found that post MMC exposure, FANCA (SI449A) cells illustrated reduced levels 
of mono-ubiquitinated FANCD2 compared to wild-type FANCA levels, confirming the 
functional importance of FANCA phosphorylation at SI449 in the FA pathway. This reduction 
in FANCD2-L was attributed to differences in the distribution of cells between the various cell 
cycle stages in the wild type and phospho-mutant cells, as FANCD2 is predominantly 
ubiquitinated in S-phase.
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1.4.9 Fanconi anaemia FANCD2 
1.4.9.1 FANCD2 protein
Extensively utilized for cell and molecular biology model of study are human fibroblasts 
immortalized by Simian Virus 40 (SV40) (Wood et al, 1987). In 1996 through chemical 
mutagenesis with ethyl methane sulphonate (EMS) of SV40 transformed primary fibroblasts, 
Jakobs et al. (1996). reported the generation of four immortalized FA fibroblast cell lines 
(PD20i, PD220i, PD224i and PD259i) which maintained their FA phenotype (Wood et al, 1987) 
and pointed out their potential to be used in cloning FANCA, FANCD genes and in functional 
studies as well as their practical use as the former (GM6914) isolated fibroblasts.
Timmers et al, (2001) findings illustrates the heterogeneity of Fanconi anaemia group D which 
include FANCD 1 and FANCD2 genes, thus, two distinct genes, BRCA2/FANCD1 and 
FANCD2 belong to the heterogeneous complementation group D up to this date. FANCD2, like 
other FA proteins has no recognized functional domains; however, FANCD2 is highly conserved 
in organisms such as Drosophila, A, thaliana, and C. elegans which can be easily employed for 
genetic study .While the lack of sequence homologs in FANCA, C, E, in non-vertebrates, made 
these genetic studies difficult to conduct. BRCA1 co-localizes and interacts with FANCD2 
(Garcia-Higuera et al, 2001). FANCD2 is part of at least two complexes in the FA pathway; 
the FA-ID complex comprising both FANCI and FANCD2 proteins and the G-BRCA2 complex 
comprising (FANCD2, FANCD 1, FANCG and XRCC3) proteins. FANCD2 consists of many 
phosphorylation sites that are thought to control and regulate its activities. In 2009, Knipscheer 
et al, (2009) illustrated FANCD2 resection function of the ends surrounding cross-links in DNA 
repair. Huang and D’Andrea et al, (2010), demonstrated the occurrence of FANCD2-FAN1
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binding. These facts, taken together make FANCD2 very interesting to study as it may further 
clarify the functional roles it plays along with the components of the FA pathway in DNA repair.
1.4.9.2 Functional and non functional FANCD2 isoforms
In 2005, Montes de Oca et al., identified two FANCD2 isoforms; [isofonn (a) and isoform (b)] 
producing a functional protein from (FANCD2 -isoform b with 44 exons) and a non functional 
protein from (FANCD2 -isoform (a) with 43 exons). The two FANCD2 proteins variants differ in 
their carboxy terminal 24 amino acids. The functional protein (FANCD2-44), depending on its 
mono-ubiquitination could be found either in its long fonn (FANCD2-L) or in its short non 
ubiquitinated form (FANCD2-S).
1.4.9.3 The mono-ubiquitination of FANCD2 and the FA-core complex
When DNA damage is encountered; FANCD2 is known to relocate to chromatin in a still poorly 
defined mechanism. Mono-ubiquitination of FANCD2 protein at (lysine 561) requires the FA- 
core complex, a conjugating enzyme (UBE2T) and FANCI. This FANCD2 mono-ubiquitination 
requires FANCE and FANCD2 proteins interaction (Pace et al., 2002; Taniguchi and 
D'Andrea, 2002) and this mono-ubiquitination is needed to translocate (FANCD2-L) to 
chromatin fraction, and form nuclear foci consisting of proteins such as RAD51, BRCA1, 
FANCD1 (Taniguchi et al., 2002b) and FANCI. Knowing the roles of RAD51, BRCA1 
(Moynahan et al, 1999) and FANCD1 (Moynahan et al, 2001a; Moynahan et al, 2001b) 
play in HRR; these foci are likely to be the sites of HRR in the nucleus. FA characteristic 
clinical and cellular features, including MMC hypersensitivity result from FA/BRCA pathway
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disruption (Auerbach et aL, 1989). FANCD2 seem to have a critical role in the FA-pathway as 
the core complex activates FANCD2 by mono-ubiquitination and translocates it to chromatin 
where it is thought to be involved in supporting DNA damage bypass and repair through TLS 
and HRR pathways (Thompson et aL, 2005; Wang, 2008).
1.4.9.4 FANCD2 mono-ubiquitination requirement for functional 
complementation and foci formation
Garcia-Higuera et aL, (2001) utilized PD20, PD20-K561R and PD20-D2WT cells to 
demonstrate the functional significance of mono-ubiquitination at lysine 561 in regulating the 
activity of FANCD2 and in FANCD2 foci construction. PD20-D2WT expressed both forms of 
FANCD2 (FANCD2-S and FANCD2-L), producing FANCD2 foci at DNA lesion sites and 
restoring cellular resistance to agents MMC and IR, while PD20-K561R cells failed to mono- 
ubiquitinate FANCD2 expressing only (FANCD2-S), did not produce FANCD2 foci at DNA 
lesion sites and had cellular hypersensitivity to agents MMC and IR. FANCD2 deficient (PD20) 
cells failed to express FANCD2 completely. Based on these results Garcia-Higuera et aL, 
(2001) concluded the importance of mono-ubiquitination of FANCD2 at lysine 561 in the FA 
pathway through FANCD2 nuclear foci formation and accumulation.
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1.4.9.5 FANCD2 phosphorylation by ATM and ATR and the role of 
CHK1 kinase
Post DNA damage FANCD2 phosphorylation can be carried by ATM (Taniguchi et ah, 2002a; 
Ho et al, 2006) and ATR (Pichierri and Rosselli, 2004 ; Andreassen et at, 2004) can 
phosphorylate FANCD2. FANCD2 serine 717 and threonine 691 are phosphorylated by ATR 
promoting FANCD2 mono-ubiquitenation (Ho et al, 2006). In 2009, Zhi et ah, (2009) 
suggested that serine 331 is phosphorylated by the S-phase checkpoint kinase (CHK1) in order 
for FANCD2- BRCA2 interaction to occur to sustain cellular resistance to mitomycin C. CHK1 
also phosphorylates FANCE threonine 346 and serine 374, an event which is vital for FANCD2 
mono-ubiquitenation (Wang et aly 2007b). Zhi et al., (2009) also suggested that S331 can be 
efficiently phosphorylated independently from either the FA-core complex or FANCD2 mono- 
ubiquitination and is critical for FANCD2 mono-ubiquitenation and the restoration of normal 
cellular phenotype post MMC exposure.
1.4.9.6 Hypersensitivity of FANCD2 mutant cells PD20, PD20-K561R 
and PD20-S331A to cross linking agent MMC
Montes de Oca et al., (2005) illustrated that PD20 and PD20-K561R had MMC hypersensitivity 
and explained that FANCD2 proteins produced by PD20 and PD20-K561R failed to become 
mono-ubiquitinated and thus failed to relocate and bind chromatin leading to the inability to 
correct the ICLs damage induced by MMC and restore the cellular phenotype to that observed in 
the corrected wild type. Montes de Oca et al., (2005) findings suggest that FANCD2 binding to 
chromatin is regulated through FANCD2 mono-ubiquitination and predicts that the FANCD2
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protein produced by FANCD2-isoform (b) has a carboxy terminus which may be important in 
DNA damage sensing or repair. Testing for in vivo phosphorylation of FANCD2 at S331 in 
2009, Zhi et ah, used FANCD2-deficient PD20 cells and their derivative mutants (K561R, 
S331A) and suggested serine 331 to be a phosphorylation site needed for FANCD2- BRCA2 
interaction to sustain cellular resistance to mitomycin C.
1.4.9.7 FANCD2 phosphorylation at S331 is critical for its in vivo 
interaction with FANCD1/BRCA2
Using yeast two-hybrid analysis in 2004, Hussain et ah, showed that FANCD2 did not interact 
with RAD51 also illustrated the binding of FANCD2 to a highly conserved carboxy terminus of 
FANCD1/BRCA2 and their coimmunoprecipitation in mammalian cells. Wang et al, (2004) 
stressed the importance of the FANCD1/BRCA2 conserved carboxy terminus in the interaction 
between FANCD2 and FANCD1. Wang et ah, (2004) also showed how FANCD2 mono- 
ubiquitination followed by its translocation to chromatin promoted FANCD1/BRCA2 loading 
into chromatin complexes which seems to be essential for HRR. FANCD1 directly interacted 
with RAD51 and thus has a role in HRR (Goodsell, 2005; Davies and Pellegrini, 2007; Esashi 
et ah, 2007). In 2008, Wilson et ah, (2008) demonstrated that FANCD2 and FANCD1 interact in 
vivo in core complex mutants such as FANCC and FANCA. In 2004, Hussain et ah, illustrated 
that for FANCD2 and FANCD1 to interact a sequence of amino acid residues (248-359) 
encompassing S331 is vital. In 2009, Zhi et ah, (2009) illustrated through the use of 
immunoprecipitation-immunoblotting experiments employing FANCD2-mutant PD20 cells 
(PD20-FANCD2 deficient cells, PD20 phospho-mutant (S331A; S331D) cells that S331 
phosphorylation is critical for FANCD2 and FANCD1 interaction. FANCD2 with BRCA2
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interaction was absent only in both cell lines PD20 and PD20-S331A while present in corrected 
wild type and PD20-S331D cells. FANCD2 isoforms (long and short) interact with FANCD1 in 
corrected wild-type FANCD2 cells (Wilson et at, 2008) and in FANCD2-S331D but not in 
FANCD2-S331A suggesting a critical role of S331 phosphorylation by CHK1 kinase in the 
interaction between FANCD2 and FANCD1 (Zhi et al, 2009). The point mutation in S331A 
compromised both the FANCD2 mono-ubiquitination and the Fanconi anaemia pathway leading 
to the observed MMC hypersensitivity in FANCD2-deficient PD20 cells (Zhi et al., 2009). Zhi 
et al, (2009), suggested that FANCD2 mono-ubiquitination is independent of FANCD1 and also 
suggested the simultaneous requirement of S331 phosphorylation for FANCD2-FANCD1 
interaction and FANCD2 mono-ubiquitination promotion.
Zhi et al, (2009) illustrated that unlike PD20-S331 A, phospho-mimetic mutation S331D (PD20- 
S331D) where aspartic acid replaces serine in position 331 did not affect FANCD2 mono- 
ubiquitination or the MMC cellular resistance and predicted that the failure of PD20-S331A cells 
to mono-ubiquitinate FANCD2 is possibly due to substantial structural modifications rather than 
nuclear localization failure as supported by previous fluorescence microscopy imagery showing 
the co-localization of mutant FANCD2 and wild type FANCD2 at the nuclear foci (Marte, 
2002).
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1.4.9.8 FANCD2 forms with FANCD1/BRCA2, FANCG and XRCC3 the 
G-BRCA2 complex
FANCD2 and FANCD1 are two components of the (G-BRCA2) protein complex which also 
encloses FANCG and XRCC3 (RAD51 paralogue) (Hussain et al, 2006; Wilson et aL, 2008). 
Wilson et at, (2008) illustrated using mammalian cells that FANCG (S7) phosphorylation is 
also critical for FANCD2 and FANCD1/BRCA2 interaction. The mechanistic coordination 
between the FANCG-(S7) and the FANCD20 (S331 A) is not clear yet.
1.4.9.9 FANCD2 and FANCI form the FAN CD2-F AN Cl complex
Comprising the heart of the FA pathway and ICL repair is the 296 kD FANCI-FANCD2 (ID) 
complex (Joo et al, 2011) whose activation occurs post DNA damage and is controlled via ATR 
phosphorylation (Moldovan and D’Andrea, 2009) and mono-ubiquitination via the ubiquitine 
ligase activity of the FA core complex (Timmers et al., 2001; Meetei et al., 2003; Dorsman et 
al, 2007; Moldovan and D’Andrea, 2009). FANCI interacts with FANCD2 composing the ID 
complex (Smogorzewska et al, 2007). Post replication fork stress or DNA damage, FANCD2 
and FANCI are independently mono-ubiquitinated and translocated to nuclear foci (Sims et al, 
2007) at DNA damage sites organizing DNA repair through nucleolytic alteration of the DNA 
near by the DNA lesion followed by bypass synthesis through a still unclear mechanism.
In 2009, Knipscheer et al, illustrated FANCD2 resection function of the ends surrounding 
cross-links in DNA repair. Huang and D’Andrea et al, (2010), demonstrated the occurrence of 
FANCD2-FAN1 binding. FAN1 is involved in cleaving branched and nicked structures due to its 
intrinsic 5'-3' exonuclease and endonuclease activity (Kratz et al, 2010; MacKay et al, 2010).
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Smogorzewska et alf (2010) proposed that the ubiquitinated ID complex binds (FAN1) 
engaging this repair nuclease (FAN1) to sites of DNA crosslink lesions. In addition to (FAN1), 
Smogorzewska et aL} (2010) also points out the involvement of another essential nuclease 
(EXDL2) in the crosslink repair. FANCD2 and FANCI comprise 1451 and 1328 amino acids, 
respectively. A homology region of about 150-amino acids is shared between FANCD2 and 
FANCI around their mono-ubiquitination sites (Joo et al, 2011).
1.4.9.10 FANCD2 and its roles in sustaining chromosomal integrity
In Fanconi anaemia cells, elevation of chromosome breakage (Porflrio, et al„ 1991; Fundia et 
al, 1994; Hewlett et al, 2005) and micro-nucleation (Willingale-Theune et al, 1989; Maluf 
and Erdtmann, 2001) have been reported. Fundia et al, (1994) findings do not agree with 
views that adopt randomness in chromosome breakage and suggest very strongly that the 
occurrence of break points at explicit chromosome points is connected with site fragility and 
breakpoints related to acute myeloid leukemia. Thus providing supportive explanation of the 
observed elevated predisposition to leukemia, and also sustaining the hypothesis that 
carcinogenesis results from the loss of chromosomal integrity or stability.
Valeria and Filippo, (2009) examined FANCD2 localization during cellular mitosis in order to 
explore a probable function of FANCD2 in chromosomal segregation. Valeria and Filippo, 
(2009) utilized FANC-deficient cells including PD20 (FANCD2 deficient) cells along with the 
corrected wild type and FANC-proficient human fibroblasts. At anaphase-telophase stage the 
occurrence of unequal chromosome partitioning, lagging chromosomes, lagging fragments, 
anaphase bridges, was considerably elevated in FANC-deficient cells compared to both the wild 
type and to the FANC-proficient human fibroblasts as noted by Valeria and Filippo, (2009),
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suggesting that chromosome segregation is severely affected in Fanconi anaemia cells. Valeria 
and Filippo, (2009) suggested that although the mitotic progression in Fanconi anaemia cells 
was not hindered, elevation in chromosomal aberrations resulting from segregation defects 
implicates the involvement of FANC pathway in maintaining chromosome stability. This is done 
through chromosome instability and aneuploidy prevention throughout mitosis, especially post 
replication stress. This role is in addition to the role that FA pathway plays in sustaining 
chromosome stability through its DNA damage response (Wang, 2007a).
In 2009, Valeria and Filippo found that FANCD2 targets discrete spots on mitotic 
chromosomes and hypothesized that these sites may be replication fork stalling sites. Chan et al, 
(2009) and Valeria and Filippo, (2009), have shown that in response to replicative stress, 
FANCD2 protein translocates to chromosomes during mitosis and is exclusively found at 
aphidicolin (APH)-induced chromatid gaps and breaks, which indicates its targeting to chromatid 
fragile sites. (Howlett et al, (2005) findings are consistent with and support findings of Chan et 
ah, (2009) and Valeria and Filippo, (2009). Chan et ah, (2009) suggested that the unresolved 
replication figures are a more critical source of bridges compared to end-to-end fusions between 
chromosomes and suggested that these observed aberrant bridges lead to non-programmed DNA 
breakage that consequently brings about the illegitimate DNA repair resulting in the observed 
chromosomal and chromatid exchanges.
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1.5 Model systems to study Fanconi anaemia
1.5.1 Model systems utilized in FA research
Various model systems are utilized in the research of FA. The model systems include cell lines 
that have been derived from the transparent roundwonn called nematode, Caenorhabditis 
elegans (Collis et aL, 2006; Youds et ah, 2009), fruit fly, Drosophila melanogaster (Marek and 
Bale, 2006), zebrafish, Danio rerio (Titus et al, 2006; Titus et al, 2009), chicken, Gallus 
gallus (Matsushita et al, 2005; Takata et at, 2007), the African clawed frog , Xenopus lavis 
(Stone et al, 2007), mouse, Mus masculus (Houghtaling et al, 2003) and Chinese hamster, 
Cricetulus griseus (Busch et al., 1996,; Lamerdin et al, 2004; Tebbs et al, 2005; Wilson et 
al, 2001).
1.5.2 Use of Chinese hamster cell mutants to study FA and FANCG
1.5.2.1 The use of hamster model in cloning homologous recombination 
repair genes
The availability of naturally occurring cell mutants or mutants isolated in the laboratory through 
chemical mutagenesis has bridged the progress made in DNA damage response and DNA repair 
understanding (Hickson and Harris, 1988). Chinese hamster mutant cell lines that are 
hypersensitive to clastogens have become primary models utilized in genetic analysis of DNA 
repair pathways and recombination processes (Thompson, 1998; Zdzienicka, 1996; Lee et al, 
1995).
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The molecular cloning of human repair ERCC (.Excision Eepair Cross Complementing) ox XRCC 
(Array Eepair Cross Complementing) genes that are involved in maintaining genome stability has 
been made possible through the use of (CH) mutants that are hypersensitive to UV or ionizing 
radiation. These genes which are required for nucleotide excision repair (NER) include 
ERCC2/XPD, ERCC3/XPB, ERCC4/XPF and ERCC5/XP (Thompson, 1998). Using CH 
mutants termed irsl and irslSF; other genes which are involved in homologous recombination 
repair such as XRCC2 and XRCC3, RAD51-family members were cloned (Tebbs et al., 1995; 
Liu et at, 1998).
1.5.2.2 Use of a hamster model to express FANCG mutations
Human FANCG and XRCC9 proved to be the same gene (de Winter et at, 1998). The human 
FANCG/XRCC9 gene was first cloned by genetic complementation of the MMC sensitivity of 
CHO mutant UV40 (Liu et al, 1997). UV40 mutant cells exhibits extreme sensitivity to 
mitomycin C (11 fold) and is about 2-fold sensitive to ionizing radiations and UV (Lamerdin et 
al, 2004; Busch et al, 1996). By introducing CHO FANCG gene into mutant NM3 it had been 
illustrated that hamster FANCG fully corrects the 10- fold hypersensitivity to MMC (Lamerdin 
et al, 2004; Wilson et al, 2001). Based on a 7-fold hypersensitivity to the crosslihking agent 
nitrogen mustard, Meyn et al. isolated NM3 from the CHO cell line AA8 (Meyn et al, 1991). 
NM3 is hypersensitive to MMC and is around 3-fold hypersensitive to UV and gamma-rays 
(Meyn et al, 1991). NM3 and UV40 have been allocated to the same complementation group 
due to similar but not identical patterns of hypersensitivity to various DNA damaging agents. For 
example: NM3 and UV40 are both about 3-fold hypersensitive to ionizing radiation and UV and
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are both hypersensitive to MMC, nevertheless, NM3 displays nonnal levels of spontaneous sister 
chromatid exchanges (SCEs) (Wilson et ah, 2001) compared to (3- to 4-fold) of SCEs of 
UV40 cells (Meyn etaL, 1991; Busch etal, 1996).
FANCG was originally cloned from a Chinese Hamster Ovary cell line hypersensitive to MMC 
and ionizing radiation, (Liu et al., 1997; de Winter et ah, 1998). Hence the preference to use the 
hamster model in performing these transgenic tests to express FANCG mutations. Fibroblast 
Chinese Hamster cell lines readily form colonies, thus making clonal fonning assays such as 
clonal survival assays or clonal HRR assays suitable to use. The findings of the clonal forming 
assays utilized were added to those of growth inhibition assays which are also capable of 
determining the hypersensitivity of the selected cell lines. Human lymphoblastic FANCG cell 
lines were avoided as it was unfeasible to implement the clonal forming assays used on slow 
growing, non-clonal fonning lymphoblastic cells. In Chapters 3 and 4, FANCG Chinese hamster 
ovary (CHO) mutant NM3 cell lines were utilized.
1.5.3 Use of human FANCA fibroblasts (GM6914) in FA research
1.5.3.1 Isolation of GM6914 cells and assigning them to FA 
complementation group A
Extensively utilized for cell and molecular biology model of study are human fibroblasts 
immortalized by Simian Virus 40 (SV40) (Wood et al,, 1987). Duckworth-Rysiecki et al, 
(1986) characterized and isolated a SV40-transformed human fibroblast cell line (GM6914) 
derived from an FA patient in 1986. Similar to FA cells, GM6914 cells expressed cellular 
hypersensitivity to MMC and elevated chromosomal instability. The growth rate of both
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GM6914 and SV40 human fibroblasts is similar and both cell lines are immortalized human 
fibroblasts. GM6914 cells are classed in to FA complementation group A, according to 
complementation analysis studies performed by Duckworth-Rysiecki et al, (1986) utilizing 
lymphoblasts derived from two affected brothers of the FA patient from which GM6914 cells 
were obtained.
1.5.3.2 FANCA protein is found in both the cytoplasm and the nucleus
In 1997, GM6914 cells were employed by Kupfer et al, (1997) after correcting with retroviral 
FAA cDNA to test for FANCA and FANCC interactions. Kupfer et al, (1997) found that 
protein binding correlated with the functional activity of FANCA and FANCC, as mutant 
FANCC protein, (Leucine 554 to Proline), did not bind FANCA protein. Kupfer et al (1997) 
concluded that FANCA interacts with FANCC forming a FAA-FAC complex. Taken together, 
that both proteins FANCA and FANCC are abundant in the cytoplasm, and FAA-FAC complex 
found in similar levels in cytoplasm and nucleus, this leads to the suggestion that this FAA-FAC 
complex has a nuclear function.
1.5.3.3 FANCA protein is a FA-core complex component
FANCA protein is part of the multi-protein nuclear FA core complex which also include proteins 
FANCC, FANCE, FANCF, FANCG, FANCL (reviewed by Soulier et al, 2005) and FANCM 
(Meetei et al, 2005). This nuclear FA core complex is required to activate FANCD2 protein 
mono-ubiquitination during the S phase of the cell cycle and post exposure to DNA cross-linking
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agents (Garcia-Higuera et al., 2001). Meetei et al suggested in 2003 that FANCL is likely to 
be the crucial catalytic subunit in the FA core complex and considered the other components 
functioning as regulatory subunits.
1.5.3.4 FANCA mutant cells exhibit cellular hypersensitivity to MMC 
In 1999, Kupfer et al., employed GM6914 fibroblasts to test the effect of a homozygous 
mutation in the FANCA gene (3329A>C) on FANCA function, using retroviral-mediated 
transduction to express FANCA(H1 HOP) and wild type FANCA protein. Unlike wild-type 
FANCA, FANCA (HI HOP) did not correct cellular hypersensitivity the mitomycin C, nor did it 
succeed in nuclear accumulation in the transduced cells, emphasizing the impact of the 
phosphorylation of FANCA, its binding to FANCC, and the FANCA /FANCC nuclear 
accumulation on the FA pathway.
Utilizing GM6914 fibroblasts in response to DNA damage, Adachi et al, (2002) findings 
indicate that no activation of FA-pathway occurred in FANCA-null cells, while altered FANCA 
proteins activated the FA pathway to variable degrees, as assessed by FANCD2 mono- 
ubiquitination. Adachi et al, (2002) used various FANCA point-mutations (19 mutations) some 
of which were disease-associated and other mutations were mis-sense variants presenting wild 
type (WT-FANCA) behaviour. Adachi et al, (2002) suggested that the various FANCA point- 
mutations affected the tertiary structure of FANCA which leads to compromised FANCA 
proteins phosphorylation and interaction with FANCC and FANCF affecting FANCA interaction 
with other proteins. Adachi et al, (2002) concluded that various FANCA patient-derived 
mutants have variable degrees of influence on FANCA functions.
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1.5.3.5 Reported cytogenetic profile of GM6914 cell line
GM6914 cells show elevated rates of spontaneous CA and are hypersensitive to DNA-cross- 
linking agents such as MMC or nitrogen mustard (Duckworth-Rysiecki et al.f 1986). 
Characteristically similar to all FA cell types examined, elevated rates of CA are observed in 
GM6914 cells post exposure to cross linking agents such as MMC compared to spontaneous 
levels of aberrations in control cells (Sasaki and Tonomura, 1973; Weksberg et al, 1979; 
Cervenka et al, 1981; Duckworth-Rysiecki et aL, 1984).
1.5.4 Use of human FANCD2 fibroblasts (PD20) in FA research
1.5.4.1 Pin pointing the FANCD2 gene using PD20 cells and mutation 
analysis
Employing microcell-mediated chromosome transfer into PD20 cell line (Whitney et al, 1995) 
reported that the gene mutated in PD20 is located in the short ann (p) of chromosome number 3. 
The candidate region for the FANCD2 gene was narrowed down to about 200 kb via further 
detailed analysis to five overlapping micro-deletions surrounding the locus in five microcell 
hybrids (Hejna et al,, 2000). Three candidate expressed sequence tags (ESTs) were identified as 
present in or near FANCD2 critical region (Hejna et ah, 2000).
Full-length cDNAs were obtained by employing 5' and 3' rapid amplification of cDNA ends 
(RACE), then followed by genes sequencing and expression pattern analysis via Northern blot. 
Like earlier cloned FA genes, EST (SGC34603) had reduced ubiquitous mRNA expression 
levels (de Winter et al, 1998; Tlmmers et al, 2001).
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The open reading frames for EST TIGR-A004X28, AA609512, and SGC34603 were in length 
(234, 531, and 4413 bp respectively) Timmers et al, (2001). Through sequencing cloned RT- 
PCR products, the three were analyzed to detect mutations in PD20 cells. SGC34603 had five 
sequence changes, while TIGR-A004X28 and AA609512 had no sequence changes Timmers et 
ah, (2001). Further analysis to the five sequence changes revealed three alleles to be 
polymorphic variations; while the other two represented maternally and paternally inherited 
mutations. In determining SGC34603 gene structure Timmers et al, (2001) discovered forty- 
four exons with exon 2 enclosing the start codon. Timmers et al, (2001) findings led them to 
suggest that SGC34603 is the FANCD2 gene.
1.5.4.2 PD20 cells are FANCD2 deficient and FANCD2 cDNA 
complemented functionally FANCD2 deficient cells
Using immunoblotting, survival assays and cytogenetic analysis, Timmers et al, (2001) findings 
illustrated that the cloned FANCD2 cDNA encoded the non-mono-ubiquitinated form of 
FANCD2 protein, which was post translationally modified into the mono-ubiquitinated 
FANCD2 protein correcting the MMC hypersensitivity of PD20-FANCD2 deficient cells. 
Timmers et al, (2001) using a specific (SGC34603) antibody in Western blots confirmed 
SGC34603 gene as FANCD2 and illustrated the expression of both mono-ubiquitinated and non- 
mono-ubiquitinated FANCD2 in wild-type cells and the diminished FANCD2 levels in all PD20 
cells.
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1.6 Aims
• To characterize the role of the FANCG protein and its two phosphorylation sites, located 
at serine-7 and serine-387, in the repair of inter-cross links (ICLs) and the homologous 
recombination repair (HRR) of double-strand breaks. FANCG mutant cell lines have been 
utilized to investigate the precise roles of the FANCG protein in the FA-BRCA pathway 
and specifically in ICL repair and HRR.
• To characterize the function of the G-BRCA2 protein complex (comprising 
BRCA2/FANCD1-FANCD2-FANCG-XRCC3) in homologous recombination repair of 
DSB that either: 1) arise indirectly in ICL repair or 2) are directly induced by a radio- 
mimetic agent (phleomycin). Mitomycin C was used to induce interstrand cross-links and 
phleomycin was used to induce DNA strand breaks.
• In order to achieve these aims I characterized mammalian FANCG, FANCA and 
FANCD2 mutant cell lines by establishing their cellular and cytogenetic responses to the 
cross-linking agent MMC and radiomimetic strand-breaker phleomycin. A plasmid-based 
reporter assay was used to measure homologous recombination repair (HRR) in selected 
cell lines.
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Chapter-2
Material and methods
2.1 Materials and methods
2.1.1 Materials
2.1.1.1 Cell lines used
2.1.1.1.1 Chinese hamster (CH) cell lines (FANCG lines)
AA8: Wild type (parental) Chinese hamster ovary fibroblast cell line (Thompson et ah, 1980; 
Meyn et al.f 1991; Wilson et al„ 2001)
NM3: is an AA8 derivative fancg mutant fibroblastic cell line which is sensitive to nitrogen 
mustard. It contains a point mutation which leads to a premature stop codon in exon 3 resulting 
in a highly unstable truncated protein (Meyn et ah, 1991; Wilson et al., 2001; Lamerdin et al., 
2004).
NM3-(gWT): Human full length fancg cDNA in the pCEP4 hygromycin resistant vector was 
transduced into NM3 and a cell line established.
NM3-TPR6: Human fancg cDNA mutated at TPR6:G521Q in the pCEP4 hygromycin resistant 
vector was transduced into NM3 and a cell line established.
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NM3 SCneo2 pMMP-gWT: NM3 cell line transfected with the SCneo2 construct and 
transduced with pMMP vector containing the human full length fancg cDNA (Dr. N.J. Jones 
and Dr. J.B. Wilson personal communication). It will be referred to as NM3-gWT 
NM3 SCneo2 pMMP-VO: NM3 cell line transfected with the SCneo2 construct and transduced 
with pMMP vector. It will be referred to as NM3-VO (Dr, N.J. Jones and Dr. J.B. Wilson 
personal communication).
NM3 SCneo2 pMMP-S7A: NM3 cell line transfected with the SCneo2 construct and transduced 
with pMMP vector containing the human fancg cDNA mutated at phosphorylation site (S7) 
serine to alanine substitution. It will be referred to as NM3-S7A.
NM3 SCneo2 pMMP-S387A: NM3 cell line transfected with the SCneo2 construct and 
transduced with pMMP vector containing the human fancg cDNA mutated at phosphorylation 
site (S3 87) serine to alanine substitution. It will be referred to as NM3-S387A.
2.1.1.1.2 Human fibroblast FA cell lines
2.1.1.1.2.1 FANCA cell lines
GM6914 (FA-A) SCneo: Immortalized FA-A complementation group human fibroblast cell line 
transfected with the SCneo construct and transduced with pMMP vector (Duckworth-Rysiecki 
et al, 1986; Collins et al, 2009).
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GM6914 + FANCA SCneo: Immortalized FA-A complementation group human fibroblast cell 
line transfected with the SCneo construct and transduced with full length human FANCA cDNA 
tagged with Flag in the pMMP vector (Collins et at, 2009).
GM6914-S1449A SCneo: is a FANCA mutant immortalized human fibroblast cell line 
transfected with the SCneo construct and transduced with human FANCA cDNA that has been 
mutated via site-directed mutagenesis in FANCA at serine 1449 to alanine (S1449A) (Collins et 
al., 2009).
v
\
2.1.1.1.2.2 FANCD2 cell lines j
PD20: is a FA-D2 complementation group human fibroblast cell line, (FANCD2-deficient)
(Whitney et al., 1995; Jakobs et al., 1996; Zhi et al, 2009).
PD20 SCneo: is a PD20 cell line transfected with the SCneo construct and transduced with an 
empty vector. The cell line produced at the Jones’ laboratory (Dr. N.J. Jones and Dr. J.B. 
Wilson personal communication). It will be referred to as PD20.
PD20 K561R SCneo: is a PD20 cell line transfected with the SCneo construct, then retrovirally 
transduced with pMMP vector containing site-directed mutagenesis mutated human cDNA of 
FANCD2 so that arginine replaces lysine in position 561 produced at the Jones’ laboratory 
(Garcia-Higuera et al, 2001). It will be referred to as PD20-K561R.
PD20 S331D SCneo: is a PD20 cell line transfected with the SCneo construct, then retrovirally 
transduced with pMMP vector containing site-directed mutagenesis mutated human cDNA of
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FANCD2 so that aspartic acid replaces serine in position 331 and tagged with FLAG produced at 
the Jones’ laboratory (Zhi et al, 2009; Dr. Gary M Kupfer personal communication). It will 
be referred to as PD20-S331D.
PD20 S331A SCneo: is a PD20 cell line transfected with the SCneo construct, then retrovirally 
transduced with pMMP vector containing site-directed mutagenesis mutated human cDNA of 
FANCD2 so that alanine replaces serine in position 331 (Zhi et at, 2009; Dr. Gary M Kupfer 
personal communication). It will be referred to as PD20-S331A.
PD20 + FANCD2 SCneo: is a PD20 cell line transfected with the SCneo construct, then 
retrovirally transduced with pMMP vector containing FANCD2 full length human cDNA (Zhi et 
ah, 2009; Dr. Gary M Kupfer personal communication). It will be referred to as PD20- 
D2WT.
PD20 -3-15 SCneo: is a PD20 cell line transfected with the SCneo construct, then corrected by 
microcell mediated transfer of human chromosome fragment enclosing FANCD2 gene produced 
at the Jones’ laboratory (Whitney et al, 1995; Naim and Rosselli, 2009). It will be referred to 
as PD20-315.
Cell lines (GM6914, PD20 S331A, PD20 S331D, and PD20 + FANCD2) were a kind gift from 
Dr. Gary Kupfer, Yale University School of Medicine, USA. Cell lines (PD20, PD20 K561R 
and PD20 -3-15) were a kind gift from Dr. Alan D’Andrea, Dana-Farber Cancer Institute, 
Harvard Medical School, USA.
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2.1.1.2 Vectors for HRR assay
SCneo: is a direct recombination reporter substrate construct SCneo inserted into pUC9 plasmid 
(Johnson et al, 1999) as shown in Fig. 2.1.
2.1.1.3 Antibodies for Western blotting
2.1.1.3.1 Primary antibodies
Antibody to FANCG (H: 83-622, R#2924-2944) (anti-FANCG) is a kind gift from Dr. Maureen 
Hoatlin of Oregon Health and Science University, Portland (Waisfisz et al, 1999).
Beta ((3)-actin (ab6276) (anti-|3-actin) were obtained from Abeam Limited, UK.
2.1.1.3.2 Secondary antibodies
Anti-rabbit and anti-mouse bourse radish peroxide (HRP) labeled antibodies were obtained from 
GE Health-care (RPN2108), UK.
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2.1.1.4 Chemical agents used 
2.1.1.4.1 Mitomycin C (MMC)
Mitomycin C (MMC) (Sigma-Aldrich, UK) was prepared to obtain a ImM stock solution by 
dissolving 2mg of MMC powder into 5,89 ml of Hanks balanced salt solution without calcium 
and magnesium and with phenol red (HESS) (Lonza, Belgium). The preparation was filter 
sterilized and stored at -18°C into 130 pi aliquots. During preparation direct light was avoided as 
MMC is light sensitive.
2.1.1.4.2 Phleomycin
Phleomycin (Sigma-Aldrich, UK) was prepared to obtain a 1 mg/ml stock solution by dissolving 
5mg of Phleomycin powder into 5 ml of PCR distilled water (BDH, UK). The preparation was 
filter sterilized and stored at -18°C into 130 pi aliquots.
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2.1.2 Methods
2.1.2.1 Cell culture and maintenance
CH and human fibroblast cell lines were cultured and sub-cultured routinely and maintained in a 
state of exponential growing phase utilizing Dulbecco’s Modified Eagle’s medium with Ultra 
glutamine and 4.5 g/L glucose (Lonza, Belgium), supplemented with 10% (v/v) foetal calf serum 
(Autogene Bioclear, UK), 100 pl/ml penicillin and streptomycin sulphate (Lonza, Belgium) and 
1% (v/v) non-essential amino acids (100X concentration) (Lonza, Belgium) (Wilson et at, 
2001).
2.1.2.2 Cell storage
Cell lines stocks have been stored in liquid nitrogen at -196°C. To safely freeze down cell lines 
cryovials containing about (IxlO6 cells) re-suspended in 1ml of complete medium containing 
10% DMSO (Sigma-Aldrich, UK) was placed in a isopropanol freezing-down vessel in order to 
gradually reduce the cellular temperature overnight at the -80°C freezer before transfer to liquid 
nitrogen.
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2.1.2.3 Growing ceU lines from frozen stocks
Cell lines (in cryovials) retrieved from liquid nitrogen have been thawed before transferring and 
diluting into 10ml culture medium followed by centrifragation at 2000 rpm for five minutes at 
room temperature. Then the cell pellets were re-suspended in 5ml of complete medium and 
transferred into a 75 cm2 culture flask ( Greiner bio-one, Germany) containing 10ml culture 
medium followed by incubation at 37°C, 5% and CO2 until approaching 70% confluence.
2.1.2.4 Cell passage
In order to obtain cells growing at the exponential growing phase to be utilized, cells have been 
passaged only when they approached confluence (about 70% confluence). Cell passage was 
carried out by removing growth medium from the culture flask followed by washing the cells 
with HESS. Then the cells were detached from the flask’s surface by the addition of a trypsin 
solution [0.12% (v/v) trypsin with 0.008% (w/v) ethylene diaminotetraacetic acid (EDTA) 
(Lonza, Belgium)].
2.1.2.5 Fibroblast cell line growth inhibition assay
1x106 cells in culture medium suspension were seeded in to 75cm2 culture flasks and then the 
appropriate clastogen doses were added to culture flasks before incubating them into 37°C, and
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5% CO2. The incubation period was until the untreated flasks (controls) approached 70% cellular 
confluence. Then, cell cultures were trypsinised and cell pellets were collected by centrifugation 
at 2000 rpm for five minutes at room temperature. Then the cell pellets were re-suspended in 2ml 
of medium and cellular densities determined through a haemocytometer count, and then these 
cellular densities were compared to that of the control cultures.
2.1.2.6 Transfection
Following lipofectamine transfection, the SCneo vector transfection into selected cell lines was 
performed. Lipofectamine reagent (50pl) and plasmid DNA (100 ng) (Invitrogen, UK) were 
mixed individually each with 1.5 ml of OPTI-MEM I (Invitrogen, UK) and kept for fifteen 
minutes (15 min) at room temperature. The two mixtures were then mixed together and farther 
incubated for another thirty minutes (30 min) before adding three mis of 37°C pre-warmed 
OPTI-MEM I giving the six mis transfection mixture. This transfection mixture was added to the 
70% confluent cells which were seeded in to 75 cm2 culture flasks (after washing them twice with 
HESS). These culture flasks were then incubated for five hours at 37°C, and 5% CO2 before 
replacing the transfection mixture with fresh culture medium and incubated again at 37°C, and 
5% CO2 overnight. The transfected cell lines in the culture flasks were trypsinised and pellet 
collected, then seeded into tissue culture dishes with cellular numbers of (200, 500, 5000 and 
10000). Five tissue culture dishes were used for each plating number. All tissue culture dishes 
were then incubated at 37°C, and 5% CO2 overnight. Finally, a selecting agent (500 pg/ml 
hygromycin B) was added to these tissue culture dishes.
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2.1.2.7 Homologous recombination repair (HRR) assay
2.1.2.7.1 Introduction
HRR assay is used to evaluate the rate of homologous recombination repair occurring within cell 
lines after induction of DNA damage especially DSBs and stalled or collapsed replication forks 
(Saleh-Gohari et al., 2005). The SCneo construct is a DNA recombination reporter segment 
comprising two non-functional copies of the neomycin phosphotransferase (neo) gene; (3'neo) 
and (S2neo) joined by a functional hygromycin resistant gene (hygR) (Johnson et al.9 1999). This 
SCneo construct is introduced via a pMMP vector to trasfect NM3 cell line for future testing in 
the HRR assay. Successfully transfected cells consisting of the SCneo construct have been 
isolated through hygromycin selection and the cells were allowed to grow in culture medium 
normally before use in HRR assays. Cell lines consisting of the SCneo2 construct were further 
transduced with various pMMP vectors to produce other cell lines for the HHR assay.
In principle as shown in Fig. 2.1, when DSBs are induced in these cell lines containing SCneo 
construct, the error-free HRR process will join the two non-functional genes producing a 
functional G418 resistant gene (neoK) (Saieh-Gohari and Helleday, 2004). Isolating cells with 
successful HRR events can he achieved through G418 selection by exposing the cells to 
geneticin (G418) antibiotic. Only cells which have successful HHR event will form colonies. 
Calculating HRR frequency in a specific cell line is possible through calculating the successful 
HRR events represented by the average rate of G418 resistant colony count over the total cell 
population with plating efficiency corrected. Recombination frequency fold increase can be
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calculated through comparison of recombination frequency of damage induced (treated cells) 
with spontaneous recombination frequency of (untreated cells). Exposing cell lines to clastogens 
such as phleomycin and MMC is carried out in HRR assays to determine the rate of HRR 
occurring in each cell line and hence evaluating the requirement of the proteins in question and 
their phosphorylation at specific sites for proficient HRR.
2.1.2.7.2 HRR Protocol
For each cell line, two culture flasks were set up and cells were seeded in to: untreated (control) 
culture flask and a drug treated culture flask with the clastogen added for a period of 24 hours. 
Then the cells in the culture flasks were trypsinised and pellet collected and seeded into 10 ml 
tissue culture dishes which contained either 1 nonnal culture medium (control) or (1 mg/ml G418) 
culture medium. The control culture dishes (6 plates with 200 cells per plate) used to determine 
plating (cloning) efficiency and the G418 culture dishes (10 plates with 3xl05 cells per plate). 
All the culture dishes were incubated for ten days at 37°C, and 5% CO2. The colonies produced 
were stained and fixed by 10% methylene blue. Colonies produced in the culture dishes were 
counted and in order to calculate the level of HRR (recombination frequency) the following 
formula was applied;
Recombination Frequency =
Average colony number in G418 selective medium
(3 x 105)x Average colony number in nonselective medium 
200
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2.1.2.8 Survival assays
Exponentially growing cells were trypsinised and plated into tissue culture petri dishes. Diluted 
clastogens (MMC or phleomycin) were added in gradually increasing doses to the culture 
medium. The dishes were placed in a 37°C incubator for 10 days permitting colony formation. 
Five control dishes with no clastogen were set at 200 cells/dish, those containing the drug were 
set in triplicate with increasing cell numbers used at higher doses. Uninterrupted clastogen 
exposure was applied for 10 days. Following the 10 day period culture media was removed and 
dishes were stained with methylene blue for 1 hour, then water rinsed and air-dried. Only 
colonies greater than 50 cells/colony were considered and counted. Survival data presented after 
correction by comparison to untreated cell cloning efficiencies. Graphs of dose-response 
sensitivity represent the mean of the experiments performed. Numbers were drawn on a semi-log 
plot and the dose required to reduce survival to 37% was determined for each cell line (D37). 
Once established this D37 value has been a starting point in determining the cytotoxicity of the 
selected clastogens, which allowed a selection of the suitable doses required for other assays 
including the CA assay.
2.1.2.9 Immunoblotting (Western Blot)
Western blotting was performed as described by Wilson et al in 2001. Antibodies to beta actin 
(ab6276) which is a mono-clonal antibody raised in mouse and FANCG (a kind gift from 
Hoatlin) which is a poly-clonal antibody raised in rabbit were obtained from Abeam Limited
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(Cambridge, UK). Cells were grown to near-confluence in 75 cm2 peel-back flasks (Greiner, UK) 
followed by washing extensively with HESS. Protein extraction buffer was used to lyse cells (50 
mMTris-HCl, pH 6.8, 1% sodium dodecyl sulphate (SDS), 1% EDTA, 0.25% glycerol, 0.25% 
B-mercaptoethanol) followed by lysate boiling for 10 min. Then 10 minutes centrifugation 
followed by subjecting the supernatant to polyacrylamide SDS gel electrophoresis. Using a 
submerged transfer apparatus (Wolf laboratories) the proteins were transferred to nitrocellulose 
filled with 25 mM Tris base, 192 mM glycine and 20% methanol. Following blocking with 5% 
non-fat dried milk in TBS-T (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Tween 20) the 
membranes were incubated with the anti-beta actin (ab6276) and anti FANCG polyclonal 
antibody diluted in a TBS-T solution (1:1000 dilution). Following extensive wash of the 
membrane, it was incubated with anti-rabbit horseradish peroxidase-linked secondary antibody 
and chemiluminescence used for detection (Amersham, Little Chalfont, UK).
2.1.2.10 Cytogenetic methods
2.1.2.10.1 Cytogenetic methods introduction
Classical cytogenetic analysis has been implemented in this investigation (using Giemsa stain). 
Structural chromosomal aberrations were determined, classified and analyzed through metaphase 
spread analysis. Selected cell lines are cultured in the presence and absence of the cross-linking 
agent. Metaphase spreads were scored and analyzed for chromosomal breakage as well as for the 
formation of complex chromosomal arrangements. Findings for FANC mutant cell lines are
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compared with findings from corrected control cells. Cellular cultures without the DNA 
clastogenic agent were used to measure the spontaneous breakage rate. Results are reported as 
the number of aberrations per cell, the percentage of aberrant cells and the total number of 
chromatid breaks per cell.
The aberrations are categorized into two main types which are chromosome and chromatid 
aberrations. Further classification of these aberrations is made into breaks and exchanges. 
Chromatid exchanges are further classified in to three sub-sections which include the radial 
forms triradials, quadri-radials and complex exchanges (see Table 2.1). The complex chromatid 
exchanges are classified based on the number of chromosomes that are involved in each 
complex. FA cell lines after treatment with MMC illustrated elevated rates of chromosomal 
breakage and radial formation a mark of chromosomal breakage syndromes.
Elevated chromosome alterations constitute most of the spontaneous or induced mutations found 
in somatic mammalian cells linked to cancer. Post exposure to carcinogenic agents and the 
occurrence of initial molecular damage represented by specific chromosomal aberrations are 
likely to lead to a sequence of events preceding the formation of a cancerous tissue. In principle 
the type of chromosomal aberrations presented, and their breakpoints, may highlight the 
influence of structural or functional features that chromatin may have on processes of DNA 
repair or mis-repair after encountering DNA damage. Also the analysis of this type of 
information can point out the genes and controlling dynamics whose expression or suppression 
set the molecular grounds from which malignant transfonnations stem. Therefore, cytogenetic 
data may provide valuable means for more detailed studies on the dynamics of repair.
Given the accessibility to repair deficient mutant cell lines or knockdown strategies, protein 
immunecytochemical detection apparatus combined with cytogenetics in addition to the
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advanced molecular cytogenetics such as (F.I.S.H.) or (C.G.H), it can be seen that cytogenetics 
can provide valuable data about the DNA repair process and its associated protein interactions 
that can be logically interpreted to further clarify the details of the dynamic bigger picture of 
DNA repair processes. In this thesis classical cytogenetic analysis has been utilized.
2.1.2.10.2 Cytogenetic protocols
2.1.2.10.2.1 The Micronucleus Assay
The micronucleus (MN) assay determines the frequency of micronuclei formation, structures that 
may result from either chromosome breakage or chromosome loss. The MN assay is used to 
evaluate spontaneous and drug induced numerical and structural instability. Exponentially 
growing CHO cells (5 xlO5) were plated in 25-cm2 tissue culture flask with 5ml culture medium. 
The cells were allowed to attach and were left to grow for 48 hours at 37°C, 5% C02. Duplicate 
cultures were prepared for each treatment group and negative controls were included. 
Cytochalasian-B (Cyto-B) and MMC were added 48 hours after culture initiation. Based on 
earlier reports (Fenech and Morley, 1985; Krishna et al., 1989) the optimum Cyto-B 
concentration has been used (3pg/ml) and the final concentration of dimethyl sulfoxide (DMSO) 
did not exceed 0.3% (Ellard et ah, 1991). Selected MMC doses used were 300nM and 600nM 
(Krishna et al., 1989; Lynch et aL, 1993; Gabriele et aL, 1995). Cyto-B (Sigma Chemical 
Company) was dissolved in DMSO and stored at -80°C.
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The flasks were re-incubated and cells were allowed to grow for further 20 hours at 37°C and 5% 
CO2 before harvesting. Harvesting began with removing the culture medium by aspiration 
followed by washing the flasks twice with phosphate buffer solution (PBS), then trypsinising 
using 5ml trypsine solution (0.12% trypsin and 0.008% EDTA) and removing the cells from the 
culture flasks into centrifuge tubes containing 5ml medium. Tubes were centrifuged at 1700 
RPM for 5 minutes followed by removal of most of the supernatant keeping the pellet in 0.5 ml 
supernatant. The pellet was re-suspended by flicking or pipetting, then fixed by adding cool, 
fresh fixation solution (acetic acid-methanol solution, 1:25) drop by drop (5mls) and leaving 
tubes for 15 minutes in fixative at room temperature. Tubes were spun again, supernatant 
removed, new fixation solution is added and the pellet is dropped on slides. Three slides were 
prepared for each treatment group by the dropping method and after air drying the slides were 
stained before scoring in accordance to the recommended criteria (Fenech, 2000).
2.1.2.10.2.2 Metaphase spreads preparation for cytogenetic analysis
Experimentation was perfonned on exponentially growing cells. Routinely cells were re­
suspended in culture medium (DMEM, BioWhittaker, Cambrex Corp., Nottingham, UK 
supplemented with 10% foetal calf serum, penicillin and streptomycin antibiotics) and were 
allowed to grow in a 37° C with 5% C02 incubator until cells were about 70% confluent enough 
to be utilized (usually 48 hours for either CHO or human cells). The cells were harvested by 
trypsinization from culture flasks. CHO cell numbers of (0.5xlO5, IxlO5 and 2xl05cells) then 
were allowed to firmly attach on glass slides for 3 hours before adding further culture medium 
and allowing a growth period of (24 hours). Clastogens such as MMC or phleomycin were added
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to the CHO cells for 24, 18 hours respectively after cell-slide attachment. Human fibroblast cell 
numbers of (0.3xlO5, 0.5xlO5 and lxl05cells) were allowed to firmly attach on glass slides for 3 
hours before adding further culture medium and allowing a growth period of 30 hours. 
Clastogens such as MMC or phleomycm were added to the human fibroblasts for 40 hours.
By adding 100 pi demecolcine solution (10 pg/ml in Hanks Buffered Saline Solution (HBSS) 
(CAS No. 477-30-5) cellular growth arrested at the metaphase stage at a final concentration of 1 
pg/ml to cell cultures inlO ml of culture medium. The cells remained in demecolcine 
concentration of 1 pg/ml for three hours. The cells were then treated with 37°C pre-warmed 
0.075 M KC1 for 15 minutes at room temperature, then fixed with cold methanol: glacial acetic 
acid (3:1, v/v) for about 30 minutes, the slides were air dried and stained with 5% Giemsa for 5- 
10 min, followed by scoring 100 cells for chromosomal aberrations from controls and treated 
cells when possible, or 50 cells for each treated cell line. The slides were coded to ensure 
unbiased judgment of any possible aberrations.
Solutions were freshly prepared each time for each experiment. The exposure time for both 
MMC and phleomycin in all experiments was 24, 18 hours respectively. MMC (CAS No. 50-07- 
7) and phleomycin (CAS No. 11006-33-0) were purchased from Sigma. Stock solutions of MMC 
and phleomycin were prepared in HBSS and water respectively and stored at (- 20°C). 
Metaphase chromosome spreads were prepared as described above. All slides were coded, and 
then scored for chromatid and chromosome aberrations. Chromatid and chromosome gaps were 
scored and presented separately in the data tables.
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2.1.2.10.3 Chromosomal aberration scoring
It is possible to identify certain chromosomal aberrations (CA) in metaphase chromosomes 
through light microscopy using specific chromosomal preparation and staining procedures 
(Appendix-l). CA that could be recognized in this project until this stage include; chromosome 
exchanges such as; di-centrics (Appendix-2), rings (Appendix-3), or chromatid exchanges such 
as; tri-radials (Appendix-4), quad-radials (Appendix-5) or complex structures (Appendix-6) or 
chromosome or chromatid breaks (Appendix-7), or gaps (Appendix-8) (Passarge, 1995; 
Verma and, Babu 1994). Advantages of Giemsa staining technique include its cost 
effectiveness and the simplicity with which it is performed (Sra et aL, 2005). However, the 
procedure requires dividing cells which can be time consuming and may fail to detect cryptic 
translocations, deletions, insertions or duplications (Sra et aL, 2005). CA such as, 
iso chromosomes, reciprocal translocations or other micro-rearrangements have not been 
addressed as they are beyond the cytogenetic scope of this part of the project. The gaps observed 
in stained chromosomes may reflect problems in DNA replication such as stalled replication 
forks or may result sometimes from staining variation. In order to overcome this problem in 
interpretation of the results, gaps were scored as a separate type of aberration and placed 
separately in the scoring tables. A simplistic definition of a break can be: an achromatic area 
more than a chromatid in width (Auerbach et ah, 1979). In this project the aberrations were 
classified into chromosome or chromatid aberrations as described by (Kirkland, 1990; Savage, 
1976). Appendix (9-A and 9-B) illustrates some of the main aberrations and their classification 
(adopted from Kirkland, 1990). Similar to Chinese hamster cells, these aberrations can also be 
found in human cells 6914 FANCA and PD20. Appendix-11 and Appendix-12 illustrate normal
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metaphase spreads of 6914 FANCA cells. These can be compared to 6914 FANCA cells with 
aberrations (Appendix-13 and Appendix-14). Normal metaphase spreads of PD20 cells are 
shown in Appendix-15 and Appendix-16 and can be compared to PD20 cells with aberrations 
(Appendix-17 and Appendix-18). Human cells 6914 FANCA and PD20 lines are immortalized 
cell lines with chromosomal counts ranging between 50-70 chromosomes per metaphase as 
observed in untreated culture conditions.
2.1,2.10.4 Converting exchanges to chromatid breaks
In order to calculate the total number of chromatid break, firstly, chromsome breaks, 
chromosome exchanges and chromatid exchanges including triradials, quadri-radials and 
complex arrangements were converted to the minimal number of chromatid breaks required for 
the formation of each specific type of aberration. Then this minimal number of chromatid breaks 
required for the fonnation of those aberrations was added to the observed number of chromatid 
breaks. Then this total number of chromatid breaks has been presented as total chromatid breaks 
per cell. The conversion was made according to Table: 2.1 showing the minimal number of 
chromatid breaks required to form the complex arrangement and explained in Figs. 2.2, 2.3, 2.3 
and 2.4. From Table: 2.1 and Figs. 2.2, 2.3, 2.3 and 2.4 it can be seen that for example; a 
chromosome break is equivalent to two chromatid breaks and that for rings or dicentrics to form 
a minimal number of four chromatid (telomeric) breaks are required to form the chromosomal 
arrangement. Likewise, for a complex chromatid exchange involving four chromosomes (or four 
centromeres) will require a minimum of six chromatid breaks. For a dicentric triradial a 
minimum of three chromatid breaks are needed for this figure to form; one chromatid break
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along the length of a chromatid arm and two chromatid (telomeric) breaks. In the same way, for 
a quadri-centric quadri-radial to form a minimum of eight chromatid (telomeric) breaks is 
required. Clearly other numbers of chromatid breaks are possible to have the same chromosome 
or chromatid arrangements, however our calculation takes into consideration the minimal 
possible number required of chromatid breaks to form these structures.
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Converting cbromosome and chromatid exchanges into chromatid breaks
Aberration type Minimal number of
chromatid breaks
Chromosome 
type aberrations
Chromosome break 2
Chromosome exchange 
(Dicentrics and Rings) 4
Complex
chromatid
arrangements
involving
Two chromosomes 2
Three chromosomes 4
Four chromosomes 6
Five chromosomes 8
Triradials
Monocentric 3
Dicentric 3
Tricentric 6
Quadriradials
Monocentric 4
Dicentric 2
Tricentric 6
Quadricentric 8
Table 2.1: Showing the minimum number of chromatid breaks required to have the 
chromosome or chromatid various complex figures described.
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X
Dicentric
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"i r
+
chromosome
X
Fragment
• Stickv end
Mono-centric rings can form when both telomeres 
at each end of the same chromosome are deleted 
and the sticky ends join together 
(four chromatid breaks)
Dicentrics can foim when both telomeres at 
each end from two chromosomes are deleted 
and the sticky ends join together (four 
chromatid breaks)
A chromosome break is foimed when two 
breaks along the length of both chromatids or 
when the telomeric ends of both chromatids 
are deleted leaving sticky ends 
(two chromatid breaks)
deletion
Q O Centromere 4" Adding or Joining
Figure (2.3): Chromosome breaks produce two chromatid breaks, on the other hand chromosome 
exchange such as dicentrics and rings require a minimum of four chromatid breaks.
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Chapter-3
Investigating the role of FANCG protein in the repair of induced inter 
cross links (ICLs)
3.1 Introduction
FANCG is a phospho-protein with phosphorylation sites identified at serine 7 (Qiao et al, 
2004), serine 387 and serine 383 (Mi et aL, 2004); it also contains seven tetratricopeptide repeat 
(TPR) motifs (Blom et al.9 2004, and Mi et al., 2004). FANCG protein is known to be involved 
in at least three protein complexes, each of which are thought to be involved in the repair of 
DNA lesions through the FA-BRCA pathway. This is supported by recent evidence suggesting 
the involvement of FANCG protein in the unhooking of DNA inter cross links (Wang and 
Lambert, 2010). These three FANCG multiple protein complexes are termed the FA-core 
complex (Kupfer et al, 1997; de Winter et al, 2000a; Medhurst et al, 2001), the G-BRCA2 
complex (Wilson et al, 2008) and the G-XPF-ERCC1 complex (Wang and Lambert, 2010).
3.1.1 FANCG and the repair of ICLs
ICL repair at stalled replication forks is a multi-stage complex process that is proposed to 
comprise several DNA repair mechanisms. These include lesion unhooking, lesion bypass or 
translesion synthesis, excision of unhooked crosslink by nucleotide excision repair (NER), the
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production of a double-strand break at stalled replication fork sites and subsequent homologous 
recombination repair (reviewed by Niedernhofer et at., 2005; Patel and Joenje, 2007; 
Thompson and Hinz, 2009). However, the order in which these events take place is unclear and 
the subject of much discussion in the literature (reviewed by Deans and West, 2011). There is 
evidence that FANCG is involved in several of these stages. Post-treatment with DNA cross- 
linking agents, FANCG has been shown to co-localize with the HRR proteins, BRCA2 and 
RAD51 (Hussain et al, 2004). This suggests that FANCG is directly linked with HRR, which is 
involved in ICL repair after the unhooking of the ICL by the ERCC1/XPF endonuclease and the 
generation of a double-strand break (Thompson et al, 2005; Bhagwat et al, 2009). The main 
role of FANCG in the FA core complex appears to be in stabilizing replication forks that 
encounter gaps, nicks, or replication-blocking lesions, thereby promoting a number of repair 
pathways such as translesion synthesis of blocking lesions, HRR and possibly non-homologous 
end joining of broken replication forks (Tebbs et al, 2005; Hinz et al, 2006). In addition, 
FANCG was recently shown to directly interact with the ERCC1/XPF endonuclease (Wang and 
Lambert, 2010).
3.1.2 FANCG is a scaffold phospho-protein central to many repair 
complexes
The tetratricopeptide repeat (TPR) motifs and phosphorylation sites of FANCG have been shown 
to play a role in its protein interactions and the fonnation of the various FANCG complexes such 
as the FA nuclear core, G-BRCA2 and the G-XPF-ERCC1 complexes (Wang et al, 2007b; 
Wilson et al, 2008; Wang and Lambert, 2010), In an attempt to further characterize the role of
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FANCG in the repair of DNA ICLs investigations were carried out to determine how FANCG is 
involved in maintaining chromosome stability in response to ICLs. To do this a FANCG 
deficient Chinese hamster cell line was used (Meyn et al, 1991; Wilson et al, 2001) and 
chromosomal aberrations induced after MMC treatment were assayed using metaphase analysis 
(Wiegant et al, 2006; Auerbach et al, 1979; Rosendorff and Bernstein, 1988; Savage, 1976; 
Marx et al, 1983). Concurrent to these experiments the role of FANCG in homologous 
recombination repair (HRR) of ICL adducts was analysed using an integrated vector based 
system in the same FANCG deficient cell line.
3.1.3 Cell lines used in this chapter
The cell lines used in this chapter were all derived from Chinese hamster ovary (CHO) cell line 
AA8 (Meyn et al, 1991). The cell lines used are either wild type or corrected to wild type 
compared to FANCG defective cell lines. For full details of NM3 cells see sections 1.5.1.1 and 
I.5.I.2.
Cell lines used include NM3, NM3-VO, NM3-S7A, and NM3-S387A and NM3-gWT. NM3 
is a FANCG mutant cell line containing a point mutation resulting in a highly unstable truncated 
protein. Based on its seven fold hypersensitivity to cross linking agent (nitrogen mustard), Meyn 
et al isolated NM3 in 1991 from the CHO cell line AA8. NM3-VO is an NM3 cell line 
transfected with the SCneo2 recombination reporter construct (Johnson et al, 1999; Saleh- 
Gohari and Helleday, 2004), and then transduced with an empty pMMP vector (Qiao et al, 
2001; Qiao et al, 2004; Mi et al, 2004). NM3-gWT is an NM3 cell line transfected with the 
SCneo2 recombination reporter construct and transduced with the wild type fancg cDNA to
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restore its phenotype to that of the wild type cell line (AA8). NM3-S7A is an NM3 cell line 
transfected with the SCneo2 recombination reporter construct and transduced with pMMP vector 
containing the human fancg cDNA mutated at phosphorylation site (S7) serine to alanine 
substitution. NM3-S387A is an NM3 cell line transfected with the SCneo2 recombination 
reporter construct and transduced with pMMP vector containing the human fancg cDNA mutated 
at phosphorylation site (S387) serine to alanine substitution and transfected with the SCneo2 
construct as explained in Methods (Sections 2.1.1.1.1, 2.1.2.7 and Fig. 2.1.
3.1.4 Role of FANCG in HRR and ICL repair
To further investigate the DNA repair pathway through which FANCG is thought to be involved, 
another assay tenned homologous recombination repair (HRR) assay, ‘HRR assay’, which is a 
plasmid based reporter assay has been implemented to evaluate the ability of FANCG deficient 
cells to repair ICLs through the repair pathway HRR. The findings should point out the ability of 
the FANCG mutant cell lines in repairing ICLs through a specific repair pathway which is 
homologous recombination repair and hence the extent of involvement of FANCG protein in 
ICL repair through HRR. Details of the HRR assay are explained in the Methods (Section 
2.1.2.7 and Fig. 2.1).
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3.2 Results
3.2.1 Validation and growth inhibition responses of cell lines used for 
metaphase analysis
3.2.1.1 Immunoblotting
Western blot analysis was performed to confirm the protein expression profile for FANCG in all 
cell lines prior to utilization in other experiments. Figure 3.1 illustrates FANCG protein 
expression detected in cell lines AA8, NM3-gWT and NM3-TPR6 but not in NM3 the FANCG 
null cell line. The loading control p-actin (Figure 3.1) shows an equal amount of protein loaded 
for each cell line tested, thus validating the use of these cell lines in subsequent tests.
Figure 3.2 shows that in the SCneo transfected cell lines, FANCG is detected in NM3-gWT and 
NM3-S7A, NM3-S387A but not in NM3-VO, thus validating the use of these cell lines in 
subsequent tests.
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Western blot of FANCG protein in NM3 cell lines
FANCG
Beta actin
Figure (3.1): Western blot illustrating the absence of FANCG protein from the NM3 cell line and the 
presence of FANCG protein in cell lines AA8, NM3-TPR6 and FANCG-coirected cells NM3-gWT. - Beta 
actin antibody was used as loading control. NM3-TPR6 was obtained by transfecting NM3 with a human 
fancg cDNA mutated at a TPR motif (TPR6). NM3-TPR6 was not used in subsequent experiments.
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Western blot of FANCG protein in NM3 cell lines
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Figure (3.2): Western blot illustrating the absence of FANCG protein from the NM3-VO cell 
line and the presence of FANCG protein in cell lines NM3-S7A, NM3-S387A and FANCG- 
corrected cell line NM3-gWT. Beta actin antibody was used as loading control.
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3.2.1.2 Growth inhibition assays results
To assess the degree of cellular hypersensitivity of these cell lines to the ICL inducing agent 
mitomycin C (MMC), growth inhibition assays were carried out as described in the Methods 
(Section 2.1.2.5), determining the GI-50, which is the dose of agent that allows 50% of the cells 
to grow was determined. From Figure 3.3 it can be seen that NM3-VO was the most 
hypersensitive with a GI-50 value of 38 nM compared to 110 nM seen in NM3-gWT. NM3-VO 
is therefore 2.9-fold more hypersensitive to MMC than the corrected wild type NM3-gWT (Fig. 
3.3). These findings of NM3-VO hypersensitivity to MMC can be compared to the clonal 
survival experiments of Wilson et al in 2001 that showed about 4-fold hypersensitivity to MMC. 
From the graph it can be seen that NM3-S7A had a GI-50 value of 52.5 nM and is 2.1-fold 
hypersensitive to MMC and NM3-S387A has a GI-50 value of 57 nM and is 1.9-fold 
hypersensitive to MMC. These sensitivities observed here are comparable to the sensitivities 
reported by Mi et al., in 2004 and by Qiao et ah, (2004) using a clonal survival assay. On the 
basis of the D37 values, which is the dose of agent that allows 37% of the cells to survive, NM3- 
VO is about 4.3 fold hypersensitive to MMC, NM3-S7A about 3 fold hypersensitive to MMC 
(Qiao et al, 2004) and NM3-S387A about 2,6 fold hypersensitive to MMC (Mi et al, 2004). 
This shows that mutating the phosphorylation sites with the FANCG protein leads to an increase 
in hypersensitivity, which reflects that phosphorylation of FANCG is required to get optimal 
levels of repair when exposed to DNA inter-strand linking agents. This highlights the importance 
of FANCG and its phospho-sites S7 and S3 87 in the ICL repair pathway.
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Growth Inhibition -IMM3- MMC
10 -
Concentration MMC (nM)
Mm3 Scneo2 Pmmp- gWT 
Nm3 Scneo2 Pmmp- VO 
Nm3 Scneo2 Pmmp- S7A 
Nm3 Scneo2 Pmmp- S387A
Figure (3.3): Illustrating MMC growth inhibition data using four cell lines: NM3-gWTt 
NM3-VO, NM3-S7A and NM3-S387A. Three experiments were performed. Error bars 
show the standard error of the mean.
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3.2.2.1 Chromosome and chromatid aberration rates in control cell 
cultures
It can be noted that the number of aberrations per cell in untreated cell lines showed a 
spontaneous rate which did not exceed 0.12 aberration/cell as shown in Tables; 3.1.A, 3.2.A, 
3.3.A and Fig. 3.4. Very few aberrations were recorded for untreated NM3-gWT, only one 
chromatid break as shown in Table 3.3.A. The highest number of aberrations for the untreated 
cells was that recorded for NM3-VO (0.12 aberration/cell) followed by NM3-S7A (0.1 
aberration/cell) then NM3-S387A (0.08 aberration/cell). Also from the same Tables 3.1.A, 
3.2.A, 3.3.A and Fig. 3.5 it may be seen that the percentage of aberrant cells that have occurred 
spontaneously was lowest in NM3-gWT and highest in NM3-VO, whereas NM3-S7A and 
NM3-S387A presented similar numbers of aberrant cells spontaneously.
3.2.2.2 Chromosome and chromatid aberration rates in treated cell 
cultures
Table 3.1.A shows that using doses of 100 nM MMC resulted in NM3-VO, NM3-S7A, NM3- 
S387A producing higher rates of chromosomal aberrations per cell, 1.3, 0.84 and 0.74 
aberration/cell respectively, compared to 0.44 aberration/cell found in NM3-gWT which 
represented about 3, 1.9 and 1.7 fold increases respectively. The same experimental conditions 
were obtained and despite slight variation, the readings of each experiment illustrated that the 
three mutant cell lines presented an increased number of CA compared to NM3-gWT. It is clear
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that in mutant cell lines; NM3-VO, NM3-S7A, NM3-S387A and control cell line NM3-gWT 
that chromatid type aberrations predominate, involving both breaks and exchanges. To a lesser 
extent chromosome type aberrations such as dicentrics or rings have appeared as shown in 
Tables 3.1.A, 3.2.A and 3.3.A. These chromosome exchanges (dicentrics or rings) were not 
observed in the untreated cell lines cultures (controls), but were present, albeit rarely, in some of 
the NM3-VO and NM3-S7A MMC-treated cell line cultures. Based on their findings, Sasaki 
and Tonomura, (1973) made the assumption that these chromosome type aberrations may have 
been derivatives of some cells that have gone through at least a second cellular cycle of mitosis 
in culture. Although this may be possible, these structures may also be formed in some cells after 
the first mitotic division in culture, hi the experiments described here, the time given for cellular 
division allowed one cycle of mitosis in culture, thus the aberrations recorded are most likely a 
reflection of the primary aberrations encountered post the first cellular division and not due to 
cells undergoing a second mitosis.
In the work described here, chromosome breaks were higher than chromosome exchanges in all 
cell lines. Chromosome breaks generally, were still considerably lower in numbers compared to 
chromatid breaks. This can especially be seen in treated mutant cell line cultures; NM3-VO, 
NM3-S7A and NM3-S387A in Tables 3.1.A, 3.2.A and 3.3.A.
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From the Pooled Table 3.4 it can be seen that when using the higher dose of 100 nM MMC the 
average aberrations per cell in the NM3-VO, NM3-S7A, NM3-S387A cell lines were 1.23, 0.91 
and 1.05 respectively, which is 3.3 , 2.5 and 2.8 fold respectively higher than that of the 
corrected NM3-gWT cells. Also, using the higher dose of 100 nM MMC, the average 
percentage of aberrant cells in the NM3-VO, NM3-S7A, and NM3-S387A cell lines were about 
54.6%, 52% and 51.3% aberrant cells respectively, which is 2.1, 2.5 and 2.8 fold respectively 
higher than that of the corrected wild type NM3-gWT cells. The average number of total 
chromatid breaks per cell (after converting all the exchanges into chromatid breaks as described 
in Section 2.1.2.10.4, Table 2.1, Figs. 2.2, 2.3, 2.3 and 2.4 for the same higher dose of 100 nM 
MMC was in NM3—VO, NM3—S7A, NM3—S387A cell lines 2.65, 1.89 and 1.88 chromatid 
breaks/cell respectively, which is 3.1, 2.2 and 2.2 fold respectively higher than that of NM3- 
gWT cells.
This elevation in the level of structural aberrations in FANCG mutant cell lines can be clearly 
observed as average aberrations per cell (Fig. 3.4), average percentage aberrant cells (Fig. 3.5), 
or as average total chromatid breaks (Fig. 3.6). This indicates that the absence of FANCG or 
mutating its phospho-sites S7 or S387 will compromise the ICL repair pathway and this repair 
defect will be visualised as gross cytogenetic aberrations. As seen when using the higher dose of 
100 nM MMC, most CAs are found in the complete absence of FANCG, then followed by high 
CAs rates in FANCG phospho-mutants S7 and S3 87, showing their importance in sustaining 
cellular resistance to inter-strand cross linking agent (MMC).
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3.2.2.3 Aberration types and predominance
Chromatid exchanges were either similar to or higher than chromatid breaks in NM3-gWT 
NM3-VO and NM3-S7A, particularly at the higher dose of 100 nM MMC. Whereas, in the 
NM3-S387A cell line it appears that chromatid breaks consistently exceeded chromatid 
exchanges, in both treated and untreated cellular cultures as seen in Tables 3.1.A, 3.2.A and 
3.3.A. For example in Table 3.1.A, when treating NM3-S387A with a higher dose of 100 nM 
MMC, the number of chromatid breaks in fifty cells scored was 20 breaks compared to 9 
chromatid exchanges, while NM3-S7A at the same MMC dose showed 15 chromatid breaks 
compared to 15 chromatid exchanges. Also, in Tables 3.3.A; at the higher dose of 100 nM 
MMC and fifty cells scored; NM3-S387A had 44 chromatid breaks compared to 24 chromatid 
exchanges, while NM3--S7A at the same MMC dose showed 18 chromatid breaks compared to 
26 chromatid exchanges. This distinct difference in the types of chromatid aberrations suggests 
that phosphorylation of FANCG at serine-7 and serine-387 have distinct roles from one another 
in the repair of ICL.
For further analysis, the findings of the cytogenetic structural experiments presented in Tables 
tagged (A) were further extended in Tables tagged (B) where chromosome and chromatid 
exchanges were further subdivided into other more defined types such as dicentrics, rings, 
triradials, quadri-radials, taking into account the number of chromosomes and centromeres that 
are involved in complex exchanges. Also, in these tables the average number of total chromatid 
breaks per cell has been calculated after converting all the exchanges (chromosome and 
chromatid) into chromatid breaks as described in the Methods (Section 2.1.2.10.4), Table 2.1, 
Figs. 2.2,2.3, 2.3 and 2.4.
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From Tables 3.1.B, 3.2.B and 3.3.B, it can be seen that the predominant type of chromatid 
exchanges are those which involve two chromosomes (classified under complex arrangements). 
These chromatid exchanges involving two chromosomes are higher in occurrence than those 
involving three chromosomes. The involvement of more than three chromosomes in these 
complex arrangements does occur; however, it does so in a lesser extent, as illustrated in the 
same Tables 3.1.B, 3.2.B and 3.3.B. This can be seen in all cell lines especially in mutant cell 
lines, with the highest rate in FANCG null cell line NM3-VO.
3.2.2.4 Classification of cytogenetic aberrations
Both triradials and quadri-radials were noted separately despite the fact that they are classified 
together as chromatid exchanges. Monocentric, dicentric and tricentric triradials were noted. 
Also monocentric, dicentric, tricentric and quadri-centric quadri-radials were observed and 
recorded in Tables 3.1.B, 3.2.B and 3.3.B. The cytogenetic findings were recorded and 
classified in this way in order to account for the number of chromosomes involved in configuring 
any complex chromatid exchange-arrangement. This clear classification method allows the 
calculation of the minimal number of chromatid breaks required for the formation of any 
chromatid exchange by accounting for all the chromosomes that contribute to the formation of 
these complex chromatid exchange-arrangements.
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3.2.3 Homologous recombination repair assay results
As can be seen from Fig 3.7 the HRR-non-induced recombination frequencies of the selected 
cell lines are not very different from the spontaneous recombination frequency found in NM3- 
gWT, which was 1.4 X 10’6. NM3-VO, NM3-S7A and NM3-S387A presented recombination 
frequencies of 1.2 X 10"6, 2.2 X 10"6 and 1.7 X 10‘6 respectively.
After exposure to 100 nM MMC the induced level of recombination detected in the wild type cell 
line raised approximately 1000 fold compared to non-induced (from 1.4 x 10"6 to 10.3 x 10*4). 
From Fig 3.8, NM3-YO, NM3-S7A and NM3-S387A exhibited reduced recombination 
frequencies of 1.8 X 10"4, 3.4 X 10"4 and 4.9 X 10’4 respectively, which are equivalent to about 
5.8, 3 and 2 fold reductions in HRR respectively compared to that of NM3-gWT 10.3 X 10'4. 
The highest homologous recombination rate is seen in NM3-gWT and the lowest HRR rate is 
shown in NM3-VO, while an intermediate HRR rate is demonstrated by NM3-S7A and NM3- 
S387A cells. This indicates that homologous recombination is induced in all these cell lines post 
MMC treatment including the null cell line, indicating that some level of HRR takes place even 
in the absence of the FANCG protein. However, NM3-VO did exhibit the greatest reduction in 
HRR indicating the importance of FANCG in proficient HRR, while partial reduction in FANCG 
phospho-mutant NM3-S7A and NM3-S387A cell lines suggests the occurrence of partial or sub- 
optimal repair in these FANCG phospho-mutant cells. This is compared to the highest HR rate 
presented by NM3-gWT that suggests that for proficient HRR of ICL to occur, FANCG presence 
and its phosphorylation sites S7 and S387 are critical for ICL repair.
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3.3 Discussion
The role of FANCG in ICL repair has been investigated in this chapter. Here, it has been shown 
that expression of FANCG is required for optimal repair of ICLs. This is based on the result that 
in the complete absence of FANCG, NM3-VO (Fig. 3.1 and Fig. 3.2) cells are hypersensitive to 
the DNA inter-strand linking agent MMC. Furthemaore, it has been shown that even if FANCG 
is being expressed, but carries specific mutations at known phosphorylation sites, then the 
function of FANCG is compromised as the cells are also hypersensitive to MMC. This indicates 
that FANCG must play a role in the repair processes to remove ICLs from the DNA and that 
post-translational modifications of FANCG are required for this.
It was also determined that NM3 FANCG null cells exhibit a severe reduction in homologous 
recombination repair in the vector-based assay. In addition, cells expressing the phosphorylation- 
site mutations S7A and S3 87A exhibit levels of HRR intennediate to that of the null and wild 
type cell lines. It is, however, important to remember that the HRR defects observed may not 
necessarily indicate a direct defect in homologous recombination. Failure to correctly process the 
ICLs induced by MMC (for example by ICL unhooking and subsequent steps may not generate 
substrates upon which homologous recombination can act. The reduction of HRR observed in 
NM3-VO, NM3-S7A or NM3-S387A may represent a defect or defects in the repair of ICLs that 
is upstream of HRR.
It is proposed that the first stage in ICLs repair is unhooking of the ICL (Section 1.2.7.2 for 
details). It is known that the FA core complex is involved and promotes this process, but exactly 
how does this occur remains unclear (Wang and Lambert, 2010). In addition, it is known that 
the FA core complex promotes translesion synthesis across the unhooked lesion (Moldovan and
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D’Andrea, 2009; D'Andrea, 2010). FANCG is an integral part of the FA core complex and if 
not expressed this complex fails to form, so that unhooking and translesion synthesis will be 
compromised. In the cell lines carrying the specific phosphorylation mutations, the core complex 
does form and so that it might be assumed that the ICL unhooking and translesion synthesis is 
normal in these cell lines. This may explain why an intennediate cellular sensitivity is observed 
in these cell lines compared to the complete null, NM3-VO. However, it remains a possibility 
that the presence of a FANCG protein mutated at its phosphorylation sites in the core complex 
may result in sub-optimal activity of the complex even though FANCD2 mono-ubiquitination 
still occurs.
The accumulation of unrepaired ICLs is a serious cellular problem. ICLs lead to stalled 
replication forks that will require a combination of repair pathways to restart the replication 
process. The exact mechanism of mammalian ICLs repair is still not very clear (Wang and 
Lambert, 2010). However, it is believed that removal of the unhooked ICLs may involve several 
repair pathways including NER and may involve several mismatch repair proteins including the 
MMR protein complexes MutSJI and MutLa (Zhang et al, 2007; Peng et al.f 2007). In 2010, 
Wang and Lambert established through the use of yeast two hybrid analyses that FANCG 
interacts with ERCC1-XPF endonuclease which mediates the unhooking of ICLs (Bhagwat et 
al., 2009), suggesting that FANCG is a key player in the ICL unhooking repair process, through 
functioning both in the FA core complex and in the ERCC1-XPF complex. It would be 
interesting to determine whether the XPF-ERCC1 complex forms in the phospho-specific 
mutated cell lines and whether the S7A and S387A proteins interact with XPF-ERCC1.
Once the ICLs are removed by a combination of unhooking and lesion removal then, the 
resulting double strand breaks have to be repaired by either HRR or NHEJ (Sections 1.2.6.1 and
136
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1.2.6.2 for details). Previous work in the Liverpool laboratory has shown that FANCG forms the 
G-BRCA2 complex (Wilson et ah, 2008). This complex, through its association with the HRR 
proteins BRCA2, and XRCC3, is postulated to be part of the HRR pathway. Here, further 
evidence is shown that this is the case as in the complete absence of FANCG (NM3-VO), HRR 
is severely compromised after exposure to MMC (Fig 3.8). Furthennore, if either S7 or S387 is 
mutated, the level of HRR detected is also reduced, but not to the extent seen in the null mutant. 
This supports the findings of Wilson et ah, (2008), who showed that phosphorylation of serine 7 
is required for the G-BRCA2 complex to form. Therefore, if HRR is compromised then it is 
thought that NHEJ is the favoured pathway for double-strand breaks. This would mean if the 
error-prone NHEJ was taking place in the absence of error-free HRR, then this would be 
detectable as gross chromosome aberrations. It was also shown that NM3-S387A exhibited a 
reduction in HRR. It has been shown previously that the FANCG-S387A protein is able to form 
the G-BRCA2 complex (Wilson et al, 2008). It may be that the NM3-S387A cells are proficient 
for homologous recombination per se, but are defective in processing ICLs upstream of 
homologous recombination.
From the results section it is clear that when FANCG is missing, a distinct abnormal cytogenetic 
profile is noted post MMC treatment. An elevated rate of chromosome aberrations, mainly of the 
chromatid type, was recorded in the FANCG mutant cells. This response of FANCG mutant cells 
to MMC is clearly seen in Tables 3.1.A, 3.2.A and 3.3.A, where the distribution profiles of 
chromatid aberrations is presented. FANCG mutant cell lines illustrated amplified cytotoxicity 
(elevated hypersensitivity) by the cross-linking agent MMC. Accumulation of chromosomal 
aberrations post exposure to MMC was observed. This suggests that the defective ICL repair
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resulting from FANCG absence or mutating its phospho-sites S7 and S387 is visualised as gross 
cytogenetic aberrations.
The cytogenetic findings of predominance of chromatid type aberrations rather than 
chromosomal type aberrations post MMC treatment is in agreement with findings of Godthelp et 
al, (2006) who reported predominance of MMC induced chromatid type aberrations (exchanges 
and breaks) utilizing FA human B lymphoblastoid cells. Godthelp et al.f (2006) reported 
predominance of chromatid breaks in HSC72 (FA-A) and HSC62 (FA-D1) cells, while 
EUFA423 (FA-D1) cells had predominance in chromatid exchanges.
The cytogenetic findings of predominance of chromatid exchanges is consistent with Marx et 
al., (1983) who indicated the predominance of complex exchange configurations in 
diepoxybutane (DEB) - treated FA human lymphocytes. MMC induced chromatid exchanges 
have also been reported as the predominant aberration type in 1996 by Busch et al, who used an 
MMC-sensitive rodent line, UV40 which is a FANCG mutant cell line mutated at exon 1 
(Lamerdin et al, 2004). These findings of predominance of chromatid exchanges are also 
consistent with Wiegant et al, findings in 2006 who utilised V-C8 Chinese hamster mutant cell 
line defective in BRCA2 and have demonstrated higher levels of MMC induced CAs, 
particularly of the chromatid type compared to that of the wild-type cells. These findings of 
chromatid exchange aberrations predominance are consistent with our findings of chromatid 
exchange aberrations predominance in NM3-VO and NM3-S7A cells. This predominance of the 
chromatid exchange aberrations in NM3-YO and NM3-S7A cells suggest that NHEJ was the 
main available repair pathway in G-BRCA2 complex deficient NM3-VO and NM3-S7A cells to 
repair MMC induced DNA cross links, as exchanges reflect mis-repair by error prone-NHEJ.
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Nevertheless, one paper by Liu et ai, in 1997 reported MMC-induced chromatid breaks to be 
predominant in UV40 (FANCG mutant).
On the other hand, the cytogenetic findings of predominance of the chromatid breaks in (NM3 - 
S387A) cells post MMC treatment is not an isolated finding, as others have also reported similar 
observations. Utilizing human dermal fibroblasts, Latt et ah, (1975) also reported increased 
MMC induced chromatid breaks. Prevalent MMC induced chromatid breaks with sporadic 
quadri-radials occurrence have been pointed out by Duckworth-Rysiecki et al.f (1984) using FA 
human lymphocytes post MMC or DEB treatment. Moreover, Auerbach et ah, (1979) had 
reported predominance of DEB induced chromatid breaks in FA human fetal cells. The 
predominance of DEB and MMC induced chromatid breaks have been also demonstrated by 
Rosendorff and Bernstein, (1988) using FA human lymphocytes and have been illustrated by 
Tomkins et ah, (1998) using a mouse cell line defective in FA (C) particularly post MMC 
exposure. These findings of chromatid breaks predominance are consistent with our findings 
chromatid breaks predominance in NM3 -S387A cells. This predominance of the chromatid 
breaks suggests that the NHEJ repair pathway in NM3 -S387A may have been less involved in 
the repair of (ICLs) and that HRR or other repair pathways may have been more available. In 
NM3 -S387A cells, the FANCG complexes are present (the FA-core and the G-BRCA2 
complexes), nevertheless predominance of chromatid breaks is observed. It is not clear why 
chromatid breaks predominate in NM3 -S387A cells, however one can speculate that the 
occurrence of chromatid breaks rather than chromatid exchanges in NM3 -S387A could have 
resulted from partial FANCG activity that sustains its ability to suppress NHEJ. If so, this might 
explain the predominance of chromatid breaks in these cells, as intennediates of ICL repair in 
NM3-S387A would not be mis-repaired by NHEJ (that would lead to exchanges) but instead
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would remain unrepaired, leading to the observed chromatid breaks. The sub-optimal FANCG 
activity in NM3 -S387A cells could have affected only processing double strand breaks down 
stream without affecting the unhooking step upstream. Alternatively, the fonnation of the G- 
ERCC1-XPF complex may be dependent on S3 87 phosphorylation reducing the unhooking of 
ICLs upstream which may have led to the prevalence of chromatid breaks.
Taken these findings together, these observations further support the view that the G-BRCA2 is 
very likely promotes proficient HRR to sustain genomic stability.
If HRR were compromised in the FANCG mutated cell lines then one would expect to observe 
an increase in the number of exchanges in these cell lines. From Tables 3.1.A, 3.2.A and 3.3.A 
it is clear that this is indeed the case, with NM3-VO and NM3-S7A having predominantly 
chromatid exchanges after MMC damage. This gives further evidence that in response to ICL 
damaging agents that action of FANCG is required through the three distinct complexes; FA core 
complex, G-ERCC1-XPF for unhooking and G-BRCA2 for HRR.
FANCG phospho-mutant cells S7A and S3 87A had intennediate levels of MMC hypersensitivity 
as shown by growth inhibition data (Fig.3.3), intermediate levels of CA as shown by the average 
of total chromatid breaks per cell (Fig.3.6) at 100 nM MMC and illustrated intermediate levels of 
HRR as shown in Fig.3.8. This suggests the occurrence of partial repair in these phospho-mutant 
cells. The core complex which forms in NM3-S7A may contribute to this partial repair. In NM3- 
S387A, despite the fact that both the FA core and G-BRCA2 complexes are formed, the function 
of FANCG may have become sub-optimal due to the phospho-mutation at S387 site. 
Alternatively, phosphorylation of serine-387 may be required for the interaction of FANCG with 
the ERCC1-XPF endonuclease and reduced unhooking of ICLs might lead to the prevalence of
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chromatid breaks in the NM3-S387A cell line. This possibility needs further investigation. The 
different predominating types of aberrations produced by NM3-S7A (chromatid exchanges) and 
NM3-S387A (chromatid breaks), indicate that NHEJ has been more active in NM3-S7A, 
probably due to the absence of G-BRCA2 complex resulting in more chromatid exchanges. 
Conversely, NHEJ has been less active in NM3-S387A, probably due to the presence of G- 
BRCA2 complex, and possibly also to continued suppression of NHEJ, even when FANCG is 
mutated at S387 resulting in the predominance of chromatid breaks. This signifies the 
importance of FANCG and its phosphorylation sites in determining the repair pathway in ICE 
repair.
It is worth mentioning that with the introduction of molecular cytogenetics, florescent in situ 
hybridization (F.LS.H.) around the mid 90’s, it revealed the more subtle chromosomal-exchanges 
that could not be detected through classical cytogenetics. Such chromosomal-exchanges would 
include small para-centric or peri-centric inversions, balanced or non-balanced translocations, 
micro-deletions, or amplifications. Florescent in situ hybridization implemented whole 
chromosome paints, whole arm chromosome paints, centromeric, telomeric and specific 
sequence probes in order to reveal a higher degree of chromosomal instability than previously 
reported (Savage and Simpson, 1994; Savage, 2002; Obe etal, 2002). Had these methods been 
implemented in this project they would have possibly given a more in depth insight of the extent 
of instability encountered by FA cells and further explored the types of chromosome and 
chromatid aberrations produced by FA cells (Van Limbergen, et at, 2002; Sra et al., 2005).
As pointed earlier in this discussion the reduction in the HRR assay utilized may either reflect a 
direct defect in homologous recombination repair of the DSB generated during the course of ICE 
processing by the FA pathway, or alternatively, a defect in processing the ICE correctly to
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generate a substrate upon which homologous recombination may act. In order to further elucidate 
the function of FANCG and the role of the phosphorylations in HRR and the FA pathway it was 
decided to carry out an investigation using an agent (phleomycin) that directly induces both 
single-strand and double-strand breaks in DNA. As these lesions may be acted upon by 
homologous recombination directly, without further processing (unlike ICLs), it should be 
possible to gain insight into whether FANCG and its phosphorylated isoforms function directly 
in homologous recombination. If, as suggested above, the G-BRCA2 complex has a direct role in 
homologous recombination repair, it would be anticipated that NM3-S7A and NM3-VO cells 
would be defective in the repair of the DNA strand-breaks induced by phleomycin. This 
hypothesis will be tested in the next chapter (Chapter-4).
3.4 Summary of the chapter
• It has been demonstrated that NM3 cell lines expressing FANCG proteins mutated at its 
serine 7 and serine 387 phosphorylation sites exhibit intennediate hypersensitivity to the 
inter-strand cross-linking agent MMC, indicating the importance of these post- 
translational modifications in ICL repair.
• Consistent with their cellular hypersensitivity to MMC, NM3-S7A and NM3-S387A cells 
exhibit reduced rates of MMC-induced homologous recombination repair in a plasmid- 
based reporter assay, at a level that is intermediate to that shown by the null mutant cell 
line (NM3-VO) and the wild type cell line (NM3-gWT).
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• NM3-V0 cells exhibit a large increase in MMC-induced chromosomal aberrations, these 
aberrations being predominantly chromatid aberrations, with chromatid exchanges being 
the most prevalent aberrations observed.
• Consistent with their intermediate cellular hypersensitivity to MMC, NM3-S7A and 
NM3-S387A cells exhibit increased levels of chromosomal aberrations in response to 
MMC, although these are at a lower level than those observed in NM3-VO.
• Despite showing similar overall increases in MMC-induced chromosomal aberrations, the 
predominant type of aberration differs in NM3-S7A and NM3-S387A. Chromatid 
exchanges are more common in NM3-S7A, while chromatid breaks are more common in 
NM3-S387A. This suggests different functions of FANCG are associated with these two 
phosphorylation sites of FANCG.
• As FANCG is known to participate in at least 3 different protein complexes in the FA 
pathway (FA core complex, G-BRCA2 complex and G-XPF-ERCC1 complex), it is 
possible that the differing functions of the phospho-Ser7-FANCG and phospho-Ser387- 
FANCG proteins are mediated through different protein complexes.
• As it is known that phosphorylation of FANCG at Ser7 is required for the formation of 
the G-BRCA2 complex (that contains two proteins, BRCA2 and XRCC3, known to 
participate in HRR), it seems likely that this complex is required for the repair, by HRR, 
of the double-strand breaks that arise indirectly from the processing of ICLs. This 
hypothesis will be tested in the next chapter using an agent (phleomycin) that induces 
direct DNA strand breaks.
• Given that mutation of S3 87A has no effect on the formation of the G-BRCA2 complex, 
it is proposed that this Ser387 phosphorylation is important “upstream” of HRR in the
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repair of ICLs, possibly in unhooking or translesion synthesis stages. The observed 
reduction of HRR in NM3-S387A using the SCneo assay may result from the failure to 
process ICLs to a point where they are substrates for HRR. The presence of 
predominantly chromatid breaks in NM3-S387A also suggests that NHEJ is not 
significantly active in NM3-S387A (be it through the failure to generate double-strand 
breaks upon which NHEJ can act or continued suppression of NHEJ).
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Chapter-4
Investigating the role of FANCG protein in the repair of induced DNA 
double strand breaks
4.1 Introduction
4.1.1 DNA strand breaks
In chapter 3 it was shown that FANCG functions in the repair of ICL, most likely in upstream 
events that lead to the generation of a DNA double-strand break (DSB) and subsequently repair 
of that DSB by HRR. In this chapter, the focus is on the repair of another type of DNA damage, 
DNA strand breaks, and more specifically, directly-induced DNA double-strand breaks (DSBs). 
DSBs may be produced post exposure to exogenous elements such as chemical DNA-damaging 
agents, radiation or X-rays. DSBs may also appear at natural replication pause sites when DNA 
polymerases stall (Rothstein et ah, 2000).
4.1.2 NM3 cells hypersensitivity to radiomimetic agents
Evidence for FANCG being involved in other repair pathways other than the repair of ICL 
comes from work showing that the FANCG mutated cell line NM3, exhibited hypersensitivity 
not only to cross linking agents such as MMC, DEB and chlorambucil but also to radiomimetic 
agents bleomycin and streptonigrin and the monofunctional alkylating agent EMS. The
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hypersensitivity of NM3 to bleomycin was 7.5 fold compared to 4.3 fold hypersensitivity to 
MMC (Wilson et al, 2001). This hypersensitivity to bleomycin had also been reported in other 
FANCG mutant Chinese hamster ovary cell lines (Busch et al, 1996; Tebbs et al, 2005).
As previously mentioned the G-BRCA2 complex is composed of FANCD1/BRCA2-FANCD2- 
FANCG-XRCC3 (Wilson et al, 2008) and research has shown that the CHO cell lines mutated 
for either XRCC3 (irslSF) or BRCA2 (VC-8) are hypersensitive to radiomimetic agents (Fuller 
and Painter, 1988; Overkamp et al, 1993). Given this information, further backed by research 
showing that both XRCC3 and BRCA2 interacted directly with FANCG (Hussain et al, 2003; 
Hussain et al, 2004; Hussain et al, 2006), it was decided to investigate whether FANCG is 
involved in the repair of DSB induced by the radiomimetic agent, phleomycin. Furthermore, to 
investigate whether the post translational modifications of FANCG optimize this function, as 
they do for the repair of ICLs.
4.1.3 Cell lines used in this chapter
The cell lines used in this chapter are the same cell lines used in Chapter 3; NM3, NM3-VO, 
NM3-S7A, NM3-S387A and NM3-gWT.
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4.2 Results
4.2.1 Survival assays results
To assess the degree of cellular hypersensitivity of these cell lines to phleomycin, initial survival 
experiments were carried out. From Figure 4.1 it can be seen that NM3-VO is 4.6 fold 
hypersensitive to phleomycin compared to NM3-gWT in survival assays on the basis of D37 
values (dose required to reduce survival to 37%). The NM3-S7A cell line was 3.6-fold 
hypersensitive to phleomycin, and is similar in response to NM3-VO Fig. 4.1. This shows that 
FANCG is involved in the repair of phleomycin-induced DNA damage and that phosphorylation 
of serine 7 is required for optimal repair of this damage. The D37 for NM3-S7A was 350 ng/ml 
and 270 ng/ml for NM3-VO, compared to a D37 of 1240 ng/ml for NM3-gWT cell line (Fig. 4.1). 
NM3-S387A cell line survival data were very similar to NM3-gWT cell line (Fig. 4.1) 
suggesting that phosphorylation of serine 387 is not critical for the repair of phleomycin-induced 
DNA damage. Once established, the D37 value was the starting point for determining the doses 
required for the CA assay. The highest dose selected for testing reduced extensively the mitotic 
index (MI), but only to the extent where sufficient mitotic cells could still be found for 
chromosomal analysis. Triplicate cultures from each cell line for each dose were set allowing 
more cells to be scored and improving the assays’ sensitivity.
4.2.2 Growth inhibition assays results
As phleomycin-hypersensitivity had not previously been shown in NM3 cells, growth inhibition 
assays were performed to confirm the survival assay results. NM3-VO has a GI-50 value of 265
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ng/ml compared to 1030 ng/ml for NM3-gWT (Fig. 4.2). This makes NM3-VO 3.9-fold 
hypersensitive to phleomycin compared to the corrected wild type NM3-gWT. NM3-S7A had a 
GI-50 value of 240 ng/ml and so is 4.3-fold hypersensitive to phleomycin. NM3-S387A had a 
GI-50 value of 690 ng/ml and so is only 1.5-fold more sensitive to phleomycin (Fig. 4.2). Thus 
the results of the growth inhibition assays are consistent with findings of survival assays Fig. 4.1. 
This supports FANCG involvement in repairing DSBs and the importance of the phosphorylation 
of serine 7 in this repair.
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4.2.3 Chromosomal aberration analysis results
4.2.3.1 Preliminary metaphase analysis in NM3 and NM3-gWT post 
exposure to low doses of phleomycin
At this point it was decided to further investigate these findings at the chromosomal level 
through the exposure of NM3-YO and NM3-gWT to appropriate doses of phleomycin. In order 
to reach optimal experimental conditions, a reasonable growth index had to be obtained in 
metaphase spreads with minimal chromosomal overlapping (Appendix-10). Initially, in the 
course of optimization, lower phleomycin doses were utilized and were gradually increased. 
Tables 4.1 and 4.2 illustrate the type and number of chromosome aberrations presented when 
using these low doses of phleomycin. Table 4.1 shows that using doses of 40 and 120 ng/ml 
phleomycin resulted in NM3 producing higher rates of chromosomal aberrations 0.16 and 0.23 
aberration/cell respectively than that seen in NM3-gWT which are 0 and 0.01 aberration/cell 
respectively. The following experiment (Table 4.2) using doses of 80,120 and 160 ng/ml 
phleomycin resulted in CA rates in NM3 slightly higher that that shown by NM3-gWT Table 
4.1. Also, when using the dose 120 ng/ml in both experiments (Tables 4.1 and 4.2) different 
numbers of CA per cell were obtained for NM3, 0.23 and 0.06 aberrations per cell respectively, 
despite using identical experimental conditions and this could not be explained. Although these 
readings illustrated that FANCG mutant cells presented an increased number of CA compared to 
NM3-gWT, it was decided to increase the phleomycin dose in an attempt to have a more distinct 
separation between the numbers of aberrations scored in the two cell lines and to avoid possible 
over lapping as a consequence of using low doses.
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Table 4.3 demonstrates chromosome aberrations presented when using higher doses of 
phleomycin. Doses of 400, 600 and 800 ng/ml phleomycin resulted in NM3 producing 
chromosomal aberrations around 8-fold higher that NM3-gWT in response to the highest dose 
(800 ng/ml). There is a dose related increase in chromosomal aberrations in the NM3 cell line. 
However, NM3-gWT illustrated some resistance and presented fewer aberrations even at higher 
doses of phleomycin.
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4.2.3.2 The introduction of NM3-S7A cell line to phleomycin cytogenetic 
structural aberration assays using selected doses
After deciding the phleomycin doses to use in these cytogenetic experiments, a number of 
experiments were carried out using phleomycin doses of 1200 ng/ml and 1600 ng/ml on three 
cell lines; NM3-VO, NM3-S7A and NM3-gWT Tables 4.4.A and 4.5.A. However, the dose of 
1600 ng/ml proved to be too high, resulting in excessive reduction of the mitotic index. 
Therefore, in the third experiment Tables 4.6.A the 1200 ng/ml dose was kept and a dose of 600 
ng/ml used instead of 1600ng/ml. Another dose of lOOOng/ml phleomycin has been used in these 
experiments (Table 4.7.A). The metaphase scores remained at 100 metaphases scored for the 
untreated negative controls, but was reduced to either 50 or 20 metaphases scored for the higher 
doses due to the prevalence of chromosomal aberrations. The percentage of aberrant cells was 
calculated and presented in Tables 4.4.A, 4.5.A, 4.6.A and 4.7.A.
4.2.3.3 The introduction of NM3-S387A cell line to phleomycin cytogenetic 
structural aberration assays using selected doses
Following the introduction of NM3-S7A cell line to the aberration assays, it was decided to 
include NM3-S387A cell line and use a phleomycin dose of 1000 ng/ml for these four cell lines; 
NM3-VO, NM3-S7A, NM3-S387A and NM3-gWT as shown in Tables 4.7.A, 4.8.A, 4.9.A, 
4.10.A and 4.11.A.
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4.23,4 Chromosome and chromatid aberration rates in control cell cultures
It can be noted that the number of aberrations per cell in untreated cell lines presented a 
spontaneous rate which did not exceed 0.16 aberration/cell as shown in Tables 4.4.A, 4.5.A,
4.6. A, 4.7.A, 4.8.A, 4.9.A, 4.10.A and 4.11.A and shown in Figures 4.3, 4.4 and 4.5. Virtually 
no aberrations were recorded for untreated NMS-gWT. The highest number of aberrations per 
cell for the untreated cells was that recorded for NM3- S7A 0.16 aberration/cell (Table 4.9.A) 
followed by NM3- VO 0.15 aberration/cell (Table 4.4.A), then NM3-VO 0.09 aberration/cell 
(Table 4.8.A). For NM3--S387A the highest number of aberrations per cell for the untreated cells 
was 0.06 aberrations per cell (Table 4.9.A). Also, from the same Tables 4.4.A, 4.5.A, 4.6.A,
4.7. A, 4.8.A, 4.9.A, 4.10.A and 4.11.A and Figs. 4.3, 4.4 and 4.5 it can be seen that the 
percentage of aberrant cells that have occurred spontaneously was lowest in NM3-gWT and 
generally highest in both NM3-VO and NM3-S7A, followed by NM3-S387A.
4.2.3.5 Chromosome and chromatid aberration rates in treated cell cultures
Table 4.4.A shows that using doses of 1200 ng/ml phleomycin resulted in NM3-VO and NM3- 
S7A, producing higher rates of chromosomal aberrations per cell 1.72 and 2.61 aberrations per 
cell respectively compared to 0.1 aberration/cell found in NM3-gWT, which represents a 17.2- 
and 26.1-fold increase respectively. The same experimental conditions were used in Table 4.5.A 
and despite slight variation, the readings illustrated that FANCG mutant cell lines NM3-VO and 
NM3-S7A presented an increased number of CA compared to NM3-gWT. Table 4.5.A 
illustrates NM3-VO, NM3-S7A, producing higher rates of chromosomal aberrations per cell 1.6
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and 3.25 aberration/cell respectively compared to 0.25 aberrations per cell found in NM3~gWT 
which represents about 6.4 and 13 fold increases respectively.
The same can be seen in Table 4.7.A when using doses of 1000 ng/ml phleomycin, where NM3- 
VO, NM3-S7A, produced higher rates of chromosomal aberrations per cell 1.18 and 1.5 
aberration/cell respectively compared to 0.12 aberration/cell found in NM3-gWT, which 
represented 9.8 and 12.5 fold increase respectively. This suggests that in the absence of G- 
BRCA2 complex the phleomycin-induced damage repair pathway was defective, which led to 
increased levels of CAs in NM3-VO and NM3-S7A. On the other hand, NM3-S387A cells 
produced rates of chromosomal aberrations per cell similar to that of NM3-gWT cells as shown 
in Tables 4.8.A, 4.9.A, 4.10.A, 4.11.A. For example, in Table 4.8.A using a dose of 1000 ng/ml 
phleomycin, NM3-S387A cells produced 0.36 CA per cell compared to NM3-gWT with 0.32 CA 
per cell. This suggests that the mutation of the phosphorylation site FANCG-S387 did not affect 
the repair pathway for phleomycin-induced strand breaks and consequently that phosphorylation 
of FANCG at serine 387, unlike serine 7, is not required for efficient repair.
4.2.3.6 Average aberrations per cell, percentage aberrant cells and number 
of total chromatid breaks per cell
From the Pooled Table 4.12 it can be seen that when using a dose of 1000 ng/ml phleomycin, 
the average aberrations per cell in the NM3-VO and NM3-S7A cell lines was 1.31 and 1.76 
respectively, which is 5- and 6.8-fold respectively higher than that of the corrected wild type
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NM3-~gWT cells. NM3-S387A had 0.15 average aberrations per cell similar to the average for 
NM3-gWT (0.26 aberrations per cell).
In addition, for 1000 ng/ml phleomycin, the average percentage of aberrant cells in the NM3- 
VO and NM3-S7A was 56.8 and 67.2 % aberrant cells respectively, which is 3.1 and 3.7 fold 
higher than that of the corrected NM3-gWT cells. For NM3-S387A the average percentage of 
aberrant cells was 11.5% compared to an average of 18.2% for NM3-gWT (Table 4.12).
The average number of total chromatid breaks (after converting all the exchanges into chromatid 
breaks) per cell for 1000 ng/ml phleomycin was 3.25 and 4.12 chromatid breaks/cell in NM3- 
VO andNM3-S7A respectively, which is 7.2- and 9.2-fold higher than that of the corrected 
NM3-gWT cells. For NM3-S387A, the average number of total chromatid breaks was 0.27 
chromatid breaks per cell compared to 0.45 chromatid breaks/cell for NM3-gWT (Table 4.12). 
This elevation in structural aberrations in FANCG mutant cell lines NM3-VO and NM3-S7A 
can be clearly seen in graphs as average aberration per cell (Fig. 4.3), average percentage 
aberrant cells (Fig. 4.4), or as average total chromatid breaks per cell (Fig. 4.5). All of the NM3- 
phleomycin cytogenetic data shown in Figs. 4.3, 4.4 and 4.5 supports one another and are 
consistent with the cellular survival and growth inhibition data. NM3-S387A and NM3-gWT 
cell lines exhibit proficient repair of phleomycin DNA induced damage and a reduced ability of 
NM3-VO and NM3-S7A cells to repair this phleomycin-induced DNA damage. This suggests 
that a mutation of the phosphorylation site FANCG-S387 did not affect the repair pathway for 
phleomycin induced DNA strand breaks, which is expected, as phosphorylation of this site is not 
required for the formation of the G-BRCA2 protein complex. It also suggests that in the absence 
of G-BRCA2 complex in NM3-VO and NM3-S7A cells, the repair pathway required to process 
phleomycin induced DNA damage in an error-free pathway, that does not result in chromosomal
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aberrations was defective. It is likely that a more error-prone pathway, such as NHEJ, acted on 
these lesions instead.
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4.2.3.7 Aberration type and predominance
It is clear that in FANCG mutant cell lines; NM3-VO, NM3-S7A, NM3-S387A and in the 
control cell line NM3-gWT, that chromatid type aberrations predominate, involving breaks and 
exchanges as illustrated in Tables 4.4.A, 4.5.A, 4.6.A, 4.7.A, 4.8.A, 4.9.A, 4.10.A and 4.11.A, 
When comparing CA types in NM3-VO and NM3-S7A cells, it can also be seen that the 
occurrence of chromatid breaks in NM3-S7A cells is generally higher than that recorded in 
NM3-VO as seen in Tables 4.4.A, 4.5.A, 4.6.A, 4.7.A, 4.8.A, 4.9.A, 4.10.A and 4.11.A. From 
the same tables it can be noted that chromatid exchanges predominate in NM3-VO and NM3- 
S7A, while chromatid breaks predominate in NM3-gWT and NM3-S387A. From Tables 4.4.B,
4.5. B, 4.6.B, 4.7.B, 4.8.B, 4.9.B, 4.10.B, and 4.11.B, it can be seen that in NM3-VO and NM3- 
S7A, the predominant type of chromatid exchanges are exchanges that involve either two or 
three chromosomes (classified under complex arrangements). These chromatid exchanges 
involving two or three chromosomes seem to be higher in occurrence than those involving four 
chromosomes. The involvement of more than four chromosomes in these complex arrangements 
does occur; however, it does so in a lesser extent, as illustrated in the same Tables 4.4.B, 4.5.B,
4.6. B, 4.7.B, 4.8.B, 4.9.B, 4.10.B, and 4.11.B.
This variation in aberration type produced in these cell lines suggests the presence of different 
repair pathways used to process the phleomycin induced DNA damage. These findings suggest 
that NF1EJ was the main available repair pathway in G-BRCA2 complex deficient NM3-VO and 
NM3-S7A cell lines to repair phleomycin induced DNA strand breaks, as exchanges reflect mis- 
repair by error prone-NHEJ. This data also suggests that HRR was the main available repair 
pathway in NM3-gWT and NM3-S387A cell lines in repairing phleomycin induced DNA
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damage (DNA strand breaks), as fewer exchanges are observed in these two cell lines, that are 
both able to form the G-BRCA2 complex.
The presence of dicentrics or rings has been observed occasionally in untreated cultures 
(controls) and had been noted more often in treated cultures especially in NM3-YO and NM3- 
S7A cell lines as shown in Tables 4.4.B, 4.5.B, 4.6.B, 4.7.B, 4.8.B, 4.9.B, 4.10.B and 4.11.B. 
Generally, chromosome breaks were slightly higher than chromosome exchanges in all cell lines, 
especially NM3-gWT and NM3-S387A cell lines and were similar to the number of 
chromosome exchanges in NM3-VO and NM3-S7A. Chromosome breaks generally, were still 
considerably lower in numbers compared to chromatid breaks. This is particularly seen in treated 
FANCG mutant cell lines cultures NM3-VO and NM3-S7A as shown in Tables 4.4.B, 4.5.B, 
4.6.B, 4.7.B, 4.8.B, 4.9.B, 4.10.B and 4.11.B. Whereas, NM3-gWT and NM3-S387A presented 
similarly low numbers of both chromosome breaks and chromatid breaks. Once again suggesting 
that HRR was the main available repair pathway in NM3-gWT and NM3 -S387A cell lines in 
repairing phleomycin induced DNA damage (DNA strand breaks).
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4.2.3.8 Cytogenetic numerical aberration rates in control and treated cell
cultures
CHO cell lines are immortalized cell lines with chromosomal counts ranging between 18-20 
chromosomes per metaphase as observed in unstressed culture conditions. However, this 
numerical range increases when FANCG deficient CHO cell lines are exposed to phleomycin to 
reach 21 to 25+ chromosomes per metaphase as illustrated in Tables 4.13, 4.14, 4.15, 4.16, and 
4.17. Table 4.18 shows an average summary of Tables 4.13,4.14, 4.15, 4.16, and 4.17. It can be 
noted, that while both NM3-VO and NM3-S7A exhibit an elevation of chromosome numbers 
when exposed to phleomycin doses of 1000 ng/ml, 1200 ng/ml and 1600 ng/ml, NM3-gWT 
demonstrates numerical stability spanning the usual range of 18-20 chromosomes when exposed 
to same doses of phleomycin.
Both NM3-VO and NM3-S7A exhibit elevated rates of chromosome numbers in Tables 4.13, 
4.14, 4.15, 4.16, and 4.17 compared to NM3-gWT. For example, in response to a dose of 1200 
ng/ml, NM3-VO and NM3-S7A showed in Table.4.13 an average chromosome number of 23.2 
and 24.4 respectively, compared to an average of 19.52 chromosomes in NM3-gWT. Also in 
Table.4.14, in response to a dose of 1200 ng/ml, NM3-VO and NM3-S7A exhibit an average 
chromosome number of 23.5 and 24.5 respectively compared to an average of 17.85 
chromosomes for NM3-gWT. This numerical elevation is also observable in Table.4.16 in 
response to a dose of 1000 ng/ml, where NM3-VO and NM3-S7A showed an average 
chromosome number of 22.65 and 23.65 respectively compared to an average of 19.75 
chromosomes presented in NM3-gWT. This data illustrates that NM3-S7A is exhibiting a degree
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of chromosomal numerical instability similar to that of NM3-VO suggesting and supporting 
evidence indicating the importance of phosphorylation of FANCG-serine at position 7 in 
sustaining chromosomal integrity.
This chromosomal numerical elevation in YA-FANCG deficient cell lines NM3-VO and NM3- 
S7A was not observed in NM3-S387A cell line, which demonstrated wild type NM3-gWT 
chromosomal numerical levels spanning the usual range of 18-20 chromosomes when exposed to 
same doses of phleomycin, as shown in Table 4.17. These observations have been consistent and 
can be seen in Fig. 4.6 and in Table 4.18 that shows an average summary of Tables 4.13, 4.14, 
4.15,4.16, and 4.17.
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Data- Table (4.13) Phleomycin treated NM3 cell lines - 
Average chromosome numbers count in experiment
Cell line
Treatment
Phleomycin
ng/ml
Total 
number 
of cells 
sampled
Average
chromosome
numbers
count
NMS-gWT 0 100 19.14
NM3-gWT 1200 100 19.52
NM3-gWT 1600 100 19.48
NM3-VO 0 100 19.9
NM3-VO 1200 100 23.2
NM3-VO 1600 100 24.09
NM3-S7A 0 100 20.14
NM3-S7A 1200 100 24.4
NM3-S7A 1600 100 23.82
185
Abdulaziz Aladwani PhD
Data- Table (4.14) Pbleomycin treated NM3 cell bnes - 
Average chromosome numbers count in experiment
Cell line
Treatment
Phleomycin
ng/ml
Total 
number 
of ceUs 
sampled
Average
chromosome
numbers
count
NM3-gWT 0 100 18.84
NM3-gWT 1200 20 17.85
NM3-gWT 1600 20 20.35
NM3-VO 0 100 19.97
NM3-VO 1200 20 23.5
NM3-VO 1600 20 21.8
NM3-S7A 0 100 19.82
NM3-S7A 1200 20 24.5
NM3-S7A 1600 20 23.65
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Data- Table (4.15) Phleomycin treated NM3 cell lines - 
Average chromosome numbers count in experiment
Cell line
Treatment
Phleomycin
ng/ml
Total 
number 
of cells 
sampled
Average
chromosome
numbers
count
NM3-gWT 0 100 19.06
NMS-gWT 600 20 19.3
NMa-gWT 1200 20 19.85
NM3-VO 0 100 19.53
NM3-VO 600 20 22.65
NM3-VO 1200 20 25.05
NM3-S7A 0 100 19.78
NM3-S7A 600 20 23.8
NM3-S7A 1200 20 22.25
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Data- Table (4.16) Phleomycin treated NM3 cell lines - 
Average chromosome numbers count in experiment
Cell line
Treatment
Phleomycin
ng/ml
Total 
number 
of cells 
sampled
Average
chromosome
numbers
count
NMS-gWT 0 50 19.02
NM3-gWT 1000 100 19.75
NM3-VO 0 100 19.73
NM3-VO 1000 20 22.65
NM3-S7A 0 100 19.8
NM3-S7A 1000 20 23.65
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Data- Table (4.17) Phleomycin treated NM3 cell lines - 
Average chromosome numbers count in experiment
Cell line
Treatment
Phleomycin
ng/ml
Total
number
of cells 
sampled
Average
chromosome
numbers
count
NM3-gWT 0 100 19.78
NM3-gWT 1000 20 21.35
NM3-VO 0 100 19.6
NM3-VO 1000 20 23
NM3-S7A 0 100 20.09
NM3-S7A 1000 20 23.5
NM3-S387A 0 100 19.97
NM3-S387A 1000 20 20.45
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Data- Table (4.18) Phleomycin treated NM3 -Average Number of
chromosome in five experiments as shown in tables (4.13, 4.14, 4.15, 4.16, and 
4.17). STDEV: Standard deviation, SE: Standard error of the mean.
Cell line
Treatment
phleomydn
ng/ml
Total number 
of cells 
sampled
Average
no. of
chromosomes 
in All
Experiments
STDEV
of no. of 
chromosomes 
in All
Experiments
SE
of the mean of 
no. of
chromosomes 
in All
Experiments
NM3-gWT 0 450 19.17 0.36 0.16
NM3-gWT 600 20 19.30
NM3-gWT 1000 120 20.55 1.13 0.80
NM3-gWT 1200 140 19.07 1.07 0.62
NM3-gWT 1600 120 19.92 0.62 0.44
NM3-VO 0 500 19.75 0.19 0.08
NM3-VO 600 20 22.65
NM3-VO 1000 40 22.83 0.25 0.17
NM3-VO 1200 140 23.92 0.99 0.57
NM3-VO 1600 120 22.95 1.62 1.15
NM3-S7A 0 500 19.93 0.17 0.08
NM3-S7A 600 20 23.80
NM3-S7A 1000 40 23.58 0.11 0.06
NM3-S7A 1200 140 23.72 1.27 0.73
NM3-S7A 1600 120 23.74 0.12 0.09
NM3-S387A 0 100 19.97
NM3-S387A 600
NM3-S387A 1000 20 20.45
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4.2.3.9 Chromatid Gaps in phleomycin-treated cell lines
Tables 4.4.A, 4.5.A, 4.6.A, 4.7.A, 4.8.A, 4.9.A, 4.10.A and 4.11.A illustrate the increase in the 
number of gaps scored in FANCG mutant cell lines NM3-VO and NM3-S7A particularly when 
using the higher doses of 1000 ng/ml, 1200 ng/ml and 1600 ng/ml of phleomycin. This elevation 
in scored gaps may indicate these gaps as actual breaks in response to clastogen treatment rather 
than staining variation. For example, NM3-VO and NM3-S7A exhibit gaps in Table 4.4.A at 
4.3 and 4.5-fold higher than NM3-gWT at a phleomycin dose of 1200 ng/ml. NM3-VO and 
NM3-S7A cells also showed gaps (Table 4.8.A) at 5.7 and 5-fold higher rates than NM3-gWT at 
a phleomycin dose of 1000 ng/ml. Whereas, NM3-S387A exhibits a similar number of gaps to 
that observed in the wild type NM3-gWT for the same dose, as illustrated in Tables 4.8.A, 
4.9.A, 4.10.A and 4.11.A. The numbers of gaps were small in comparison to the number of 
chromatid breaks induced. Therefore, even if they were considered as genuine clastogen-induced 
breaks, and included in the analyses described above, this would not alter the overall 
interpretation of the data.
4.2.4 Homologous recombination repair assay results
As can be seen from Fig. 4.7, the non-induced homologous recombination frequencies of the cell 
lines were very similar. The spontaneous recombination frequencies were 1.4 X 10‘6 for NM3- 
gWT, 1.32 x 106forNM3-VO, 1.23 x 106forNM3-S7Aand 1.53 xl06forNM3-S387A.
This is compared to findings presented in Fig. 4.8, where the same cell lines were exposed to a 
dose of (800 ng/ml) phleomycin inducing DNA damage, and analyzed following a recovery
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period allowing HRR to take place. As illustrated in Fig. 4.8, NM3-VO, NM3-S7A and NM3- 
S387A exhibited recombination frequencies of 3.23 X 10‘4, 0.5 X 10"4 and 5.6 X 10"4 
respectively, which are equivalent to 2.8, 18 and 1.6 fold reduction in HRR respectively 
compared to that of NM3-gWT with a recombination frequency of 9 X 10'4. The highest 
homologous recombination rate is observed in NM3-gWT and the lowest HRR rate is shown in 
NM3-S7A. It is interesting to note that NM3-S7A actually shows a much lower rate of HRR than 
the null mutant NM3-VO. The rate of HRR in NM3-S387A cells was only slightly reduced 
compared to wild type NM3-gWT cells. These findings are broadly consistent with survival, 
growth inhibition and cytogenetic data presented in this chapter.
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4.2.5 MN assay
4.2.5.1 Optimizing the MN assay procedure
The micronucleus assay (See section 2.1.2.10.2.1) provides an alternate and more cost effective 
cytogenetic approach. The reason why the micronucleus assay has been chosen to be utilized is 
to have a better evaluation of the numerical instability seen in Fig. 4.6, Tables: 4.13, 4.14, 4.15, 
4.16, 4.17 and 4.18. The increase in chromosome counts in both cell lines NM3-VO and NM3- 
S7A compared to NM3-gWT could be due to the presence of lagging chromosomes, centric, or 
acentric fragments with in a metaphase spread. The micronucleus assay is ‘a cytokinesis-block 
method for the analysis of micronuclik The technique is based on the use of cytochalasin B, an 
inhibitor of actin polymerisation, which blocks mitotic cytokinesis but not nuclear division in 
cultured cell lines. Micronuclei may contain either acentric chromosomal fragments, or lagged 
chromosomes that have failed to segregate into a daughter macronucleus during mitosis 
(Hermine et al, 1997). Micronucleus testing could be carried out by utilizing immune- 
fluorescence labeling (Lindh et al, 2006). Through the use of centromeric probes (or anti- 
kinetochore antibodies) chromosome breakage can be distinguished from chromosome loss. 
Chromosome migration impairment would result in increased frequency of micronuclei that 
enclose a single centromere while centrosome amplification would induce micronuclei with three 
or more centromeric signals. The use of micronucleus assay and crest staining allows an 
evaluation of spontaneous and drug induced numerical and structural instability.
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For hamster cell lines a number of papers have implemented the MN assay (Krishna et al, 
1989; Eastmond and Tucker 1989; Jones et aL, 1993; Lynch et aL9 1993; Gabriele et al9 
1995; Hermine et al., 1997). The literature regarding MN assay is considerably variant in the 
type of cell lines used, initial cellular densities, slide preparation, fixation, and staining methods. 
Most researchers have used or recommend the implementation of a cytocentrifuge to centrifuge 
cells directly onto slides to be scored for micronuclei (Fenech and Morley, 1985; Fenech, 
2000; Channarayappa et al., 1990; Ellard et al, 1991; Lynch et al, 1993; Hermine et al, 
1997). However, an alternative procedure for laboratories lacking a cytocentrifuge has been 
described in the literature (Fenech, 2000) and this was used in this study. The cellular density 
selected (5 xlO5) ensured the presence of a dividing cellular population before and after adding 
.both cytochalasian-B (Cyto-B) and MMC. This cellular density also ensured that the cellular 
confluence prior harvesting has been 60-70% and the dividing cells are allowed to accumulate in 
the bi-nucleated cellular state suitable for scoring. A free suspending router centrifuge has been 
used ensuring proficient collection of the pellet of cells prior fixation. The best fixation method 
without using a cytocentrifuge has been through the use of acetic acid and methanol fixation 
solution in 1:25 ratio respectively (Fenech, 2000; Suzuki et al, 2000). Acetic acid-methanol 
fixation solution gave a better result compared to the methanol fixation method. Following 
fixation in culture tubes, the cells were dropped on horizontally held slides and allowed to dry 
for 10 minutes before staining. Staining has been conducted using either standard Giemsa stain 
(20% Giemsa solution) (Ellard et al, 1991; Jones et al, 1993), or acridine orange fluorescent 
stain which is a more specific DNA dye (Fenech, 2000; Suzuki et al, 2000). When using 
acridine orange the wet slides were immediately covered with cover glass slips prior to scoring. 
Both types of staining yield bi-nucleated cells that could be scored (Fig. 4.9).
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4.2.S.2 Problems encountered in the MN procedure
Two problems hindered progress leading to the discontinuation of the optimization process for 
the MN assay and initiated consideration of other means to investigate numerical stability of FA 
cell lines. The main problem has been the low percentage of bi-nucleated cells produced from the 
pellet obtained. At best up to 30-35% of cells could be classified as viable cells wither they are 
mono-nucleated, bi-nucleated (Fig. 4.9-A), tri-nucleated or multinucleated. The other 60-65% of 
cells had an unclear-unspecific appearance (Fig. 4.9-B). This percentage of bi-nucleated cells 
reduced when using MMC doses 300nM and 600nM. This problem has been persistent in control 
flasks despite altering cellular density, increasing Cyto-B incubation time up to 24 hours for 
CHO cells (Gabriele et al., 1995) reducing Cyto-B final concentration or altering staining time
nor staining density or even briefly exposing cells to hypotonic treatment (0.075 M KCL) prior 
fixation (Krishna et al., 1989; Suzuki et al., 2000). It was concluded that the cells with an 
unclear appearance result as a consequence of the improper spreading of the bi-nucleated cells. 
This would be probably achieved proficiently through the use of a cytocentrifuge 
(Channarayappa et al, 1990), ensuring proper cytoplasmic spreading to obtain proficient 
scoring.
The second problem, although minor, but worthy of reporting has been the appearance of the 
CHO bi-nucleated cells which fitted the scoring criteria however, at times the cytoplasmic 
boundary although encapsulates both nuclei and any micronuclei present but it didn’t always
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seem to be circular (Fig. 4.9) as seen in lymphocytes. Both of these problems seem to be 
resolved through the use of a cytocentrifuge.
Subsequent to the difficulties encountered in the micronucleus assay, the plan to investigate the 
numerical stability of FA cell lines, if time allowed, would have been through the 
implementation of fluorescent in situ hybridization (FISH) probes. Where the utilization of two 
selected centromeric probes for chromosomes number 2 (Fatyol et ah, 1994) and chromosome 
number 5 (Faravelli et al, 1998) on metaphase spreads would reflect the loss or gain of these 
chromosomes (numerical instability) in FA cell lines spreads (Griffin et al, 2000) which have 
been exposed to clastogens such as MMC or phleomycin. These two probes have been 
previously tested by other research groups for hamster chromosomes; they were therefore 
prefered as their use allows comparison to the previous studies. As it turned out, insufficient time 
resulted in discontinuing further research in this area. The expectation had these experiments 
been conducted successfully, would be to have observed aneuploidy and further chromosomal 
structural instability in mutant cell lines.
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Micronucleus assay cells
Figure (4.9): Illustrating two types of cells found in the micronucleus assay: (A): the formation of 
binudeated cells after induction with cytochalasian-B, shown using giemsa stain and acridine orange 
fluorescent stain. (B): non-dividing or badly spread cells.
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4.3 Discussion
4.3.1 Discussion
The role of FANCG in DSBs repair has been investigated in this chapter. Here it has been 
shown that expression of FANCG is required for optimal repair of the DNA damage induced by 
phleomycin, an agent that induces a variety of DNA damage including DNA double-strand 
breaks. This is based on the result that in the complete absence of FANCG as in NM3-VO 
(Figures 4.1 and 4.2), the ceils are hypersensitive to phleomycin. Furthennore, I also show that 
the phosphylation site at serine? is important in this repair pathway but phosphorylation at serine 
387 is much less important. This indicates that FANCG must play a role in the repair processes 
to repair phleomycin-induced DSBs and that post-translational modifications at FANCG serine 7 
is also essential. The assays used to investigate FANCG role in HRR include: survival, growth 
inhibition assays, cytogenetic experiments (structurally and numerically analyzed) and HRR 
assays.
4.3.2 Survival and growth inhibition data
In this chapter, genetic evidence has been provided for a role of FANCG in HR as measured by 
different assays. Firstly, by survival assay and growth inhibition experiments, where it was 
shown that when exposed to phleomycin, hypersensitivity resulted in FANCG deficient cells. 
This observation gives support to the model presented in chapter 3, in that the G-BRCA2 
complex is involved in HRR, probably in response to the presence of DSBs. This observation is
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based on the results produced in the phospho-mutated cell line NM3-S7A. As previously stated, 
FANCG presence is required for the G-BRCA2 complex to form and is part of the core complex. 
In the serine 7 mutated cell line, the core complex still forms but the G-BRCA2 complex does 
not (Wilson et al.t 2008). This suggests that to repair the phleomycin induced DSBs, G-BRCA2 
complex formation is required, as the level of hypersensitivity is similar to or greater than when 
the FANCG protein is totally absent. However, these results provide infonnation about the post 
translational modifications of FANCG required to bring about repair of phleomycin induced 
damage, as when phosphorylation at serine 387 is prevented this leads to only a very slight 
hypersensitivity to phleomycin. This is in sharp contrast to the results described in chapter 3 
where the level of sensitivity of the two phosphorylation site mutations resulted in similar MMC 
hypersensitivity.
4.3.3 Cytogenetic data
4.3.3.1 Chromosomal aberrations rate and type in FANCG cell lines
At the cytogenetic level, analyses of the rate of structural chromosomal aberrations, the type of 
observed chromosomal aberrations and chromosomal numerical aneuploidy all provide evidence, 
implicating FANCG in the process of HRR as discussed below.
G-BRCA2 deficient cells NM3-VO, NM3-S7A presented the highest CA rates in comparison 
with G-BRCA2 complex containing cells NM3-S387A and NM3-gWT, which presented the 
lower CAs rates, suggesting that the defective repair of phleomycin induced damage is resulting
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from the absence of the G-BRCA2 complex. In comparing the types of aberrations presented 
when using phleomycin (Tables 4.4.A, 4.5.A, 4.6.A, 4.7.A, 4.8.A, 4.9.A, 4.10.A and 4.11.A) it 
can be clearly seen that chromatid-based aberrations (breaks and exchanges) were generally 
higher than chromosome-based aberrations in FANCG mutant cell lines. This is also true when 
using MMC (Chapter-3). One can assume that chromosome fragments may result from 
unrepaired DNA damage or the failure in chromosome exchange fomiation. The exchange type 
aberrations most likely result from mis-repaired DNA DSBs.
4.3.S.2 Chromatid lesions produced post treatment with DNA strand breakers
Tables 4.4.A, 4.5.A, 4.6.A, 4.7.A, 4.8.A, 4.9.A, 4.10.A and 4.11.A also indicate that 
chromosome exchanges and chromosome breaks particularly occurred in NM3-VO and NM3- 
S7A cells, however they were considerably lower in NM3-gWT and NM3-S387A cells. From 
the same tables, when comparing only NM3-VO and NM3-S7A cells, it can be seen that the 
occurrence of chromatid breaks in NM3-S7A cells is generally higher than that recorded in 
NM3-VO. However, chromatid exchanges predominate in NM3-VO and NM3-S7A cells, while 
chromatid breaks predominate in NM3-gWT and NM3-S387A cells in response to phleomycin 
treatment. Tables 4.4.B, 4.5.B, 4.6.B, 4.7.B, 4.8.B, 4.9.B, 4.10.B, and 4.11.B, illustrate that in 
NM3-VO and NM3-S7A cells the predominant type of chromatid exchanges are chromatid 
exchanges which involve either two or three chromosomes. This is consistent with data presented 
throughout the literature by various groups and is pointed out in following sections in this 
chapter (Section 4,3.3.3).
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Although phleomycin induced DNA damage are likely to be double strand breaks, it is likely that 
the different NM3 cell lines process these DNA double strand breaks differently. This variation 
in aberration type produced in these cell lines suggests the presence of different repair pathways 
used to remove phleomycin induced damage. This predominance of the chromatid exchange 
aberrations in NM3—VO and NM3—S7A suggest that NHEJ was the main available pathway to 
process the phleomycin induced DNA damage due to the absence of the G-BRCA2 complex in 
these cells, as exchanges reflect mis-repair by error prone-NHEJ. This predominance of the 
chromatid breaks in NM3-gWT and NM3 -S387A cells suggests that NHEJ was not processing 
the phleomycin-induced damage, as HRR was functional due to the presence of the G-BRCA2 
complex in these cells. Taken together, these observations support the hypothesis that the G- 
BRCA2 is very likely to play a role in promoting proficient HRR to maintain genomic integrity. 
HRR assays were conducted to further test this hypothesis (Section 4.3.4).
4.3.3.S Cytogenetic data comparison to other repair deficient mutants
Consistent with the cytogenetic data showing high CA rates dominated by chromatid exchanges 
in G-BRCA2 complex deficient cells NM3~VO and NM3—S7A, chromatid exchanges were also 
documented by Stackpole et al, (2007) in two Chinese hamster cell lines (irs3 and irslSF) 
defective in the HRR genes RAD51C and XRCC3 in response to particulate chromate Cr (VI), 
which is known to induce DNA double strand breaks (Bryant et at, 2006). Mechilli et aL, 
(2008) observed that after acetaldehyde treatment cell lines irslSF and 51D1, deficient in HRR 
genes XRCC3 and RADS ID, had higher chromatid breaks and exchanges in comparison to the
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other cell lines including parental AA8, nucleotide excision repair deficient cell lines UV4, UV5 
and UV61 or base excision repair deficient EM9 cell line, Natarajan et al, (2008) on the other 
hand, have reported that HRR-deficient cell lines irslSF/ZKCCi and 51D1/RAD51D had higher 
X-ray induced chromatid exchanges, compared to parental AA8 cells. These data suggest that if 
HRR proteins are mutated or absent, then error-free HRR pathway is compromised, leaving the 
induced DNA double strand breaks to be repaired by error-prone NHEJ, which will cause 
genomic instability leading to the cytogenetically observed elevation in chromatid exchanges 
that cause cellular death.
These chromatid exchanges were also recorded (Chapter-3) in high rates in G-BRCA2 complex 
deficient cells NM3—VO and NM3-S7A post MMC exposure. This is consistent with findings 
presented throughout the literature by various groups using various FA cell lines treated with 
inter-strand cross-linking agents (Marx et al, 1983; Busch et aly 1996; Lamerdin et al, 2004; 
Wiegant et al, 2006) as detailed in Chapter-3 discussion. These data suggest that once the FA 
pathway is compromised, then NHEJ becomes the active DNA repair pathway producing these 
observed CA, which implies that the FA pathway may be important in suppressing NHEJ and 
promoting HRR to sustain genetic stability.
The cytogenetic data showing low wild type CA rates predominated by chromatid breaks in 
NM3-S387A, suggest that the G-BRCA2 complex is functional in this cell line and processed 
phleomycin induced DNA damage primarily through HRR. Thus phosphorylation of S3 87 did 
not severely affect the repair of directly induced DNA double strand breaks, in sharp contrast to 
the requirement of the site for proficient repair of MMC-induced ICLs. The reasons for these 
observations are not entirely clear, although it does seem that the phosphorylation of S3 87 is not 
required for proficient HRR. As discussed in the previous chapter, it may be that S3 87
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phosphorylation is important in the events that convert an ICL into a double strand break that can 
then be repaired by HRR. Thus, it could be speculated that S3 87 phosphorylation is required for 
proficient processing of ICLs into double strand breaks or the suppression of NHEJ activity on 
ICL-repair intermediates, rather than the HRR of the indirectly produced double-strand breaks 
themselves.
4.3.3.4 Numerical instability in response to phleomycin applied to FA cell lines
The phleomycin hypersensitivity of NM3-VO and NM3-S7A is consistent, not only with 
elevated rates of chromosomal structural aberrations, but is also consistent with the numerical 
changes in these cells (Fig. 4.6, Tables: 4.13, 4.14, 4.15, 4.16, 4.17 and 4.18). NM3-VO and 
NM3-S7A exhibited an increase of chromosomal number in response to phleomycin. This 
observed numerical increase in chromosomes is consistent with findings of Ohshim, (2001) of 
aneuploidy in nickel sulfate (NiS04) induced V79 Chinese hamster cell line where the majority 
of the cells were hyperdiploid. The treated V79 cells had elevated rates of cells with both 
kinetochore-positive micronuclei and kinetochore-negative micronuclei.
NM3-gWT demonstrated chromosomal numerical stability spanning the usual range of 18-20 
chromosomes when exposed to phleomycin. The increase in chromosomal number in NM3-VO 
and NM3-S7A may indicate either, an elevation in the rate of chromosomal miss-segregation, or 
a reflection of acentric chromosomal fragments resulting in a higher metaphase chromosomal 
count. This may suggest a possible effect of phleomycin on the spindle apparatus or on 
centrosomal stability which would give rise to abnormal chromosome segregation. This 
hypothesis could have been tested through an alternative approach. Two methods were available
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to further investigate this observation. One method was the micronucleus assay (Krishna et aL, 
1989; Eastmond and Tucker 1989; Jones et at, 1993; Lynch et aL, 1993; Gabriele et aL9 
1995; Hermine et aL, 1997) and the second method was through the use of fluorescent probes 
specific to hamster cell lines (Griffin et aL, 2000). It was decided to attempt employing the 
micronucleus assay for that part of the project. However, problems were encountered with the 
assay and no useable data was generated (see results Section 4.2.5.2).
4.3.4 Homologous recombination repair assay data
To further confirm that FANCG is involved in the repair of DSBs through HRR the SCneo 
neomycin-resistance assay was employed. In response to phleomycin, there is a 1000-fold 
increase in the level of HRR detected in the wild type cells. This shows that HRR is taking place 
and the assay was working as expected. In the complete absence of FANCG the rate fell 2.8 fold 
showing conclusively that FANCG is involved in the repair of phleomycin induced DSBs. 
Interestingly, the most convincing support for the G-BRCA2 complex being involved comes 
from the phospho-mutant S7 cell line. The levels of HRR detected in this cell line are less than 
that detected in the cell line lacking FANCG expression. This is consistent with the results of the 
metaphase analysis, where in many experiments NM3-S7A exhibited higher levels of aberrations 
than NM3-VO. It is somewhat unexpected that the phosphorylation site mutant should exhibit a 
greater defect than the null mutant and the reasons for this are not known. This was not the case 
for mitomycin C, where the responses of NM3-S7A were intermediate between NM3-VO and 
NM3-gWT. As NM3-S7A does retain an intact FA core complex, this data provides evidence 
that the core complex is not required for the repair of phleomycin-induced DNA damage and that
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the sensitivity of NM3-S7A is likely to be entirely attributable to its failure to form the G- 
BRCA2 complex. This hypothesis will be tested in the next chapter using a human FANCA 
deficient cell line, which lacks the FA core complex but retains an intact G-BRCA2 protein 
complex.
4.4 Summary of the chapter
• It has been demonstrated that the NM3-VO and NM3-S7A cell lines exhibit marked 
cellular hypersensitivity to phleomycin, an agent that induces DNA strand breaks (single 
and double strand breaks) and base damage. In contrast, the NM3-S387A cell line 
exhibits a response to phleomycin that is much more similar to wild type NM3-gWT 
cells.
• Consistent with this increased cellular hypersensitivity, NM3-VO and NM3-S7A cells 
exhibit elevated levels of induced structural chromosomal aberrations, with chromatid 
exchanges being the predominant type of aberration. In addition, both these cell lines also 
exhibit an increase in chromosome number in response to phleomycin. In contrast, NM3 - 
S387A cells exhibit a response very similar to wild type for both these endpoints.
• Consistent with their cellular and chromosomal hypersensitivity, NM3 -VO and NM3- 
S7A exhibit reduced rates of phleomycin-induced homologous recombination repair in a 
plasmid-based reporter assay. The HRR defect in NM3-S387A cells is much less severe 
than that observed for NM3-S7A.
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• It is concluded that FANCG is required for cellular resistance to phleomycin and that in 
absence of the protein, homologous recombination repair fails to occur resulting in the 
observed chromosomal aberrations. Furthermore, phosphorylation of FANCG at Ser-7 is 
critical for the HRR of phleomycin-induced damage, as this post-translational 
modification of FANCG is required for the fonnation of the G-BRCA2 protein complex 
(containing BRCA2, FANCD2, FANCG and XRCC3).
• It is hypothesised that in the absence of the G-BRCA2 complex, as occurs in NM3-VO 
and NM3-S7A, HRR is compromised and phleomycin DNA damage is processed by 
NHEJ. Mis-repair by NHEJ leads to the observed elevation of chromosomal aberrations, 
particularly chromatid exchanges.
• Phosphorylation of FANCG at Ser-387 is not critical for the HRR of phleomycin-induced 
DNA damage, consistent with the observation that the G-BRCA2 complex forms 
normally in these cells.
• To test this hypothesis, the next chapter will examine the induction of chromosomal 
aberrations by phleomycin in a cell line that retains an intact G-BRCA2 complex, but 
lacks the FA core complex (a human FANCA mutant cell line).
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Chapter-5
Investigating the role of FANCA protein in the repair of induced DNA double 
strand breaks and (ICLs)
5.1 Introduction
5.1.1 Cell lines used in this chapter
In this chapter focus has been made on the FANCA protein, which is known to be part of the FA 
core complex where it directly interacts with FANCG, but is not part of the FANCG-BRCA2 
complex. The aim of this chapter is to examine the role of FANCA in response to the DNA 
damaging agents MMC and phleomycin and to determine whether any differences observed 
could be attributed to specific protein complexes. It has been previously reported that in the cells 
of patients carrying mutations in the FANCA gene are hypersensitive to MMC, but little is known 
about their sensitivity to x-rays. To determine the cellular sensitivities it was decided to use 
human FANCA mutated cell lines, corrected with the FANCA gene, exposing these cell lines to 
phleomycin and MMC.
The cell lines used in this chapter are human GM6914 fibroblast cells. The cell lines used are 
either wild type or corrected to wild type compared to FANCA defective cell lines.
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Cell lines used include 6914-VO, 6914-S1449A and 6914-AWT. 6914-AWT is an immortalized 
FA-A human fibroblast cell line transduced with full length human FANCA cDNA tagged with 
Flag in the pMMP vector. 6914-VO is a FANCA mutant immortalized human fibroblast cell line 
transduced with empty pMMP vector. 6914-VO cell line does not express FANCA protein 
{FANCA-imW cells). 6914-S1449A is a FANCA mutant immortalized human fibroblast cell line 
transduced with human FANCA cDNA that has been mutated via site-directed mutagenesis in 
FANCA at serine 1449 to alanine (SI449A).
5.1.2 Investigation of the induction of chromosome aberrations in GM6914
fibroblasts
Similar to Chapter- three and four, classical cytogenetic analysis has been implemented in this 
chapter (Chapter-5) investigating and determining (using plain Giemsa stain) structural 
chromosomal aberrations, classifying and analyzing metaphase spreads. The selected cell lines 
were cultured in the presence and absence of a radiomimetic agent (phleomycin) and a cross- 
linking agent (MMC). Metaphase spreads were scored and analyzed for chromosomal breakage 
as well as the formation of radials. Findings of FANCA mutant cell lines were compared with 
findings from corrected control cells. Cellular cultures without the DNA clastogenic agent were 
used to measure the spontaneous breakage rate. Results were reported as the number of 
aberrations per cell, the percentage of aberrant cells and the total number of chromatid breaks per 
cell.
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5.2 Results
5.2.1 GM6914 fibroblasts to phleomycin growth inhibition results
From Figure 5.1 it can be seen that the FANCA deficient cell line, 6914-AVO, showed a GI-50 
value of 925 ng/ml compared to a value of 1200 ng/ml for the corrected 6914-AWT cell line. 
This meant that 6914-VO is around 1.3-fold hypersensitive to phleomycin compared to the 
corrected wild type 6914-AWT (Fig.5.1). These findings show that 6914-VO is only very 
slightly hypersensitive to phleomycin, indicating that in these cells, which lack FANCA, the 
machinery to repair the phleomycin induced damage is present and functioning almost as well as 
in the corrected cells. Certainly these FANCA deficient cells do not exhibit the levels of 
phleomycin hypersensitivity observed in FANCG deficient cells (Chapter 4). This suggests that 
the FA core complex does not play an important role in the repair of phleomycin-induced 
damage and implies that the unaffected G-BRCA2 complex functions independently of FANCA.
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5.2.2 GM6914 fibroblasts cytogenetic findings
5.2.2.1 GM6914 fibroblasts chromosomal aberration analysis results to 
phleomycin
This finding that FANCA was not hypersensitive to DNA damage induced by phleomycin was, 
further investigated at the chromosomal level. Phleomycin at a dose of 1000 ng/ml was used and 
produced the cytogenetic profile for FANCA deficient cells in response to phleomycin exposure 
as illustrated by Tables 5.1-A, 5.2-A and 5.3-A. Frequencies of both induced and spontaneous 
chromosome and chromatid aberrations in treated and untreated cell lines cultures 6914-VO, 
6914-S1449A and 6914-AWT are presented in Tables 5.1-A, 5.2-A and 5.3-A.
5.2.2.1.1 GM6914 fibroblasts chromosome and chromatid aberration 
rates in control cell cultures
It can be noted that the number of aberrations per cell in untreated cell lines presented a 
spontaneous rate which did not exceed 0.04 as shown in Tables 5.1-A, 5.2-A and 5.3-A and Fig. 
5.2. Hardly any aberrations were recorded for all untreated 6914-VO, 6914-S1449A and 6914- 
AWT fibroblasts. The highest number of aberrations per cell for the untreated cells was that 
recorded for both, 6914-VO and 6914-S1449A as 0.04 aberration/cell followed by 6914-VO, 
6914-S1449A and 6914-AWT as 0.02 aberration/cell as shown in Tables 5.1-A, 5.2-A and 5.3-
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A. Also, from the same Tables 5.1-A, 5.2-A, 5.3-A and Fig. 5.3 it can be seen that the 
percentage of aberrant cells that have occurred spontaneously was not very different amongst the 
various FANCA fibroblasts; 6914-VO, 6914-S1449A and 6914-AWT. This ranged from 0% to 
4% aberrant cells, which is the number of aberrant cells occurring spontaneously as seen in three 
independent experiments (replicates) presented in Tables 5.1-A, 5.2-A and 5.3-A.
5.2.2.1.2 GM6914 fibroblasts chromosome and chromatid aberration
rates in treated cell cultures to phleomycin
Table 5.1-A shows that using doses of 1000 ng/ml phleomycin resulted in 6914-VO and 6914- 
S1449A fibroblasts producing rates of chromosomal aberrations per cell of 0.16 and 0.2 
aberration/cell respectively compared to 0.0 aberration/cell found in 6914-AWT indicating that 
FANCA mutant cell lines 6914-VO and 6914-SI449A are insensitive to phleomycin. Keeping the 
same experimental conditions and despite slight variation, the readings of each experiment 
illustrated that FANCA mutant fibroblasts presented similar numbers of CA compared to 6914- 
AWT as shown in Tables 5.2-A and 5.3-A confirming and supporting growth inhibition findings 
of FANCA deficient cells 6914-VO insensitivity to phleomycin. This also indicates that 
phleomycin-induced damage (DNA strand breaks) is being repaired without the presence of the 
FANCA protein or its phosphorylation at serine 1449. This suggests the presence of a repair 
pathway that processes DNA strand breaks independently of both FANCA protein and the action 
of the FA-core complex.
215
Abdulaziz Aladwani PhD
n
£
.a
§
<8
a
o
’S
i
•§
1
Vi
(L>
3
=3
O
Tf
»—t
VO
i
a
‘C
s
I
s
a.
<D
•g
i
To
ta
l
C
hr
om
at
id
B
re
ak
s 
-
af
te
r
ab
er
ra
tio
n
co
nv
er
tin
g
pe
r c
el
l
o 0.
08 fHd 0.
22
0.
02
0.
52
%
A
be
rr
an
t
ce
lls o 00 3 CM 8
A
be
rr
at
io
ns
 
Pe
r c
el
l
o
800 0.0
4 8T0 0.
02
0.
38
To
ta
l
ab
er
ra
tio
ns
w
ith
ou
t
G
ap
s
o (N <T> fH crifH
G
ap
s
pe
r
ce
ll
0.
02 o O
9T
‘0 0.
04 CMd
C
hr
om
os
om
e -
 
ab
er
ra
nt
 ce
lls
Ch
ro
-
ex
ch o o rH o o fH
s " 
i 2
O J3
o o o fH o fH
C
hr
om
at
id
 
ba
se
d 
- 
ab
er
ra
nt
 ce
lls
Ct
id
-
ex
ch o o o fH o CM
•~o re
♦; a o fH fH infH
To
ta
l 
nu
m
be
r 
of
 ce
lls
 
sa
m
pl
ed
8 s s o
in S 8
Tr
ea
tm
en
t
ph
le
om
yd
n
ng
/m
l
o
10
00 o
10
00 o
10
00
£
i v
Q H
C
el
l l
in
e
69
14
 A
W
T
69
14
 A
W
T o
$
i 6914
 A
V
O
69
14
 S1
44
9A
69
14
 S1
44
9A
216
Ta
bl
e a
bb
re
vi
at
io
ns
: C
tid
-b
re
ak
: C
hr
om
at
id
 br
ea
k 
ty
pe
 ab
er
ra
tio
n,
 C
tid
-e
xc
h:
 C
hr
om
at
id
 ex
ch
an
ge
 ty
pe
 ab
er
ra
tio
n,
 C
tid
-e
xc
h:
 
Ch
ro
m
at
id
 ex
ch
an
ge
 ty
pe
 ab
er
ra
tio
n,
 C
hr
o-
br
ea
k:
 C
hr
om
os
om
e b
re
ak
 ty
pe
 ab
er
ra
tio
n,
 C
hr
o-
ex
ch
: C
hr
om
os
om
e e
xc
ha
ng
e t
yp
e 
ab
er
ra
tio
n.
Abdulaziz Aladwani PhD
1
.9
a
To
ta
l
Ch
ro
m
at
id
Br
ea
ks
-
af
te
r
ab
er
ra
tio
n
co
nv
er
tin
g
pe
r c
el
l
o 0.
18
0.
02 0.
2 CNod 0.3
6
%
A
be
rra
nt
ce
lls o OvH (N tH CN 'ICN
A
be
rra
tio
ns
 
Pe
r c
el
l
o 0.
14
0.
02 00rHd 0.0
2
0.
32
&
<8
3
o
g
To
ta
l
ab
er
ra
tio
ns
w
ith
ou
t
G
ap
s
o r-4 tn rH IDrH
D
at
a-
Ta
bl
e:
 su
m
m
ar
ie
s p
hl
eo
m
yc
in
 tr
ea
te
d 6
91
4 
ce
ll 
lin
es
 an
d a
be
i
Ta
bl
e (
5.
2-
A
)
G
ap
s
pe
r
ce
ll o
800
zoo 00r-(d 0.0
6
0.
16
Ch
ro
m
os
om
e -
 
ab
er
ra
nt
 ce
lls
C
hr
o-
ex
ch o o o o o o
11 
O _Q
o o o rH o <N
Ch
ro
m
at
id
 
ba
se
d 
- 
ab
er
ra
nt
 ce
lls 3 O
c s o
sH o o o O
13 scl o ID tH CO rH rH
To
ta
l 
nu
m
be
r 
of
 ce
lls
 
sa
m
pl
ed
om S 8 g
Tr
ea
tm
en
t
ph
le
om
yd
n
ng
/m
l
o
10
00 o
10
00 o
10
00
Ce
ll 
lin
e
69
14
 A
W
T
69
14
 A
W
T
69
14
 A
V
O o
<
i
69
14
 S1
44
9A
69
14
 S1
44
9A
217
Ta
bl
e a
bb
re
vi
at
io
ns
: C
tid
-b
re
ak
: C
hr
om
at
id
 br
ea
k t
yp
e a
be
rr
at
io
n,
 Ct
id
-e
xc
h:
 Ch
ro
m
at
id
 ex
ch
an
ge
 ty
pe
 ab
er
ra
tio
n,
 C
tid
-e
xc
h:
 
C
hr
om
at
id
 ex
ch
an
ge
 ty
pe
 ab
er
ra
tio
n,
 C
hr
o-
br
ea
k:
 C
hr
om
os
om
e b
re
ak
 ty
pe
 ab
er
ra
tio
n,
 C
hr
o-
ex
ch
: Ch
ro
m
os
om
e e
xc
ha
ng
e t
yp
e 
ab
er
ra
tio
n.
Abdulaziz Aladwani PhD
D
at
a-
Ta
bl
e:
 su
m
m
ar
ie
s p
hl
eo
m
yc
in
 tr
ea
te
d 
69
14
 c
el
l l
in
es
 an
d a
be
rra
tio
ns
 fo
un
d i
n e
xp
er
im
en
t
Ta
bl
e  (
5.
3-
A
)
To
ta
l
C
hr
om
at
id
B
re
ak
s 
-
af
te
r
ab
er
ra
tio
n
co
nv
er
tin
g
pe
r c
el
l 300 1.0
4
o 0.
46
0.
04
0.
46
%
A
be
rra
nt
ce
lls CM CMin o 8 ** a
A
be
rra
tio
ns
Pe
r c
el
l
CMO
6 0.
82 o 0.
46
0.
04
0.
46
To
ta
l
ab
er
ra
tio
ns
w
ith
ou
t
G
ap
s rH o COCM CM roCM
G
ap
s
pe
r
ce
ll
0.
04 0.
2
0.
06
0.
12
800 0.2
8
Ch
ro
m
os
om
e 
- 
ab
er
ra
nt
 ce
lls 6
6 8 o o o o o o
Ch
ro
-
br
ea
k
o CO o o o o
Ch
ro
m
at
id
ba
se
d 
-
ab
er
ra
nt
 ce
lls
Ct
id
-
ex
ch o CO o o o o
Ct
id
-
br
ea
k
xH inro o mCM CM roCM
To
ta
l 
nu
m
be
r 
of
 ce
lls
 
sa
m
pl
ed
8 s s s s s
Tr
ea
tm
en
t
ph
le
om
yd
n
ng
/m
l
o
10
00 o
10
00 o
10
00
Ce
ll 
lin
e
69
14
 A
W
T
69
14
 A
W
T
69
14
 A
V
O
69
14
 A
V
O
69
14
 S1
44
9A
69
14
 S1
44
9A
218
Ta
bi
c a
bb
re
vi
at
io
ns
: C
tid
-b
re
ak
: C
hr
om
at
id
 br
ea
k t
yp
e a
be
rr
at
io
n,
 Ct
id
-e
xc
h:
 Ch
ro
m
at
id
 ex
ch
an
ge
 ty
pe
 ab
er
ra
tio
n,
 C
tid
-e
xc
h:
 
C
hr
om
at
id
 ex
ch
an
ge
 ty
pe
 ab
er
ra
tio
n,
 C
hr
o-
br
ea
k:
 C
hr
om
os
om
e b
re
ak
 ty
pe
 ab
er
ra
tio
n,
 C
hr
o-
ex
ch
: Ch
ro
m
os
om
e e
xc
ha
ng
e t
yp
e
Abdulaziz Aladwani PhD
6914 A cells - phleomycin -Average Aberrations Per cell
0.70 n
<DU
i—
<D
Q-
|
1
XI
<
0)
-Q
Eu
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0 1000
Concentration of phleomycin ng/ml
■ 6914 AWT
■ 6914AVO
■ 6914 S1449A
Figure (5.2): Illustrating phleomycin Average Aberrations Per cell data using three cell 
lines: 6914A-WT, 6914A-VO, 6914- S1449A. Three experiments were performed. Eiror
bars show the standard error of the mean.
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From the Pooled Table 5.4, it can be seen fori 000 ng/ml phleomycin, the average aberrations 
per cell in the 6914-AWT, 6914-VO and 6914-S1449A cell lines were 0.35, 0.27 and 0.39 
aberration/cell respectively. Using the same 1000 ng/ml phleomycin dose it can be seen that the 
average percentage of aberrant cells in the 6914-AWT, 6914-VO and 6914-S1449A cell lines 
was about 23.3%, 19.3% and 29.3% aberrant cells respectively. Finding of the average number 
of total chromatid breaks (after converting all the exchanges into chromatid breaks) per cell for 
the same 1000 ng/ml phleomycin dose was in 6914-AWT, 6914-VO and 6914-S1449A cell lines 
0.43, 0.29 and 0.45 chromatid breaks/cell respectively. All of these cytogenetic findings clearly 
illustrate that FANCA mutant cell lines 6914-VO and 6914-S1449A produce chromosome 
aberrations rates similar to that of the corrected wild type when exposed to phleomycin.
This resemblance in cytogenetic profile in FANCA mutant and wild type cell lines to phleomycin 
is illustrated in graphs as average aberration per cell (Fig. 5.2), average percentage aberrant cells 
(Fig. 5.3), or as average total chromatid breaks (Fig. 5.4). This is consistent with growth 
inhibition findings, supporting the suggestion that the machinery to repair double strand breaks is 
active in FANCA mutant cell lines as in the corrected wild type cells, indicating the role of the G- 
BRCA2 complex in the repair of phleomycin induced damage independently of FANCA and the 
FA core complex.
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6914 A cells - phleomycin —Average % Aberrant cells
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Figure (5.3): Illustrating phleomycin Average percentage aberrant ceUs data using 
three cell lines: 6914A-WT, 6914A-VO, 6914- S1449A. Three experiments were 
perfonned. Error bars show the standard error of the mean.
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Figure (5.4): Illustrating phleomycin Average of Total Chromatid Breaks (after 
converting exchanges) per cell data using three cell lines: 6914A-WT, 6914A-VO, 6914- 
S1449A. Three experiments were performed. Error bars show the standard error of the mean.
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5.2.2.1.3 The cytogenetic aberration types and predominance in 
GM6914 fibroblasts to phleomycin
It is clear that in FANCA mutant cell lines 6914-VO, 6914-S1449A and 6914-AWT, the 
chromatid type aberrations predominate, involving specifically breaks but not exchanges at the 
chromatid level. Occasionally, chromosome type aberrations (such as dicentrics or rings) have 
been observed in treated cultures as shown in Tables 5.1-A, 5.2-A and 5.3-A. These 
chromosome exchanges (dicentrics or rings) were rarely observed in the untreated cell lines 
cultures (controls), but were present once as a dicentric recorded in 6914-VO untreated cell lines 
culture (Tables 5.1-A and 5.1-B). Chromosome breaks and chromosome exchanges in all cell 
lines were similarly low, with no distinct elevation in any of type of CA as illustrated in Tables 
5.1-A, 5.2-A, 5.3-A, 5.1-B, 5.2-B and 5.3-B. The occurrence of chromatid breaks and the 
absence of chromatid exchanges tend to suggest that the G-BRCA2 complex is modulating 
proficient HRR and that NHEJ is not actively involved in the repair of phleomycin induced 
damage in these cells.
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5.2.2.2 GM6914 fibroblasts chromosomal aberration analysis results to
MMC
In order to validate the phleomycin results, and confirm the FA phenotype of the 6914-VO cells, 
it was decided to perform MMC experiments at the chromosome level. It was previously shown 
that FANCA mutated cell lines used in this study are hypersensitive to MMC (Collins et aL, 
2009) and so aberrations should be detected at the chromosome level. The first experiments were 
to find the appropriate doses of MMC to be used. Initially, in the course of procedure 
optimization different MMC doses were utilized. Three doses were used eventually a lower dose 
of 30 nM, a middle dose of 50 nM and a higher dose of 100 nM MMC. Tables 5.5.A, 5.6.A, 
5.7.A and 5.8.A illustrate the type and number of chromosome aberrations presented when 
exposed to MMC. Frequencies of both induced and spontaneous chromosome and chromatid 
aberrations in treated and untreated cell lines cultures 6914-AWT, 6914-VO and 6914-SI449A 
are presented in Tables 5.5.A, 5.6.A, 5.7.A and 5.8.A.
5.2.2.2.1 GM6914 fibroblasts chromosome and chromatid aberration
rates in control cell cultures to MMC
It can be noted that the number of aberrations per cell in untreated cell lines presented a 
spontaneous rate which did not exceed 0.1 as shown in Tables 5.5.A, 5.6.A, 5.7.A, 5.8.A and 
Fig. 5.5. The highest number of aberrations per cell for the untreated cells was that recorded for 
6914-S1449A as 0.1 aberration/cell followed by 6914-AWT as 0.06 aberration/cell then 6914-
228
Abdulaziz Aladwani PhD
VO and 6914-S1449A presenting a value of 0.04 aberration/cell. Also from the Pooled Table 
5.9 and Fig. 5.6 it can be illustrated that the average percentage of aberrant cells that have 
occurred spontaneously was generally lowest in 6914-VO 1.5% aberrant cells and highest in 
6914-S1449A 4.5% aberrant cells, where as 6914-AWT presented close numbers of aberrant 
cells 2% aberrant cells to both FANCA mutant cell lines reflecting a similar spontaneous rate in 
all cell lines.
S.2.2.2.2 GM6914 fibroblasts chromosome and chromatid aberration
rates in treated cell cultures to MMC
Table 5.5-A shows that using doses of 100 nM MMC resulted in 6914-VO and 6914-S1449A 
producing higher rates of chromosomal aberrations per cell 1.58 and 2 aberration/cell 
respectively compared to 0.44 aberration/cell found in 6914-AWT which represented about 3.6 
and 4.5 fold increase respectively. However, this dose considerably reduced metaphase spreads 
in 6914-S1449A fibroblasts and a lower dose of 30 nM MMC was used in the following 
experiment. Table 5.6-A shows that using doses of 30 nM MMC resulted in 6914-VO and 6914- 
S1449A producing slightly higher rates of chromosomal aberrations per cell 0.58 and 0.94 
aberration/cell respectively compared to 0.48 aberration/cell found in 6914-AWT which 
represented about 1.2 and 2 fold increase respectively. Nevertheless, in following experiments 
this elevation of CA became more evident as seen in Tables 5.7-A and 5.8-A. For example, 
Table 5.7-A shows that using doses of 30 nM MMC resulted in 6914-VO and 6914-S1449A 
producing higher rates of chromosomal aberrations per cell 1.86 and 0.94 aberration/cell
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respectively compared to 0.16 aberration/cell found in 6914-AWT which represented about 11.6 
and 5.9 fold increase respectively. Similarly, Table 5.8-A shows that using doses of 30 nM 
MMC resulted in 6914-VO and 6914-S1449A producing higher rates of chromosomal 
aberrations per cell 2.86 and 1.68 aberration/cell respectively compared to 0.4 aberration/cell 
found in 6914-AWT which represented about 7.2 and 4.2 fold increase respectively.
A third MMC dose of 50 nM MMC was adopted in later experiments keeping the previous 30 
and 100 nM MMC doses in order to cover the dose range that would produce enough metaphase 
spreads to be scored with a readable and reliable cytogenetic profile. The same experimental 
conditions were obtained and despite slight variation, the readings of each experiment illustrated 
that FANCA mutant cells presented an increased number of CA compared to 6914-AWT. Table 
5.8-A shows that using doses of 50 nM MMC resulted in 6914-VO and 6914-S1449A producing 
higher rates of chromosomal aberrations per cell 2.8, and 1.86 aberration/cell respectively 
compared to 0.64 aberration/cell found in 6914-AWT which represented about 4.3 and 2.9 fold 
increase respectively. Table 5.7-A shows that using doses of 50 nM MMC resulted in 6914-VO 
and 6914-S1449A producing higher rates of chromosomal aberrations per cell 1.58, and 1.84 
aberration/cell respectively compared to 0.2 aberration/cell found in 6914-AWT which 
represented about 7.9 and 9.2 fold increase respectively. This elevation in CA is evident in the 
three doses used 30, 50 and 100 nM MMC, however occasionally the higher dose reduced the 
number of metaphase spreads in 6914-VO and 6914-S1449A. Doses of 30 and 100 nM MMC 
were used in three experiments while the intermediate dose of 50 nM MMC was used in two 
experiments.
It is clear that in FANCA mutant cell lines 6914-VO, 6914-S1449A and control cell line 6914- 
AWT chromatid type aberrations predominate, involving breaks and exchanges at the chromatid
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level. Chromosome type aberrations such as dicentrics or rings occasionally appeared as shown 
in Tables 5.5.A, 5.6.A, 5.7.A and 5.8.A. These dicentrics or rings were almost completely 
absent in all the untreated cell lines cultures (controls) but were occasionally present in some of 
FANCA mutant 6914-VO, 6914-S1449A treated cell lines cultures.
On the other hand, chromosome breaks were higher than chromosome exchanges in all cell lines. 
Chromosome breaks generally, were still considerably lower in numbers compared to chromatid 
breaks. This can be especially seen in treated FANCA mutant cell lines cultures 6914-VO, 6914- 
S1449A in Tables 5.5.A, 5.6.A, 5.7.A and 5.8.A.
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From the Pooled Table 5.9 it can be seen that when using the higher dose of 100 nM MMC the 
average aberrations per cell in the 6914-VO and 6914-S1449A cell lines was about 2.19 
and 2.93 aberration/cell respectively which was about 4.7 and 6.2 fold respectively higher than 
that of the corrected wild type 6914-AWT cells which is 0.47 aberrations per cell. Also using the 
higher dose of 100 nM MMC the average percentage of aberrant cells in the 6914-VO and 6914- 
S1449A cell lines was about 70.6% and 80.3% aberrant cells respectively which was about 2.1 
and 2.4 fold respectively higher than that of the corrected wild type 6914-AWT cells which is 
34% aberrant cells. The findings of the average number of total chromatid breaks (after 
converting all the exchanges into chromatid breaks) per cell for the same higher dose of 100 nM 
MMC was in 6914-VO and 6914-S1449A cell lines 6.03 and 7.6 chromatid breaks/cell 
respectively which was about 5 and 6.3 fold respectively higher than that of the corrected wild 
type 6914-AWT which is about 1.21 chromatid breaks/cell. This FANCA mutant cell line 
cytogenetic profile indicates very clearly and supports the hypersensitivity of FANCA mutant cell 
lines to MMC as observed throughout the literature and pointed out in the discussion. This 
FANCA mutant cellular hypersensitivity to MMC indicate that MMC induced damage (DNA 
ICLs) are being left unrepaired in the absence of FANCA protein or when its phosphorylation at 
serine 1449 is mutated to alanine. This suggests that the repair pathway required in processing 
ICLs has been compromised by the absence of both FANCA protein and the FA-core complex 
action.
This elevation in cytogenetic structural aberration level in FANCA mutant cell lines is shown in 
graphs as average aberration per cell (Fig. 5.5), average percentage aberrant cells (Fig. 5.6), or as 
average total chromatid breaks as shown in Fig. 5.7.
237
Abdulaziz Aladwani PhD
OJu
0)
CL
§
'i
<u
<
o
L.
<u
_Q
E
3
6914 A cells -MMC Average Aberrations Per cell
Figure (5.5): Illustrating MMC Average Aberrations Per cell data using three cell 
lines: 6914A-WT, 6914A-VO, 6914- S1449A. Four experiments were performed as 
shown in Tables 5.5-A. 5.6-A. 5.7-A and 5.8-A. Error bars show the standard error of the 
mean.
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6914 A cells -MMC Average % Aberrant cells
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Figure (5.6): Illustrating MMC Average percentage aberrant cells data using three cell 
lines: 6914A-WT, 6914A-VO, 6914- S1449A. Four experiments were performed as shown in 
Tables 5.5-A, 5.6-A. 5.7-A and 5.8-A. Error bars show the standard error of the mean.
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6914 A cells -MMC Average number of Chromatid Breaks (after
converting exchanges) per cell
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Figure (5.7): Illustrating MMC Average of Total Chromatid Breaks (after converting 
exchanges) per cell data using three cell lines: 6914A-WT, 6914A-VO, 6914- S1449A. Four 
experiments were performed as shown in Tables 5.5-A, 5.6-A, 5.7-A and 5.8-A. Error bars 
show the standard error of the mean.
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S.2.2.2.3 The cytogenetic aberration types and predominance in 
GM6914 fibroblasts to MMC
Chromatid exchanges were higher than chromatid breaks, making chromatid exchanges the 
predominant chromosomal lesion observed in FANCA mutant 6914-VO and 6914-S1449A cell 
line cultures especially in 6914-VO as seen in Tables 5.5.A, 5.6.A, 5.7.A and 5.8.A.
From Tables 5.5.B, 5.6.B, 5.7.B and 5.8.B, it can be seen that the predominant type of 
chromatid exchanges are chromatid exchanges which involve two and three chromosomes 
(classified under complex arrangements). These chromatid exchanges involving two or three 
chromosomes seem to be higher in occurrence than those involving four or five chromosomes. 
The involvement of more than three chromosomes in these complex arrangements does occur; 
however it does so to a lesser extent as illustrated in the same Tables 5.5.B, 5.6.B, 5.7.B and 
5.8.B. The same tables demonstrate that triradials and quadri-radials appear highest in treated 
6914-VO followed by 6914-S1449A compared to the corrected wild type, which is typical of and 
consistent with FA cells cytogenetic profile. These findings tend to suggest that NHEJ was the 
main available repair pathway in 6914-VO and 6914-S1449A cell lines to repair ICLs.
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5.3 Discussion
DNA-damaging agents such as radiomimetic agents or cross-linking agents activate FANCD2 
mono-ubiquitination, leading to its targeting to nuclear foci that also contain HRR proteins 
BRCA1 and FANCD1/BRCA2. The question addressed in this chapter is whether or not 
FANCA protein is involved in modulating proficient HRR as found for FANCG (as discussed in 
chapter four). To investigate this, FANCA mutant cell lines 6914-VO and 6914-S1449A were 
employed and tested for hypersensitivity to both a DNA strand break inducer (phleomycin) and 
an inter-strand crosslink inducer (MMC). The cytogenetic profile for the selected cell lines 6914- 
AWT, 6914-VO and 6914-S1449A was also analyzed. The obtained data were compared to data 
presented in the literature when available.
Growth inhibition experiments (Fig. 5.1) show low hypersensitivity of FANCA deficient cell line 
6914-VO to phleomycin suggesting that the FANCA protein is not essential to process DNA 
strand breaks induced by phleomycin. This phleomycin insensitivity is illustrated through growth 
inhibition assays is backed up by the lack of phleomycin induced chromosomal aberrations in the 
cytogenetic profile for mutant cell lines 6914-VO and 6914-S1449 which also suggests that the 
phosphorylation activity at SI449 is not critical in processing DNA strand breaks. Despite this 
lack of hypersensitivity in response to phleomycin, the expected hypersensitivities and 
cytogenetic profiles were observed after MMC induced damage. FANCA and its 
phosphorylation at SI449 seem critical in processing ICLs induced by MMC.
This may go some way in explaining the lack of published work in the literature concerning 
FANCA hypersensitivity to radiomimetic agents (phleomycin). Whereas there is a lot published 
about FANCA hypersensitivity to cross-linking agents (MMC). Over the years data has emerged
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that allowed further characterization of the FANC proteins and the roles they may play in 
different repair pathways. For example, in 2005, Nakanishi et al, tested whether cells from FA 
patients (groups A, G, and D2) and mouse FANCA~!~ cells with a targeted mutation are impaired 
for this HR repair pathway. Nakanishi et al, (2005) utilized a number of FANC deficient cells 
including EUFA326 FA-G and GM6914 FA-A cells to test for their involvement in HRR and 
single-strand annealing (SSA) repair pathways and concluded that FANCG and FANCA 
promote HRR of chromosomal double-strand breaks (DSBs). This is in agreement with my 
findings in chapter four which support the involvement of FANCG in HRR; however the data 
that I have generated in chapter five tend to suggest that FANCA protein is less involved in HRR 
in response to phleomycin damage but is still involved in HRR pathway involved in repairing 
ICLs induced damage.
Also in support of my findings that FANCA is less involved in DNA strand breaks repair 
through HRR comes from preliminary HRR assays data produced by (Vijayashree Mysore at the 
Jones laboratory) to FANCA human cell lines exposed to phleomycin (unpublished data). The 
data illustrate similar levels of HRR produced by FANCA mutant cell lines 6914-VO, 6914- 
S1449A and the corrected wild type cell line 6914-AWT following phleomycin treatment 
indicating their insensitivity to phleomycin which is consistent with both my growth inhibition 
and cytogenetic findings for FANCA human cell lines 6914-VO, 6914-S1449A and 6914-AWT 
to phleomycin in chapter five. Also consistent with my findings that FANCA mutant cell lines 
6914-VO and 6914-S1449A are hypersensitive to MMC treatment are HRR assays produced 
independently by (Vijayashree Mysore at the Jones laboratory) illustrating reduced levels of 
HRR produced by FANCA mutant cell lines 6914-VO and 6914-S1449A post MMC treatment
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which had 3.2 and 2.7 fold respectively reduced recombination frequency compared to that of the 
corrected wild type 6914-AWT.
Also consistent with my growth inhibition and cytogenetic findings are growth inhibition data 
produced independently by (Vijayashree Mysore at the Jones laboratory) to FANCA human cell 
lines exposed to phleomycin and MMC (not published). The data indicate FANCA mutant cell 
lines 6914-VO and 6914-S1449A insensitivity to phleomycin and illustrates increased 
hypersensitivity by FANCA mutant cell lines 6914-VO and 6914-S1449A following MMC 
treatment which were 3.7 and 3.4 fold respectively hypersensitive compared to the corrected 
wild type 6914-AWT.
The observed hypersensitivity recorded in cytogenetic experiments as elevation in CA as 
illustrated in Pooled Table 5.9 can be compared to previous findings made by Duckworth- 
Rysiecki et aL, in 1986 where GM6914 cells expressed cellular hypersensitivity to MMC and 
elevated chromosomal instability. Table 5.9 illustrates that when using the higher dose of 100 
nM MMC the average aberrations per cell in the 6914-VO and 6914-S1449A cell lines was 
about 2.19 and aberration/cell respectively which was about 4.7 and 6.2 fold respectively higher 
than that of the corrected wild type 6914-AWT cells which is 0.47 aberration/cell. Also finding 
of the average number of total chromatid breaks (after converting all the exchanges into 
chromatid breaks) per cell for the same higher dose of 100 nM MMC was in 6914-VO and 6914- 
S1449A cell lines about 6.03 and 7.6 chromatid breaks/cell respectively which is about 5 and 6.3 
fold respectively higher than that of the corrected wild type 6914-AWT which is about 1.21 
chromatid breaks/cell. Consistent with these findings, Duckworth-Rysiecki et aL, (1986) using 
cytogenetic analysis reported that GM6914 cells also had an elevated chromosome aberrations
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rate of about 4-fold when exposed to MMC 0.1 jig/ml MMC for 30 minutes compared to their 
equivalent controls. In support of these findings, Duckworth-Rysiecki et al also reported using 
survival assays in 1986 that GM6914 cells were 8 fold hypersensitive to MMC compared to their 
equivalent controls. Duckworth-Rysiecki et al. also pointed out their observation of about 3- 
fold hypersensitivity of GM6914 cells to another DNA-cross-linking clastogen (nitrogen 
mustard) compared to their equivalent control (GM637) cells. However, in contrast to my 
cytogenetic findings of chromatid exchanges being predominant in FANCA mutant fibroblasts 
6914-VO and 6914-S1449A, Duckworth-Rysiecki et al, (1986) reports the predominance of 
chromatid breaks and chromatid gaps post MMC treatment.
From growth inhibition graphs produced by Collins et al, (2009) for 6914-VO and 6914- 
S1449A cells were estimated to be about 5, 2.3 fold higher respectively in sensitivity to MMC 
treatment compared to corrected wild type 6914-AWT. Also from graphs produced by Collins et 
al, (2009) presenting cytogenetic data, the average number of aberrations per metaphase cell for 
6914-VO and 6914-S1449A was calculated to be 6.8, 3.6 aberration/metaphase respectively 
which is about 3, 1.6 fold higher respectively in response to MMC treatment compared to that 
produced by the corrected wild type 6914-AWT which is 2.3 aberration/metaphase. Collins et 
al, (2009) suggested that this intermediate cellular hypersensitivity that they had observed in 
6914-S1449A cells may indicate partial repair of the DNA damage induced by MMC.
This cellular hypersensitivity to MMC observed by Collins et al, (2009) is generally consistent 
with the cytogenetic findings for FANCA mutant cell lines 6914-VO and 6914-SI449A presented 
in Tables 5.5.A, 5.6.A, 5.7.A, 5.8.A and 5.9 that show increased MMC-induced chromosomal 
aberrations. However, whilst Collins et al, (2009) found the phenotype of 6914-S1449A to be
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intermediate that of 6914-VO and 6914-AWT, I found very similar levels of chromosomal 
aberrations were induced in the phosphorylation and null mutants.
5.4 Summary of the chapter
• It has been demonstrated that GM6914-VO and GM6914-S1449A cells exhibit little or 
no increased sensitivity to phleomycin in a growth inhibition assay.
• Consistent with the lack of cellular hypersensitivity, GM6914-VO and GM6914-S1449A 
cells exhibit a similar level of induced chromosomal aberrations to the wild type cell line 
GM6914-AWT in response to phleomycin.
• In contrast, both GM6914-VO and GM6914-S1449A cells exhibit increased levels of 
chromosomal aberrations in response to MMC. This is consistent with the cellular 
hypersensitivity to MMC previously reported for these cell lines (Collins et aL, 2009).
• Unpublished data from the Jones laboratory indicates that while GM6914-VO and 
GM6914-S1449A cells exhibit reduced HRR in response to MMC, there is little or no 
defect in HRR following phleomycin treatment.
• It is concluded that while FANCA is required for cellular resistance to inter-strand cross- 
linking agents and the proficient repair of ICL, it is not required for the repair of 
phleomycin-induced DNA strand breaks.
• Given that the G-BRCA2 complex is formed in cells deficient for FANCA (such as 
GM6914-VO), the data in this chapter provide further evidence that this complex is
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specifically required for the homologous recombination repair of DNA strand breaks, 
such as those induced by phleomycin.
• To further support the model that G-BRCA2 complex modulates proficient HRR of 
phleomycin-induced DNA strand breaks and not the nuclear FA-core complex, Chapter-6 
will focus on processing DNA lesions (DNA strand breaks and ICLs) in the absence of 
the G-BRCA2 complex but in the presence the FA core complex. This will involve 
utilization of FANCD2 deficient human cell lines. Cells that are deficient for FANCD2 
form a functional FA core complex but will lack the G-BRCA2 complex. In addition, 
cells expressing a FANCD2 protein mutated at a phosphorylation site required for the 
interaction of FANCD2 with BRCA2 will be investigated (Zhi et aL, 2009).
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Chapter-6
Investigating the role of the FANCD2 protein in the repair of DNA double 
strand breaks and inter-strand cross-links
6.1 Introduction
6.1.1 Introduction
In this chapter the role of FANCD2 in response to DNA double strand break and inter strand 
cross link damage has been investigated. It has been shown that FANCD2 is a member of the G- 
BRCA2 complex but is not part of the FA core complex, although it is mono-ubiquitinated by 
this complex in response to DNA damage (Sections 1.4.9.3 and 1.4.9.4). By studying the role of 
FANCD2 in response to DNA strand breaking or inter-strand cross-linking agents, it is hoped 
that the results would provide further insight into the role of the G-BRCA2 complex in HRR 
induced by phleomycin damage. To do this the human FANCD2 deficient cell line PD20 will be 
exposed to phleomycin and MMC, growth inhibition assays and chromosomal analysis will be 
conducted as previously described, (Methods Sections 2.1.2.5, 2.1.2.10.2.2 and 2.1.2.10.3). In 
doing so, the types of chromosomal aberrations induced may give some insight into the role of 
the FANCD2 in the G-BRCA2 complex.
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6.1.2 Cell lines utilized in this chapter
The FANCD2 deficient cell line used in these studies was PD20, a human patient derived 
fibroblast cell line. PD20 was transduced with either an empty pMMP vector or with pMMP 
containing full-length FANCD2 cDNA (referred to as PD20-D2WT), the FANCD2 (K561R) 
mono-ubiquitination mutant (referred to as PD20-K561R), FANCD2 (S331 A) phospho-mutant 
(referred to as PD20-S331A) or FANCD2 (S33ID) phospho-mutant (referred to as PD20- 
S331D). PD20-3-15 was chromosomally corrected with human chromosome 3p. All described 
in detail in the methods section and in (Garcia-Higuera et al., 2001; Zhi et al, 2009).
6.2 Results
6.2.1 Growth inhibition assays results of PD20 cells to phleomycin
The role of FANCD2 in response to phleomycin is shown in Figure 6.1. From the graph it can 
be seen that the FANCD2 deficient cell line, PD20, has a GI-50 value of 295 ng/ml compared to 
a value of 985 ng/ml for PD20-D2WT making PD20 3.3-fold hypersensitive to phleomycin. 
PD20-S331A had a GI-50 value of 520 ng/ml (1.9-fold hypersensitive), PD20-S331D had a GI- 
50 value of 840 ng/ml (1.2-fold), PD20-K561R had a GI-50 value of 490 ng/ml (2-fold 
hypersensitive). PD20-315 had a GI-50 value of 1005 ng/ml compared to 985 ng/ml for PD20 
D2WT, confirming a wild type phenotype for both cell lines (Fig. 6.1). Thus, PD20 cells were 
the most hypersensitive to phleomycin, PD20-S331A and PD20-K561R exhibited intermediate
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sensitivity, while the phospho-mimetic cell line PD20-S331D, was only slightly sensitive to 
phleomycin compared to the two wild type cell lines.
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6.2.2 Metaphase analysis in PD20 cells
6.2.2.1 Phleomycin-induced chromosomal aberration in PD20 cell lines
After the growth inhibition results showed that FANCD2 played a role in the repair of 
phleomycin induced damage it was decided to further investigate these results to observe what 
was happening at the chromosomal level. This was carried out by exposing these cell lines to 
500 and 1000 ng/ml of phleomycin to produce the cytogenetic profile for FANCD2 mutant and 
wild type corrected cells as illustrated in Tables 6.1-A, 6.2-A and 6.3-A. Frequencies of 
chromosome and chromatid aberrations in treated and untreated cell lines cultures PD20, PD20- 
S331A, PD20-S331D, PD20-K561R, PD20-315 and PD20-D2WT are presented in Tables 6.1- 
A, 6.2-A and 6.3-A.
6.2.2.1.1 Spontaneous chromosome and chromatid aberrations
It can be noted that the number of aberrations per cell in untreated cell lines presented a 
spontaneous rate which did not exceed 0.04 as shown in Tables 6.1-A, 6.2-A and 6.3-A and Fig. 
6.2. Very few aberrations were recorded for all untreated PD20, PD20-S331A, PD20-S331D, 
PD20-K561R, PD20-315 and PD20-D2WT fibroblasts. The highest number of aberrations per 
cell for the untreated cells was that recorded for PD20-K561R as 0.04, followed by PD20-D2WT 
as 0.02 (Tables 6.1-A, 6.2-A, 6.3-A) and (Fig. 6.3). In addition, from the same Tables it can be
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seen that the percentage of aberrant cells that have occurred spontaneously were similar for all 
cell lines, ranging from 0% to 4%.
6.2.2.1.2 Phleomycin-induced chromosome and chromatid aberrations
Table 6.1-A shows that using a dose of 1000 ng/ml phleomycin resulted in 1 and 0.32 
chromosomal aberrations per cell in PD20 and PD20-D2WT respectively, making PD20 3.1- 
fold hypersensitive to the induction of chromosomal aberrations. This indicates that FANCD2 
deficient cell line PD20 is hypersensitive to phleomycin and is unable to correctly repair or 
process phleomycin induced damage (DNA strand breaks), which then lead to the observed 
chromosomal aberrations.
The same experimental conditions were used in Table 6.2-A and two more cell lines were added 
to the cytogenetic assay to test a total of four cell lines; PD20, PD20-S331A, PD20-K561R and 
PD20-D2WT. The number of chromosomal aberrations per cell was 0.56 for PD20, 0.52 for 
PD20-S331A, 0.24 for PD20-K561R and 0.2 for PD20-D2WT. Thus PD20 and PD20-S331A 
showed a similar increase in aberrations, 2.8-fold and 2.6-fold respectively compared to PD20- 
D2WT; whereas, the response of PD20-K561R was much more similar to that observed for 
PD20-D2WT.
In a third experiment (Table 6.3-A) a dose of 1000 ng/ml phleomycin produced higher 
chromosomal aberrations per cell in PD20, 0.48 compared to 0.26 found in PD20-D2WT 
representing a 1.9 fold increase. On the other hand, PD20-S331A and PD20-K561R cells 
produced rates of chromosomal aberrations per cell similar to that of PD20-D2WT cells as
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shown in Table 6.3-A. It is noted that the result for PD20-S331A (Table 6.2-A) is at variance to 
that reported in Table 6.3-A, where the response was much more similar to that of PD20 cells.
So far, Tables 6.1-A, 6.2-A and 6.3-A indicate the hypersensitivity of G-BRCA2 complex 
deficient cell line PD20 to phleomycin, suggesting its inability to correctly process phleomycin 
induced damage (DNA strand breaks). This observation has been consistent in these three 
experiments. Also, PD20-K561R cells have been consistent in showing CA rates similar or close 
to that shown by the corrected wild type (Tables 6.2-A and 6.3-A). While for PD20-S331A cells 
the results illustrated an initial elevation in CAs, but this elevation reduced in the following 
experiment as shown in Tables 6.2-A and 6.3-A. In order to test for consistency more 
experiments were performed employing these FANCD2 cell lines PD20, PD20-S331A, PD20- 
K561R and PD20-D2WT. Unfortunately, these further experiments suffered an unidentified 
technical problem and due to time limitations these experiments could not be repeated as 
explained in the discussion section. The numbers of chromosomal aberrations recorded in each 
of the cell lines in these experiments proved to be highly variable and have been disregarded. 
Experiments which seem to have encountered this unknown problem are presented in an 
appendix at the end of this chapter.
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6.2.2,13 Aberrations per cell, percentage aberrant cells and total 
chromatid breaks per cell
From the Pooled Table 6.4 it can be seen that when using a dose of 1000 ng/ml phleomycin, the 
average aberrations per cell were 0.68 for PD20, 0.41 for PD20-S331A, 0.20 for PD20-K561R 
and 0.26 for PD20-D2WT. Thus, PD20 and PD20-S331A showed an increase in aberrations, 2.6- 
fold and 1.6-fold respectively compared to PD20-D2WT; whereas, the response of PD20-K561R 
was much more similar to that observed for PD20-D2WT.
Also using the dose of 1000 ng/ml phleomycin the average percentage of aberrant cells were 
40.7% for PD20, 29% for PD20-S331A, 14% for PD20-K561R and 19.3% aberrant cells for 
PD20-D2WT. Thus, PD20 and PD20-S331A showed an increase in aberrations, 2.1-fold and 1.5- 
fold respectively compared to PD20-D2WT; whereas, the response of PD20-K561R was much 
more similar to that observed for PD20-D2WT, as shown in Table 6.4. The average number of 
total chromatid breaks (after converting all the exchanges into chromatid breaks) per cell for the 
same dose of 1000 ng/ml phleomycin was 0.77 for PD20, 0.42 for PD20-S331A, 0.28 for PD20- 
K561R and 0.31 chromatid breaks/cell for PD20-D2WT. Thus PD20 and PD20-S331A showed 
an increase in aberrations, 2.5-fold and 1.4-fold respectively compared to PD20-D2WT; 
whereas, the response of PD20-K561R was much more similar to that observed for PD20- 
D2WT, as shown in Table 6.4.
This elevation in cytogenetic structural aberrations in FANCD2 mutant cell lines PD20 and 
PD20-S331A is presented in graphs as average aberration per cell (Fig. 6.2), average percentage 
aberrant cells (Fig.6.3), or as average total chromatid breaks per cell (Fig. 6.4).
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Phleomycin cytogenetic findings presented in Tables 6.1-A, 6.2-A and 6.3-A and illustrated in 
Figs. 6.1, 6.2 and 6.3 support the growth inhibition data in pointing out the ability of PD20- 
D2WT cell line to repair phleomycin DNA induced damage and the reduced ability of PD20 and 
PD20-S331A cells in repairing phleomycin DNA induced damage. This suggests that a mutation 
of the phosphorylation site FANCD2-S331 did affect the repair pathway for phleomycin induced 
DNA strand breaks. The in vivo interaction of FANCD2 with BRCA2 requires S331 
phosphoryaltion (Zhi et al, 2009), so mutating it would compromise this interaction and the 
fonnation of the G-BRCA2 complex. Phleomycin cytogenetic findings also suggest that in the 
absence of G-BRCA2 complex in PD20 cells, the repair pathway usually employed to handle 
phleomycin induced DNA damage was defective. On the other hand, while growth inhibition 
data point out PD20-K561R hypersensitivity to phleomycin, cytogenetic data show CAs rates of 
PD20-K561R, similar to that presented by PD20-D2WT.
While unrepaired phleomycin induced damage is cytogenetically detected in non- 
phosphorylated S331 FANCD2 (Tables 6.2-A), presumably due to a compromised G-BRCA2 
complex, FANCD2-K561R cells exhibited a cytogenetic response after phleomycin treatment 
that was very similar to wild type cells (Tables 6.2-A and 6.3-A). It should be remembered that 
mono-ubiquitination is not required for the formation of the G-BRCA2 protein complex and 
differs from PD20-S331A cells in this respect. PD20 cells, that fail to express FANCD2 (and 
therefore also lack the G-BRCA2 complex) illustrated the highest CA numbers, particularly at 
the highest dose of phleomycin (Tables 6.1-A, 6.2-A and 6.3-A). Further validation for these 
findings is required, as they are based on a limited number of experiments. Unfortunately 
attempts to do this were hampered by inconsistencies in subsequent experiments.
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6.2.2.1.4 Types of cytogenetic aberrations induced by phleomycin
Generally, chromatid type aberrations predominated, involving mostly chromatid breaks and to 
a lesser extent, chromatid exchanges, in FANCD2 cell lines PD20, PD20-S331A, PD20-K561R 
and PD20-D2WT (Tables 6.1-A, 6.2-A and 6.3-A). When comparing CA types in PD20, PD20- 
S331A, PD20-K561R and PD20-D2WT cells, it can also be seen that the occurrence of 
chromatid breaks in PD20 cells is generally higher than that recorded in PD20-S331A and PD20- 
K561R mutant cell lines. It can be seen that chromatid breaks predominate in all cell lines used. 
From (Tables 6.1-B, 6.2-B and 6.3-B), it can be seen that chromatid exchanges only emerge 
occasionally in the form of triradials, quadri-radials or complex arrangements which involve 
either two or three chromosomes.
This aberration type (chromatid breaks) predominance in these cell lines suggests an absence of 
repair pathways, such as HRR, used to repair phleomycin induced damage. In addition, these 
findings also suggest that NHEJ may have been less involved as an alternative repair pathway to 
HRR in cell lines deficient in the G-BRCA2 complex (PD20 and PD20-S331A), as mis-repair 
by error-prone NHEJ is likely to have led to exchange-type aberrations.
Dicentrics or rings were not observed in untreated FANCD2 cultures (controls) and were rarely 
observed in treated cultures (Tables 6.1-B, 6.2-B and 6.3-B). Generally, chromosome breaks 
were slightly higher than chromosome exchanges in the PD20 cell line and were absent in PD20- 
S331A and PD20-K561R. PD20-D2WT presented as shown in Tables 6.3-A and 6.3-B, a 
couple of chromosome breaks and a dicentric which is low as explained earlier. Chromosome 
breaks, were still considerably lower in numbers compared to chromatid breaks. This can be seen 
in treated FANCD2 mutant cell lines cultures PD20, PD20-S331A, PD20-K561R (Tables 6.1-A,
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6.2- A and 6.3-A). Whereas, the corrected wild type PD20-D2WT and PD20-K561R presented 
the lowest numbers of chromatid breaks.
PD20-D2WT growth inhibition data showing wild type levels of hypersensitivity to phleomycin 
is consistent with the cytogenetic data presented in Tables 6.1-A, 6.2-A, 6.3-A, 6.1-B, 6.2-B and
6.3- B. However, PD20-K561R growth inhibition data showing an intermediate level of 
hypersensitivity to phleomycin is not consistent with the cytogenetic data presented in Tables 
6.1-A, 6.2-A, 6.3-A, 6.1-B, 6.2-B and 6.3-B as PD20-K561R showed levels of CAs that were 
similar to PD20 D2WT.
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6.2.2.1.5 Phleomycin-PD20 cytogenetic experiments with high 
variability due to an unidentified technical problem
These include five experiments reported in Tables 6.5-A, 6.6-A, 6.7-A, 6.8-A, 6.9-A, 6.5-B, 6.6- 
B, 6.7-B, 6.8-B and 6.9-B and shown in an appendix to this chapter. Here, the observed 
cytogenetic structural aberration levels in FANCD2 cell lines PD20-D2WT, PD20, PD20-S331A 
and PD20-K561R show inconsistency for all endpoints recorded including average aberrations 
per cell, average percentage aberrant cells and average total chromatid breaks per cell. This 
suggests the occurrence of a problem which could be connected to the cells utilized. For 
example, using a dose of 1000 ng/ml phleomycin resulted in PD20-D2WT fibroblasts rates of 
chromosomal aberrations per cell that did not exceed 0.32 aberration/cell in initial experiments 
(Tables 6.1-A, 6.2-A and 6.3-A). However, in the subsequent experiments this value increased 
up to 0.64 aberration/cell in Table 6.7-A, and up to 1.4 aberration/cell in Table 6.9-A. This 
could indicate a number of possibilities that will be explored in the discussion section. Another 
example confirming a problem is when PD20 shows at a dose of 1000 ng/ml phleomycin average 
chromosomal aberrations per cell rates of 0.34, 0.3, 0.72, 0.82 and 1.2 aberrations per cell. 
However, PD20-D2WT at the same dose shows average chromosomal aberrations per cell rates 
of 0.4, 0.25, 0.64, 0.5 and 1.4 (Tables 6.5-A, 6.6-A, 6.7-A, 6.8-A and 6.9-A). Thus, similar CA 
rates obtained for both PD20 and PD20-D2WT.
The second dose of 1500 ng/ml phleomycin was employed to rule out the possibility that the 
observed inconsistency problem may be related to drug batch potency, but this was clearly not 
the problem as this higher dose of 1500 ng/ml phleomycin significantly reduced the mitotic 
index.
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6.2.3 Growth inhibition assays results of PD20 cells to MMC
As anticipated, the FANCD2 mutated cell lines all showed hypersensitivity to MMC, with the 
PD20 cell line having a GI-50 value of 29 nM compared to a value of 107 nM for PD20-D2WT 
(Fig. 6.5). This means PD20 cell line is 3.7-fold hypersensitive to MMC. PD20-S331A had a GI- 
50 value of 37 nM and so is 2.9-fold hypersensitive to MMC. PD20-K561R had a GI-50 value of 
42 nM and so is 2.6-fold more hypersensitive to MMC. PD20-315 and PD20-S331D had GI-50 
values of 102 and 103 nM respectively, similar to the GI-50 value of that of PD20-D2WT, 
illustrating wild type behavior for these cell lines (Fig. 6,5).
6.2.4 MMC- PD20 cytogenetic experiments that have suffered an 
unidentified technical problem
As for the later phleomycin experiments these MMC-experiments (three independent 
experiments) shown in Tables 6.10-A, 6.11-A, 6.12-A, 6.10-B, 6.11-B and 6.12-B (in the 
appendix of this chapter) exhibited an unacceptable level of variability and were inconsistent 
with the growth inhibition data. The observed level of cytogenetic structural aberrations in 
FANCD2 cell lines PD20-D2WT, PD20, PD20-S331A and PD20-K561R do not correlate with 
growth inhibition findings. The cytogenetic data indicates there may be a problem with the 
corrected wild type cell line which expressed the highest rates of chromosomal aberrations in 
average aberration per cell, in average percentage aberrant cells, and in average total chromatid 
breaks per cell. For example, using a dose of 100 nM MMC for PD20-D2WT resulted in rates of 
chromosomal aberrations per cell of 0.38, 0.8 and 0.45 which were similar to, or exceeded those,
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of the PD20 FANCD2 deficient cell line with rates of 0.24, 0.35 and 0.3 aberration/cell (Tables
6.10-A, 6.11-A and 6.12-A).
Another dose of 300 nM MMC was employed to rule out the possibility that the observed 
inconsistency problem may be related to drug batch potency, but this was clearly not the problem 
as this higher dose of MMC significantly reduced the mitotic index.
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6.3 Discussion
6.3.1 Requirement of post-translational modifications of FANCD2 for 
efficient DNA repair
The results presented here show that in response to the DNA damaging agents phleomycin and 
MMC, it is necessary to have an intact FANCD2 protein that has the ability to be mono- 
ubiquitinated at lysine 561 and phosphorylated at serine 331. PD20 cells, that lack FANCD2, are 
3.7 fold hypersensitive to MMC and 3.3 fold hypersensitive to phleomycin. The importance of 
post-translation modifications is also evident, as in the cell line PD20-K561R, where mono- 
ubiquitination is abolished, hypersensitivity to both MMC and phleomycin is observed, although 
the response of this cell line is intermediate between PD20 and PD20 D2WT. This intermediate 
sensitivity would appear to indicate that both isoforms of FANCD2 are required for optimal 
repair. This demonstration that the short isoform of FANCD2 is likely to have an active role is a 
novel finding that has not been reported previously. Similarly, phosphorylation of S3 31 is 
required to achieve optimal repair for both DNA damaging agents with the PD20-S331A cell line 
exhibiting intermediate sensitivity to both MMC and phleomycin. This phosphorylation site lies 
within the binding region of FANCD2 and BRCA2 (Hussain et aL, 2006) and phosphorylation 
of S331 has been shown to be required for the in vivo interaction of FANCD2 with BRCA2 (Zhi 
et ah, 2009). Growth inhibition experiments were performed first, early in the course of this 
investigation, using FANCD2 cell lines PD20-D2WT, PD20, PD20-S331A and PD20-K561R 
and prior to the latter cytogenetic experiments in which excessive variability was encountered.
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These findings so far suggest that an intact mono-ubiquitinated and phosphorylated FANCD2 is 
required for optimal processing of DNA lesions (double strand breaks and ICLs) via the G- 
BRCA2 and the FA-ID complexes. In addition, the intermediate sensitivity observed in both 
PD20-K561R and PD20-S331A also suggest functionally active roles for both FANCD2-S and 
the non-S331 phosphorylated FANCD2 in the repair of both MMC-induced and phleomycin- 
induced DNA damage. As yet, the roles of these unmodified proteins have to be identified.
6.3.2 Functions of S331-phosphorylated FANCD2 and non-ubiquitinated 
FANCD2
The phosphorylation of FANCD2 at S331 is required for its interaction with BRCA2, thus a 
mutation at FANCD2S3?>\ will prevent this interaction thereby compromising the formation of 
the G-BRCA2 complex. It can therefore be hypothesized that the intermediate hypersensitivity to 
clastogens observed in PD20-S331A is a result of the absence of the G-BRCA2 complex and 
compromised HRR of DNA double strand breaks, regardless of whether they are directly 
induced or arise from the processing of inter-strand cross-links. In the two usable experiments 
with phleomycin (Tables 6.2-A and 6.3-A) the level of phleomycin-induced chromosomal 
aberrations were similar to the null mutant PD20 or intermediate between PD20 and PD20 
D2WT, consistent with the hypothesis that absence of the G-BRCA2 complex results in these 
aberrations. It should be noted, that while the S331A mutation has been reported to slightly 
reduce FANCD2 mono-ubiquitination, mono-ubiquitinated FANCD2is still expressed at quite 
high levels in PD20-S331A cells (Zhi et al, 2009).
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Conversely, a mutation at the FANCD2 mono-ubiquitination site K561 sustains the interaction 
between FANCD2 and BRCA2, the G-BRCA2 complex is formed and modulates proficient 
repair of phleomycin damage via HRR. This may explain the wild type cytogenetic profile 
observed for PD20-K561R after phleomycin treatment (Tables 6.2-A and 6.3-A). The 
intermediate hypersensitivity illustrated by PD20-K561R to both phleomycin and MMC suggests 
the occurrence of partial DNA lesion repair, most likely through the action of the non- 
monoubiquitinated FANCD2-S expressed in PD20-K561R. This indicates that FANCD2-S may 
have an independent active role in mechanisms involved in DNA repair post phleomycin and 
MMC exposure. This is also supported by findings of Oestergaard et aL, (2007) indicating the 
requirements of Ubiquitin specific protease 1 (USP1) mediated FANCD2 deubiquitination for 
DNA cross link repair. Oestergaard et aL, (2007) and Kim et ah, (2009) illustrated that USP1 
deficient cells exhibited about 2-fold hypersensitivity to MMC, thus supporting a role that 
FANCD2-S may play in DNA cross link repair.
It might be further speculated that mono-ubiquitination of FANCD2 is not required for proficient 
HRR, but other steps in the repair process, such as inhibition or suppression of NHEJ in inter­
strand cross-link repair (Pace et at, 2010; Adamo et at., 2010), stabilization of stalled or broken 
replication forks (Thompson et at., 2005; Thompson and Hinz, 2009) for phleomycin-induced 
damage or localization of FANCD2 to chromatin.
To summarize, the intermediate sensitivity of PD20-S331A and PD20-K561R to DNA damaging 
agents may be due to different reasons and differing roles of the FANCD2 protein. These roles 
might include a direct involvement in HRR of some DNA damages (requiring phosphorylation 
of S331) or independently, and upstream or in parallel, of HRR (requiring mono-ubiquitination 
of K561R). It would be interesting to create a PD20 cell line that expressed a FANCD2 cDNA
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with both S331A and K561R mutations, as it might be predicted that this cell line would exhibit 
a response similar to PD20 null cells. Nevertheless, as these findings and speculations are based 
on a limited number of experiments as shown in Tables 6.1-A, 6.2-A and 6.3-A, they need 
further validation by performing further experiments. Unfortunately (see below), it was not 
possible to generate further data as part of this study.
6.3.3 Problems encountered with metaphase analysis of PD20 cell lines
Experiments to examine the chromosomal aberrations induced in the PD20 cell lines by MMC 
were conducted in parallel with the problematic phleomycin experiments shown in Tables 6.5-A, 
6.6-A, 6.7-A, 6.8-A and 6.9-A, 6.5-B, 6.6-B, 6.7-B, 6.8-B and 6.9-B. Thus, the same cell lines 
that gave rise to the inconsistent phleomycin experiments were used in parallel experiments with 
MMC. These MMC-experiments are shown in Tables 6.10-A, 6.11-A, 6.12-A, 6.10-B, 6.11-B 
and 6.12-B in the appendix to this chapter. The observed cytogenetic structural aberration levels 
in FANCD2 cell lines PD20-D2WT, PD20, PD20-S331A and PD20-K561R were inconsistent 
with growth inhibition findings and were not analyzed further.
Several possibilities may explain what might have caused the variability in these experiments. A 
first possibility would be that the cells used may have somehow lost the inserted cDNA construct 
or that construct had in some way become inactivated, thereby reverting the cells to their original 
uncorrected PD20 phenotype. A second possibility would be that a cross contamination of cell 
lines may have occurred between the various PD20 cell lines. A third possibility is that cell lines 
may have acquired resistance to the clastogens through genetic changes acquired during
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continued culture. Such changes might include changes in the metabolism of the clastogens or 
transport of the clastogen into the cell.
The practical way to confirm the findings of this chapter and continue to develop our 
understanding of the aims of this section would be to use FANCD2 cell lines PD20-D2WT, 
PD20, PD20-S331A and PD20-K561R after re-confirming their protein profile expression 
through Western blots and checking their clastogen sensitivity via growth inhibition or survival 
assays before using them into cytogenetic assays. PD20-K561R are expected to express the non- 
mono-ubiquitinated FANCD2-S, whereas FANCD2 expression would be completely absent in 
PD20 cells compared to the corrected wild type PD20-D2WT and PD20-S331A, where both 
FANCD2 forms are expressed illustrated as two bands in Western blots. Use of a phospho- 
antibody could be performed to confirm the validity of PD20-S331A cells. The cytogenetic 
profile in response to phleomycin or MMC treatment may resemble or compare to the 
hypersensitivity profile recorded in this chapter using growth inhibition curves as shown in 
Figures 6.1 and 6.5.
6.4 Summary of the chapter
• It has been demonstrated that FMiVCD2-deficient PD20 cells exhibit increased 
hypersensitivity to the radiomimetic compound phleomycin, in addition to their 
previously reported hypersensitivity to the inter-strand cross-linking agent MMC
(Whitney et al., 1995; Jakobs et al., 1996).
• PD20 cells expressing FANCD2 proteins that cannot be mono-ubiquitinated at K561 or 
phosphorylated at S331, exhibit intermediate sensitivity to both MMC and phleomycin.
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• Consistent with their cellular hypersensitivity to phleomycin, PD20 cells exhibit 
increased levels of induced chromosomal aberrations, with chromatid breaks being the 
predominant type of aberration (Tables 6.1-A, 6.2-A and 6.3-A).
• PD20-S331A cells, that are unable to form the G-BRCA2 protein complex, also exhibit 
an increase in phleomycin-induced chromosomal aberrations that were similar in number 
and type to those seen in PD20 cells (Tables 6.2-A and 6.3-A),
• In contrast, PD20-K561R cells, that are able to form the G-BRCA2 complex, do not 
exhibit an increase in phleomycin-induced chromosomal aberrations (Tables 6.2-A and 
6.3-A).
• It is therefore proposed that the observed increase in chromosomal aberrations is due to 
the absence of the G-BRCA2 protein complex and that this complex is particularly 
important for the repair of phleomycin-induced DNA damage.
• The intermediate phleomycin (and MMC) hypersensitivity observed in PD20-S331A and 
PD20-K561R is a consequence of FANCD2 having multiple roles in DNA repair. In 
addition, the data clearly indicate that non mono-ubiquitinated FANCD2 has a functional 
role in the cellular resistance to clastogens.
• The predominance of chromatid breaks in phleomycin treated PD20 and PD20-S331A 
cells suggests that unrepaired DNA breaks resulting from defective HRR are not 
processed by NHEJ (that would likely result in chromatid exchanges), but rather these 
remain unrepaired leading to the observed chromatid breaks.
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Chapter-7
General discussion
7.1 Discussion
7.1.1 Introduction
Fanconi anaemia is a human disorder characterized by cancer susceptibility and cellular 
sensitivity to DNA cross links and other replication fork stalling agents. Cells derived from FA 
patients have been shown to undergo premature senescence, spontaneously accrue chromosome 
aberrations and accumulate in G2 phase of the cell cycle (Thompson and Hinz, 2009). When 
exposed to ICL agents, like MMC, a covalent bond results in opposite strands of DNA becoming 
linked or cross-linked. The chemistry of guanine disposes itself to react with these cross linking 
agents and the majority of ICLs occur between guanines. These lesions are extremely toxic and 
block both transcription and DNA replication. The failure of a cell to repair such lesions leads to 
chromosome breaks and complex radial structure formation. The aim of this project was to 
further investigate the links between FA proteins and HRR, thereby strengthening the emerging 
data that the FA pathway is not linear, but is composed of multifunctional proteins that form 
different sub-complexes with specific functions. Here, the role that FANCG, FANCA and 
FANCD2 play promoting cell survival in response to two chemical DNA damaging agents MMC 
(ICL) and phleomycin (DSB) has been investigated. The loss of function of these proteins when 
exposed to MMC, leads to increased radial formations and chromosomal breaks. In the case of
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phleomycin, it appears that only the loss of FANCG and FANCD2 functions affects cell survival 
and consequent chromosome aberrations. Furthermore, it has also been shown that the loss of 
specific phosphorylation sites in FANCG and FANCD2 affects cellular survival and the amount 
of chromosomal damage detected.
7.1.2 DNA inter-strand cross-link repair
7.1.2.1 Unhooking
The repair of ICLs is coupled to DNA replication. Regardless of which stage of the cell cycle 
cells are treated with MMC, they will accumulate a 4N complement of DNA (Akkari et at, 
2001). Additionally, chromosomal damage and DSBs formation only occur following transit 
through S-phase of the cell cycle (Akkari et aL, 2001). Recent work has shown the importance 
of mono-ubiquitinated FANCD2 in ICL repair. Mono-ubiquitinated FANCD2 is required for 
incisions at the site of the cross-link, in the TLS step and HRR (Long et at, 2011). This 
biochemical and genetic infonnation place the FA, TLS and HRR machinery in a common 
pathway for ICLs repair. This is shown in the proposed model illustrated in Fig.7.1.
The FA-core complex mediated mono-ubiquitination of FANCD2 acts upstream of both TLS and 
HRR (Niedzwiedz et aL, 2004; Hirano et aL, 2005; Wilson et aL, 2008; Long et aL, 2011). 
FAN1 exhibits a 5’ flap endonuclease activity with an associated 5’to 35exonuclease activity 
(Kratz et aL, 2010; MacKay et aL, 2010; Crossan and Patel, 2011). This FAN1 activity could 
be connected to crosslink repair (Raschle et aL, 2008). Thus, FANCD2 recruitment of FAN1 to
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the site of DNA cross-links may be one mechanism by which one nuclease is recruited. On the 
other hand, FAN1 depletion is associated with normal kinetics of y-H2AX foci formation, which 
is a marker of DNA double strand breaks (Crossan and Patel, 2011), suggesting that FAN1 is 
not essential for generating DSBs or HRR.
The biochemical endonuclease activity of XPF-ERCC1 results in strand incision when ICLs are 
encountered (Sijbers et al.t 1996; Raschle et al, 2008). It has been shown that the biochemical 
activity of XPF-ERCC1 can be altered in a way nicking dsDNA 4 nucleotides before ICLs 
(Fischer et al.f 2008; Crossan and Patel, 2011), suggesting that XPF-ERCC1 alone is adequate 
to execute both incisions at the site of an ICL.
Discovery of the SLX4 gene may reveal another part of DNA cross-link repair process (Fekairi 
et ah, 2009, Svendesen et aL, 2009, Munoz et alf 2009). Human SLX4 interacts with the SLX1, 
which is a structure specific endonuclease. The SLX4-SLX1 complex is involved in in vitro 
resolution of Holliday junctions. Both cross-link repair nucleases XPF-ERCC1 and MUS81- 
EME1 interact with SLX4, which also enhances their biochemical action in vitro (Fekairi et al, 
2009, Svendesen et al, 2009, Munoz et al, 2009). DNA cross-linking agent hypersensitivity 
has been found in Drosophila, C. elegans, mouse, yeast and human cells depleted of SLX4 (Liao 
et al, 2007; Crossan and Patel, 2011). Thus, it would be reasonable to propose a model in 
which SLX4 has an analogous role in XPF-ERCC1 recruitment to inter-strand cross-links sites to 
that of XPA in nucleotide excision repair (NER). XPA recruits ERCC1 to UV damaged DNA 
sites in NER (Volker et al, 2001). XPA deficient cells are hypersensitive to UV but not to DNA 
cross-linking agents. On the other hand, SLX4 depletion does not bring about cellular 
hypersensitivity to UV irradiation but leads to hypersensitivity to DNA inter-strand cross-linking 
agents. Thus, it is possible that SLX4 segregates XPF-ERCC1 activity into ICL repair from its
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function in repairing UV induced DNA damage. The mechanics of Fanconi anaemia pathway 
dependent incisions at the site of ICLs remain unclear to this date.
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7.1.2.2 Processing of Double Strand Breaks in ICL Repair
As previously stated, DSB repair occurs through either HRR or NHEJ. ICL repair, from the 
results presented here, seems to require the core complex to suppress the NHEJ pathway. In the 
cell lines where the core complex does not form, due to absence of either FANCG (NM3) or 
FANCA (GM9614), the number of exchanges at the chromosome level increases in response to 
MMC. This suggests that NHEJ acts upon the DSB that arise from ICL cross-links that are not 
processed by the FA pathway. NHEJ appears to be suppressed in cell lines that have a functional 
core complex. It has yet to be detennined whether this is due to a direct inhibition of NHEJ or 
the FA pathway processing ICLs in a way that does not create substrates for NHEJ or protects 
ICL repair intermediates from NHEJ binding proteins. The G-BRCA2 complex seems to play a 
role in ICL repair as in the serine 7 mutated cell line (NM3-S7A), the core complex forms and 
the number of exchanges detected in response to MMC increase, although the highest CA level 
detected has been recorded in the complete absence of FANCG. It seems most likely that in the 
absence of the G-BRCA2 complex, the DSBs produced from the FA pathway acting upon a 
cross-link, become available for processing by NHEJ due to the absence of HRR, and these 
DSBs then result in increased numbers of chromatid exchanges. An alternative explanation, that 
seems more unlikely, is that the S7A-FANCG mutated protein has sub-optimal activity in the FA 
core complex, even though the core complex forms in NM3-S7A cells and FANCD2 is mono- 
ubiquitinated.
To summarize the sequence, it appears that after cross-link unhooking, the resultant DSB is 
repaired by HRR, with the FA core complex and FANCD2 mono-ubiquitination somehow 
playing a role in suppressing NHEJ. Recent data (Adamo et ah, 2010) suggest that FA pathway
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proteins are likely to direct DNA cross-links into accurate HRR, rather than error-prone NHEJ, 
nevertheless the exact mechanism is still undetermined. Adamo et al, (2010) showed that 
FANCD2 is critical in avoiding NHEJ repair of meiotic DSBs. In eukaryotes, the repair of DSBs 
repair can either be through error-prone repair pathway NHEJ or error-free repair pathway HRR. 
Rigorous regulation of DNA repair pathways is required to avoid inaccurate end-joining which 
could lead to harmful or lethal cellular effects such as genomic instability, chromosomal radial 
formation or apoptosis (Kitao and Takata, 2010). Bunting et al., (2010) and Bouwman et al., 
(2010) demonstrated NHEJ and HRR in vivo competition. Bouwman et al., (2010) illustrated 
using BRCA1 mutant cells, that repair through HRR pathway is restored by deleting the NHEJ 
factor 53BP1 thereby preventing radial chromosome arrangements and tumor formation. This 
suggests that the characteristic acquired FA cellular phenotype post exposure to inter-strand 
cross-linking agents, is most likely a result of inaccurate end-joining of non-homologous 
chromosomes (Bunting and Nussenzweig, 2010).
Experimental evidence supported a role of FA proteins in promoting DNA repair via HRR 
through NHEJ suppression (Pace et al, 2010; Adamo et al, 2010). Adamo et al, (2010) 
showed that treatment of human wild type M059K cells with FANCD2 siRNAs resulted in 
sensitivity to mitomycin C (MMC). However, when FANCD2 was depleted in DNA-PKcs- 
deficient M059J cells, no increase in MMC-sensitivity was observed. Furthennore, chemical 
inhibition of NHEJ with the DNA-PKcs-speciflc inhibitor NU7026 in FA-deficient cells 
substantially corrects the characteristic FA phenotype of inter-strand cross-linking agent 
hypersensitivity and chromosomal instability (Adamo et al, 2010). In NHEJ, the DNA-PKcs 
enzyme is recruited to DNA breaks and is activated by the KU70/KU80 heterodimer. Two 
studies in 2010 show that disruption of Ku70, Ku80 or DNA-PKcs in ATACD2-deficient human
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cells reverses cellular hypersensitivity to cross-linking agents, reduces chromosome instability, 
and promotes HRR (Pace et al, 2010; Adamo et aU, 2010).
7.1.2.3 Determining the role of the G-BRCA2 complex (comprising BRCA2- 
FANCD2-FANCG-XRCC3) in ICL and DSB repair
In Chapter 3, the involvement of FANCG and the G-BRCA2 complex in the error free HRR 
pathway of DNA inter-strand cross links was investigated using the CHO NM3 cell lines. 
Growth inhibition assays demonstrated that FANCG and its two phosphorylation sites at Serine 7 
and Serine 387 are important in sustaining resistance to the cross linking agent MMC. The 
MMC-hypersensitivity presented by the FANCG mutant cell lines is supported by cytogenetic 
analysis. Rates of chromosomal aberrations were elevated in the FANCG mutant cell lines, 
especially in the complete absence of FANCG protein (NM3-VO), as shown in the summary 
Table 7.1. In FANCG deficient cells, NM3-VO, all known protein complexes containing 
FANCG protein will be absent; the FA nuclear core complex, the G-BRCA2 complex and the G- 
ERCC1-XPF complex. In contrast, cell lines NM3-S7A and NM3-S387A, known to fonn one or 
more of these three complexes exhibit intermediate MMC-sensitivity and induction of 
chromosomal aberrations. NM3-S7A cells contain a fully assembled and presumably active FA- 
core complex, but are deprived of the G-BRCA2 complex (Wilson et al, 2008). The status of the 
G-ERCC1-XPF complex is unknown in NM3-S7A and the other phospho-mutant cell line NM3- 
S387A. Given that NM3-S7A cells show compromised ICL repair ability, as evidenced by their 
hypersensitivity to MMC and elevated chromosomal aberrations, this most likely indicates the
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requirement of the G-BRCA2 complex for successful and complete ICL repair and restoration of 
DNA replication. It is proposed that NM3-S7A cells were able to process ICLs through the 
action of the G-ERCC1-XPF complex and the FA-core complex by unhooking ICLs and 
performing TLS, but the resulting DSBs could not be repaired by HRR, due to the absence of the 
G-BRCA2 complex. This is consistent with the reduction of HRR in MMC-treated NM3-S7A 
cells as measured using the SCneo recombination assay. In the absence of the G-BRCA2 
complex and HRR, it is likely that the DSBs arising from the upstream processing of ICL in 
NM3-S7A are available as substrates for error-prone mis-repair by NHEJ. This is consistent with 
the increased levels and predominance of chromatid exchanges in MMC-treated NM3-S7A cells. 
In contrast, NM3-S387A cells that have an intact G-BRCA2 complex did not show chromatid 
exchanges as the predominant MMC-induced aberration.
To further investigate the role of S7-FANCG phosphorylation and the G-BRCA2 complex in the 
repair of DSBs by HRR, the radio-mimetic agent phleomycin was used (Sleigh, 1976; Povirk et 
ah, 1981). Phleomycin induces direct double-strand breaks (DSB) into DNA. It also induces 
single-strand breaks and base damage and if these remain unrepaired prior to DNA replication, it 
is likely they will result in broken replication forks and replication fork-associated DSBs. 
However, phleomycin is not known to induce ICL.
Consistent with the hypothesis that the G-BRCA2 complex is required for the repair of DSBs, 
NM3-S7A and NM3-VO cells that lack this protein complex, exhibit significant hypersensitivity 
to phleomycin. This suggests that the G-BRCA2 complex is involved in homologous 
recombinational repair of DSBs, whatever their origin, be it direct induction of DSBs by 
phleomycin or indirectly arising DSBs from the partial repair of ICLs. In contrast, NM3-S387A 
that retains an intact G-BRCA2 complex shows minimal hypersensitivity to phleomycin.
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Consistent with NHEJ processing the unrepaired phleomycin-induced DSBs, both NM3-VO and 
NM3-S7A exhibit large increases in chromosomal aberrations with chromatid exchanges being 
the predominant type of aberration. The absence of the G-BRCA2 complex in NM3-S7A (and 
NM3-VO) cells prevented DNA double strand processing in an error-free manner through HRR, 
resulting the observed hypersensitivity and elevation in CA rate as illustrated in summary Table 
7.1. For MMC, NM3-S7A displayed an intermediate response, while for phleomycin, it’s 
cellular and chromosomal hypersensitivity were as severe as (if not more severe) than that 
observed for the null mutant. In NM3-VO, all FANCG-containing protein complexes will be 
absent, yet this cell line has a response to phleomycin similar to NM3-S7A. This strongly 
suggests that repair of phleomycin-induced DNA damage does not require either the FA core or 
the G-ERCC1-XPF protein complexes.
Consistent with the idea that the repair of phleomycin-induced DNA damage requires the G- 
BRCA2 complex, but not the FA core complex or G-ERCC1-XPF complexes, levels of HRR in 
NM3-VO and NM3-S7A were reduced compared to wild type NM3-gWT cells. In fact, it 
appeared that HRR was more severely compromised in NM3-S7A than it was in NM3-VO. The 
reasons for this are presently unclear, but one possibility may be that the presence of the FA core 
complex and G-ERCC1-XPF (containing the mutated FANCG-S7A protein) might somehow 
interfere with the processing, or hinder the repair, of phleomycin-induced DNA damage.
Further evidence for the involvement of the G-BRCA2 complex in the homologous 
recombination repair of phleomycin-induced DSBs comes from the analysis of NM3-S387A and 
human FANCA mutant cell line GM6914. It is known that the G-BRCA2 complex forms in both 
these cell lines (Wilson et al, 2008; Wilson et aL, 2010). NM3-S387A cells do not exhibit 
significant cellular hypersensitivity to phleomycin compared with wild type NM3-gWT control
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cells. In addition, the levels of phleomycin induced chromosomal aberrations and the types of 
aberrations induced (predominantly chromatid breaks) are similar to NM3-gWT. While HRR 
levels after phleomycin are somewhat reduced in NM3-S387A cells, the defect is much less 
severe than that observed for NM3-S7A (Chapter 4). Thus, whatever the defect is in NM3- 
S387A cells that results in MMC-hypersensitivity, it is clear that this defect has little effect on 
the repair of phleomycin-induced DNA damage.
GM6914 cells, like NM3-S387A cells, presumably have a functional G-BRCA2 complex, as it is 
known that the formation of this complex is independent of the FANCA protein, the FA core 
complex and FANCD2 mono-ubiquitination (Wilson et ah, 2008; Wilson et al,, 2010). For 
phleomycin, GM6914 (GM6914-VO) cells showed a response that was very similar its wild type 
cDNA corrected counterpart (GM6914-AWT). Cellular sensitivity and the induction of 
chromosomal aberrations were similar in GM6914-VO and GM6914-AWT cells (Chapter 5) 
(Table 7.2) and similar levels of HRR have been observed in these two cell lines (Mysore, 
Wilson and Jones unpublished). These data, therefore provide further evidence that the G- 
BRCA2 complex is important for HRR of phleomycin-induced DSB. Furthermore, they also 
indicate that the repair of this damage does not require the formation of the FA core complex or 
FANCD2 mono-ubiquitination, as neither of these things occur in GM6914 FANCA mutant cells.
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Further support for the G-BRCA2 complex modulating proficient HRR in processing DNA 
strand breaks, and not the nuclear FA-core complex is presented in Chapter 6. The FANCD2 
deficient cell line PD20 exhibited hypersensitivity to phleomycin while the phospho-mutant cell 
line PD20-S331A and mono-ubiquitination mutant cell line PD20-K561R showed an 
intermediate level of hypersensitivity, while the phospho-mimetic PD20 S331D showed wild 
type behavior (Table 7.3). This intermediate hypersensitivity observed in FANCD2 phospho- 
mutant PD20-S331A and mono-ubiquitination mutant PD20-K561R to phleomycin, suggest a 
role for both FANCD2-S and non-phosphorylated FANCD2 S331 in partial repair of DNA 
double strand breaks. The wild type behavior in PD20 S331D is predicted as the mutation in 
PD20 S331D did not affect FANCD2 mono-ubiquitination, nor did it affect the interaction 
between FANCD2 with BRCA2 to form the G-BRCA2 complex, thus sustaining both 
phleomycin and MMC cellular resistance.
Despite showing similar cellular hypersensitivity to phleomycin, the induction of chromosomal 
aberrations in PD20-S331A and PD20-K561R was distinct. In the limited number of experiments 
performed with these cell lines, it appeared that the response of PD20-K561R was more similar 
to that of the wild type PD20-D2WT, while the response of PD20-S331A was closer to that of 
the null mutant PD20-VO. This difference in result may possibly be explained with respect to the 
formation of the G-BRCA2 complex in these cells. Phosphorylation of Serine 331 has been 
shown to be required for its interaction with BRCA2 and therefore fonnation of the complete G- 
BRCA2 complex (Zhi et al, 2009). The lack of the G-BRCA2 complex, and an inability to 
process phleomycin-induced DSBs by HRR, most likely explains the induction of chromosomal 
aberrations in PD20-S331A cells. On the other hand, mono-ubiquitination of FANCD2 is not 
required for fonnation of the G-BRCA2, thus the presence of the complex in PD20-K561R cells
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is consistent with the lack of increased chromosomal aberrations compared to PD20-D2WT cells 
and a normal ability to perform HRR. Certainly, recent unpublished data (Wilson and Jones, 
personal communication) shows that while both PD20-K561R and PD20-S331A cells show 
reduced HRR in the SCneo recombination assay, the defect is much more severe in PD20-S331A 
cells. HRR is less than 2-fold reduced in PD20-K561R compared to PD20-D2WT. However, 
while the levels of HRR observed in these two cell lines are broadly consistent with the induction 
of chromosomal aberrations, it is not consistent with their intennediate and similar cellular 
sensitivities to phleomycin. One possibility is that the mono-ubiquitination is important for a 
function of FANCD2, other than that in the G-BRCA2 protein complex.
Thus the intermediate hypersensitivity observed in PD20-K561R cells might possibly be 
explained by the failure to mono-ubiquitinate FANCD2-S to FANCD2-L. This in turn leads to 
failure of FANCD2 to bind chromatin and the failure of FANCD2 to fonn nuclear foci. Thus, 
while the G-BRCA2 complex can form in PD20-K561R cells, HRR may operate at reduced 
efficiency. Alternatively, mono-ubiquitinated FANCD2 has been implicated in a DNA damage 
cell cycle checkpoint response (Taniguchi et al., 2002b; Andreassen et al., 2004) and this may 
also go some way in explaining the intennediate response to phleomycin in K561R cells. A role 
for mono-ubiquitinated FANCD2 in the repair of DNA damage or cellular responses, such as cell 
cycle control to DNA damage, upon phleomycin exposure is consistent with the intermediate 
response of PD20-S331A cells. While the G-BRCA2 complex does not form in these cells, they 
still express mono-ubiquitinated FANCD2. It is clear that further experimentation is required to 
fully determine the role(s) of FANCD2, unfortunately attempts to repeat the initial experiments 
with PD20 cells were hindered due to unexplained variability.
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It is interesting to note that the predominant chromosomal aberrations induced by phleomycin in 
ivIACG-deficient cells (NM3) and TvlA^CD^-deficient cells (PD20) were different. Chromatid 
exchanges were prevalent in NM3, while chromatid breaks were prevalent in PD20. Neither cell 
line is able to form the G-BRCA2 complex, but the reason for the difference in aberration type is 
unknown. It might possibly relate to functions of FANCG and FANCD2 outside of the G- 
BRCA2 complex. FANCG is a component of the FA core complex and G-ERCC1-XPF 
complexes and mono-ubiquitinated FANCD2 has other functions as just discussed. However, the 
prevalence of exchanges in the /vIvVCG-deficient cells does suggest illegitimate-processing of 
breaks by NHEJ, while the prevalence of breaks in ivfACD2-deficent cells suggests a lack of 
repair by either HRR or NHEJ. Alternatively, the difference might simply be due to a species- 
specific difference between hamster (NM3) and human (PD20) cells.
Support that G-BRCA2 complex may modulate proficient HRR also comes from XRCC3 and 
BRCA2 data in the literature. Employing CHO cell line mutants of XRCC3 (irslSF), Fuller and 
Painter, (1988) illustrated their cellular hypersensitivity to ionizing radiation (DNA strand 
breaking agent). Fuller and Painter, (1988) also reported elevated numbers of chromatid 
exchanges in irslSF cells post cellular exposure to irradiation. These findings are in agreement 
with phleomycin growth inhibition and cytogenetic findings of FANCG deficient cells which 
have shown phleomycin hypersensitivity and chromatid exchange type aberration predominance. 
This agreement supports the model which explains hypersensitivity to DNA strand breaking 
agents and the predominance of chromatid exchanges in G-BRCA2 deficient cell lines at least in 
CHO cells. The use of different model systems could be the reason why chromatid exchanges 
were observed in CHO cells NM3-VO and NM3-S7A, while chromatid breaks were observed in 
human PD20 cells.
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BRCA2 cell mutants exhibit hypersensitivity to several DNA damaging agents including cross- 
linking, mono-functional alkylating agents (Overkamp et aly 1993). Rahden-Staron et al, 
(2003) showed that BRCA2 defective CHO V-C8 cells were hypersensitive, to topoisomerase I 
inhibition by camptothecin. Topoisomerases intracellular level is vital in ionizing radiation and 
oxidative damage repair (Davies et al, 1988; 1990). Pommier et al, (1994) has suggested that 
radiation and inhibitory drug induced DSBs may be repaired through a common pathway.
These two homologous recombination repair proteins XRCC3 and BRCA2 interact directly with 
FANCG (Hussain et al, 2003; Hussain et al, 2004; Hussain et al, 2006). These observations 
further support the model that proposes the G-BRCA2 complex containing FANCG, BRCA2, 
FANCD2 and XRCC3 to modulate proficient HRR in DNA lesion repair.
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7.1.3 Conclusions
Inter-strand cross-link repair requires multiple repair processes regulated through 
phosphorylation of FANC proteins which may assist in determining the sequential order of these 
processes. Phosphorylation of FANCG at serine-7 has a distinct function independent of the FA- 
core complex and arbitrates the formation of the G-BRCA2 complex. The G-BRCA2 complex 
forms separately from the FA-core complex and modulates error-free HRR proficiency. The G- 
BRCA2 complex operates either downstream (as in ICL repair) or independently of the FA core 
complex (as in DSB repair), dependent on the type of DNA lesion encountered.
The G-BRCA2 complex promotes error free HRR. In the absence of the G-BRCA2 complex, 
directly induced DSBs (phleomycin) or DSBs arising from incomplete or partial repair of ICLs 
(MMC) are processed through error-prone NHEJ, resulting in the induction of chromosomal 
aberrations and genomic instability. FANCG, its phospho-site S7 and the G-BRCA2 complex are 
essential in restoring wild type ability to repair DNA strand breaks through proficient HRR, 
which is also part of proficient ICL repair.
The FANCG phospho-site S3 87 is required for proficient ICL repair, but is not essential for the 
repair of DNA double strand breaks. The role of S387-phosphorylation in ICL repair is 
unknown. FA core complex formation and FANCD2 mono-ubiquitination appear to be 
independent of this phosphorylation event, although it is possible that the failure to 
phosphorylate S3 87 will lead to sub-optimal processing of ICL prior to the HRR step. Another 
possibility might be that phosphorylation of S3 87 is required for formation of the G-ERCC1- 
XPF complex, responsible for unhooking of ICL. A final possibility, given that the 
phosphorylation occurs in mitosis, it may be the case that phosphorylation of S3 87 is required to
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“switch off’ suppression of NHEJ by the FA core complex. It could be speculated that NHEJ is 
required to repair remaining ICL-associated DSBs that have evaded repair by HRR during S- 
phase. This explanation would at least be consistent with the additional chromatid breaks 
observed in NM3-S387A cells after MMC.
FANCD2, its phospho-site S331 and its mono-ubiquitination site K561 are important in restoring 
wild type ability to repair DNA strand breaks through proficient HRR. Both FANCD2-S and 
non-phosphorylated FANCD2 S331 seem to have a function or an active role in DNA double 
strand break and ICE repair.
FANCA and the FA-core complex are not critically required for the repair of DNA strand breaks 
that are induced directly (as for phleomycin) However, FANCA and the FA core complex are 
required for the processing of ICE upstream of HRR (ICE unhooking and lesion bypass) and in 
the suppression of NHEJ by the FA pathway.
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Appendix
Appendix-1 NORMAL METAPHASE SPREAD- NM3-WT
Appendix-1: presents a CHO metaphase spread with minimal chromosomal 
overlapping which allow reliable scoring of chromosomal aberrations. It also 
presents good chromosome morphology and staining.
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Appendix-2 (DICENTRICS) IN METAPHASE SPREAD
Appendix-2: showing the fusion of two chromosomes forming a dicentric 
which is a chromosome based aberration.
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Appendix-3 RINGS IN METAPHASE SPREAD
RING
Appendix-3: showing an example of a ring formation which is a 
chromosome based aberration usually caused by the loss of telomeric 
integrity of the chromosome which may lead the radical sticky 
chromosomal ends to form the ring structure.
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Appendix-4: presenting a triradial structure which is a chromatid based 
aberration.
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Appendix-5 QUADRI-RADIALS IN METAPHASE SPREAD
Hk.
9| STICKY END
Q UA DRI-RA DIAL S j •’V -
o
Appendix-5: presenting a quadri-radial structure which is a chromatid based
aberration.
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Appendix-6 MULTI-COMPLEX ARRANGMENTS IN METAPHASE
Appendix-6: illustrating some variable complex chromosomal arrangements indicating that a 
variable number of chromosomes can be involved in any complex arrangement
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Appendix-7 Terminal BREAK IN METAPHASE SPREAD
STICKY END
COMPLEX
ARRANGMENT
TERMINAL 
BREAK
Appendix-7: illustrating how a breakage site such as a terminal break can 
show stickiness in a step that may develop producing dicentrics, rings, 
complex or other chromatid based aberrations.
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Appendix-8: illustrating the presence of multi chromosomal aberrations in 
the same metaphase spread. This becomes more frequent as the doses used 
increase and the cells are more sensitive to the clastogen applied.
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Appendix-9-B
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Appendix-10: presents a CHO metaphase with optimal chromosomal 
spreading achieved through hypotonic solution and fixation manipulation. 
This is ideal for identifying possible chromosomal aberrations.
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